BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, Mcdonald LC, Pepin J, Wilcox MH. Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010;31:431-55. [DOI: 10.1086/651706] [Cited by in Crossref: 2197] [Cited by in F6Publishing: 1862] [Article Influence: 313.9] [Reference Citation Analysis]
Number Citing Articles
1 Li R, Lu L, Lin Y, Wang M, Liu X. Efficacy and Safety of Metronidazole Monotherapy versus Vancomycin Monotherapy or Combination Therapy in Patients with Clostridium difficile Infection: A Systematic Review and Meta-Analysis. PLoS One 2015;10:e0137252. [PMID: 26444424 DOI: 10.1371/journal.pone.0137252] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
2 Barker AK, Ngam C, Musuuza JS, Vaughn VM, Safdar N. Reducing Clostridium difficile in the Inpatient Setting: A Systematic Review of the Adherence to and Effectiveness of C. difficile Prevention Bundles. Infect Control Hosp Epidemiol 2017;38:639-50. [PMID: 28343455 DOI: 10.1017/ice.2017.7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 5.8] [Reference Citation Analysis]
3 Olling A, Leidinger H, Hoffmann R. Comparison of enzyme immunoassays and rapid diagnostic tests for clostridium difficile glutamate dehydrogenase and toxin a + B to toxinogenic culture on a highly selective chromogenic medium. Eur J Clin Microbiol Infect Dis 2016;35:1655-9. [PMID: 27323765 DOI: 10.1007/s10096-016-2706-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
4 Alcalá L. Laboratory tests for diagnosis of Clostridium difficile infection: Past, present, and future. Enfermedades Infecciosas y Microbiología Clínica 2013;31:65-7. [DOI: 10.1016/j.eimc.2012.10.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
5 Sewell B, Rees E, Thomas I, Ch'ng CL, Isaac M, Berry N. Cost and Impact on Patient Length of Stay of Rapid Molecular Testing for Clostridium difficile. Infect Dis Ther 2014;3:281-93. [PMID: 25183400 DOI: 10.1007/s40121-014-0034-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
6 Shorr AF, Zilberberg MD, Wang L, Baser O, Yu H. Mortality and Costs in Clostridium difficile Infection Among the Elderly in the United States. Infect Control Hosp Epidemiol 2016;37:1331-6. [DOI: 10.1017/ice.2016.188] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
7 Stockmann C, Rogatcheva M, Harrel B, Vaughn M, Crisp R, Poritz M, Thatcher S, Korgenski EK, Barney T, Daly J. How well does physician selection of microbiologic tests identify Clostridium difficile and other pathogens in paediatric diarrhoea? Insights using multiplex PCR-based detection. Clin Microbiol Infect. 2015;21:179.e9-179.15. [PMID: 25599941 DOI: 10.1016/j.cmi.2014.07.011] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 4.8] [Reference Citation Analysis]
8 Chhim RF, Shelton CM, Christensen ML. Recent new drug approvals, part 2: drugs undergoing active clinical studies in children. J Pediatr Pharmacol Ther 2013;18:14-38. [PMID: 23616733 DOI: 10.5863/1551-6776-18.1.14] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
9 Larson KC, Belliveau PP, Spooner LM. Tigecycline for the treatment of severe Clostridium difficile infection. Ann Pharmacother. 2011;45:1005-1010. [PMID: 21730279 DOI: 10.1345/aph.1q080] [Cited by in Crossref: 51] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
10 Cornely OA, Miller MA, Louie TJ, Crook DW, Gorbach SL. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. Clin Infect Dis 2012;55 Suppl 2:S154-61. [PMID: 22752865 DOI: 10.1093/cid/cis462] [Cited by in Crossref: 219] [Cited by in F6Publishing: 198] [Article Influence: 21.9] [Reference Citation Analysis]
11 Crew PE, Rhodes NJ, O'Donnell JN, Miglis C, Gilbert EM, Zembower TR, Qi C, Silkaitis C, Sutton SH, Scheetz MH. Correlation between hospital-level antibiotic consumption and incident health care facility-onset Clostridium difficile infection. Am J Infect Control 2018;46:270-5. [PMID: 29169938 DOI: 10.1016/j.ajic.2017.09.015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
12 Feuerstadt P, Das R, Brandt LJ. The evolution of urban C. difficile infection (CDI): CDI in 2009-2011 is less severe and has better outcomes than CDI in 2006-2008. Am J Gastroenterol. 2014;109:1265-1276. [PMID: 25001255 DOI: 10.1038/ajg.2014.167] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
13 Dubberke ER, Carling P, Carrico R, Donskey CJ, Loo VG, Mcdonald LC, Maragakis LL, Sandora TJ, Weber DJ, Yokoe DS, Gerding DN. Strategies to Prevent Clostridium difficile Infections in Acute Care Hospitals: 2014 Update. Infect Control Hosp Epidemiol 2014;35:628-45. [DOI: 10.1086/522262] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 3.1] [Reference Citation Analysis]
14 Guery B, Berger P, Gauzit R, Gourdon M, Barbut F, Dafne Study Group, Bémer P, Bessède E, Camou F, Cattoir V, Couzigou C, Descamps D, Dinh A, Laurans C, Lavigne JP, Lechiche C, Leflon-Guibout V, Le Monnier A, Levast M, Mootien JY, N'Guyen Y, Piroth L, Prazuck T, Rogeaux O, Roux AL, Vachée A, Vernet Garnier V, Wallet F; DAFNE study group. A prospective, observational study of fidaxomicin use for Clostridioides difficile infection in France. J Int Med Res 2021;49:3000605211021278. [PMID: 34162264 DOI: 10.1177/03000605211021278] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Venugopal AA, Riederer K, Patel SM, Szpunar S, Jahamy H, Valenti S, Shemes SP, Khatib R, Johnson LB. Lack of association of outcomes with treatment duration and microbiologic susceptibility data in Clostridium difficile infections in a non-NAP1/BI/027 setting. Scand J Infect Dis 2012;44:243-9. [PMID: 22077148 DOI: 10.3109/00365548.2011.631029] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
16 Garvey MI, Bradley CW, Wilkinson MAC, Holden E. Can a toxin gene NAAT be used to predict toxin EIA and the severity of Clostridium difficile infection? Antimicrob Resist Infect Control 2017;6:127. [PMID: 29270290 DOI: 10.1186/s13756-017-0283-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
17 Rätsep M, Kõljalg S, Sepp E, Smidt I, Truusalu K, Songisepp E, Stsepetova J, Naaber P, Mikelsaar RH, Mikelsaar M. A combination of the probiotic and prebiotic product can prevent the germination of Clostridium difficile spores and infection. Anaerobe 2017;47:94-103. [PMID: 28465256 DOI: 10.1016/j.anaerobe.2017.03.019] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
18 Shayto RH, Abou Mrad R, Sharara AI. Use of rifaximin in gastrointestinal and liver diseases. World J Gastroenterol 2016; 22(29): 6638-6651 [PMID: 27547007 DOI: 10.3748/wjg.v22.i29.6638] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
19 Bouza E, Rodríguez-Créixems M, Alcalá L, Marín M, De Egea V, Braojos F, Muñoz P, Reigadas E. Is Clostridium difficile infection an increasingly common severe disease in adult intensive care units? A 10-year experience. J Crit Care 2015;30:543-9. [PMID: 25791766 DOI: 10.1016/j.jcrc.2015.02.011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
20 Hecker MT, Son AH, Alhmidi H, Wilson BM, Wiest PM, Donskey CJ. Efficacy of a stewardship intervention focused on reducing unnecessary use of non-Clostridioides difficile antibiotics in patients with Clostridioides difficile infection. Infect Control Hosp Epidemiol 2020;41:216-8. [PMID: 31843033 DOI: 10.1017/ice.2019.346] [Reference Citation Analysis]
21 Curtin BF, Zarbalian Y, Flasar MH, Rosenvinge EV. Clostridium difficile-associated disease: Adherence with current guidelines at a tertiary medical center. World J Gastroenterol 2013; 19(46): 8647-8651 [PMID: 24379582 DOI: 10.3748/wjg.v19.i46.8647] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
22 Maclaren R, Kassel LE, Kiser TH, Fish DN. Proton pump inhibitors and histamine-2 receptor antagonists in the intensive care setting: focus on therapeutic and adverse events. Expert Opinion on Drug Safety 2014;14:269-80. [DOI: 10.1517/14740338.2015.986456] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
23 Greig J. Fidaxomicin in the Treatment of Clostridium difficile-Associated Diarrhoea. Clinical Drug Investigation 2013;33:93-4. [DOI: 10.1007/s40261-012-0044-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
24 Kociolek LK, Palac HL, Patel SJ, Shulman ST, Gerding DN. Risk Factors for Recurrent Clostridium difficile Infection in Children: A Nested Case-Control Study. J Pediatr 2015;167:384-9. [PMID: 26001313 DOI: 10.1016/j.jpeds.2015.04.052] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
25 Chen KT, Stephens DJ, Anderson E, Acton R, Saltzman D, Hess DJ. Clostridium difficile infection in the pediatric surgery population. J Pediatr Surg 2012;47:1385-9. [PMID: 22813801 DOI: 10.1016/j.jpedsurg.2011.12.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
26 Killeen S, Martin ST, Hyland J, O' Connell PR, Winter DC. Clostridium difficile enteritis: a new role for an old foe. Surgeon 2014;12:256-62. [PMID: 24618362 DOI: 10.1016/j.surge.2014.01.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
27 Pellissery AJ, Vinayamohan PG, Kuttappan DA, Mishra N, Fragomeni BO, Maas K, Mooyottu S, Venkitanarayanan K. Protective Effect of Baicalin against Clostridioides difficile Infection in Mice. Antibiotics (Basel) 2021;10:926. [PMID: 34438975 DOI: 10.3390/antibiotics10080926] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Konijeti GG, Sauk J, Shrime MG, Gupta M, Ananthakrishnan AN. Cost-effectiveness of competing strategies for management of recurrent Clostridium difficile infection: a decision analysis. Clin Infect Dis 2014;58:1507-14. [PMID: 24692533 DOI: 10.1093/cid/ciu128] [Cited by in Crossref: 100] [Cited by in F6Publishing: 96] [Article Influence: 12.5] [Reference Citation Analysis]
29 Mullane KM, Gorbach S. Fidaxomicin: first-in-class macrocyclic antibiotic. Expert Rev Anti Infect Ther. 2011;9:767-777. [PMID: 21810048 DOI: 10.1586/eri.11.53] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 3.2] [Reference Citation Analysis]
30 Bartoletti M, Tedeschi S, Pascale R, Raumer L, Maraolo AE, Palmiero G, Tumietto F, Cristini F, Ambretti S, Giannella M, Lewis RE, Viale P. Differences in the rate of carbapenem-resistant Enterobacteriaceae colonisation or Clostridium difficile infection following frontline treatment with tigecycline vs. meropenem for intra-abdominal infections. Int J Antimicrob Agents 2018;51:516-21. [PMID: 29410250 DOI: 10.1016/j.ijantimicag.2018.01.010] [Reference Citation Analysis]
31 Chia JH, Lai HC, Su LH, Kuo AJ, Wu TL. Molecular epidemiology of Clostridium difficile at a medical center in Taiwan: persistence of genetically clustering of A⁻B⁺ isolates and increase of A⁺B⁺ isolates. PLoS One 2013;8:e75471. [PMID: 24116048 DOI: 10.1371/journal.pone.0075471] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
32 Nayak SU, Griffiss JM, Blumer J, O'Riordan MA, Gray W, McKenzie R, Jurao RA, An AT, Le M, Bell SJ, Ochsner UA, Jarvis TC, Janjic N, Zenilman JM. Safety, Tolerability, Systemic Exposure, and Metabolism of CRS3123, a Methionyl-tRNA Synthetase Inhibitor Developed for Treatment of Clostridium difficile, in a Phase 1 Study. Antimicrob Agents Chemother 2017;61:e02760-16. [PMID: 28584140 DOI: 10.1128/AAC.02760-16] [Cited by in Crossref: 29] [Cited by in F6Publishing: 17] [Article Influence: 5.8] [Reference Citation Analysis]
33 Vaishnavi C. Clostridium difficile infection: clinical spectrum and approach to management. Indian J Gastroenterol 2011;30:245-54. [DOI: 10.1007/s12664-011-0148-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
34 Murray BE, Arias CA, Nannini EC. Glycopeptides (Vancomycin and Teicoplanin), Streptogramins (Quinupristin-Dalfopristin), Lipopeptides (Daptomycin), and Lipoglycopeptides (Telavancin). Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Elsevier; 2015. pp. 377-400.e4. [DOI: 10.1016/b978-1-4557-4801-3.00030-8] [Cited by in Crossref: 5] [Article Influence: 0.7] [Reference Citation Analysis]
35 Toro DH, Amaral-mojica KM, Rocha-rodriguez R, Gutierrez-nuñez J. An Innovative Severity Score Index for Clostridium difficile Infection: A Prospective Study. Infectious Diseases in Clinical Practice 2011;19:336-9. [DOI: 10.1097/ipc.0b013e31821895a8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 0.9] [Reference Citation Analysis]
36 Louh IK, Greendyke WG, Hermann EA, Davidson KW, Falzon L, Vawdrey DK, Shaffer JA, Calfee DP, Furuya EY, Ting HH. Clostridium Difficile Infection in Acute Care Hospitals: Systematic Review and Best Practices for Prevention. Infect Control Hosp Epidemiol 2017;38:476-82. [PMID: 28300019 DOI: 10.1017/ice.2016.324] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 8.0] [Reference Citation Analysis]
37 Sämann C, Coya E, Knochel P. Full Functionalization of the Imidazole Scaffold by Selective Metalation and Sulfoxide/Magnesium Exchange. Angew Chem Int Ed 2014;53:1430-4. [DOI: 10.1002/anie.201309217] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
38 Polage CR, Turner NA. Uncovering the Harms of Treating Clostridioides difficile Colonization. mSphere 2021;6:e01296-20. [PMID: 33441413 DOI: 10.1128/mSphere.01296-20] [Reference Citation Analysis]
39 Zacharioudakis IM, Zervou FN, Pliakos EE, Ziakas PD, Mylonakis E. Colonization With Toxinogenic C. difficile Upon Hospital Admission, and Risk of Infection: A Systematic Review and Meta-Analysis. American Journal of Gastroenterology 2015;110:381-90. [DOI: 10.1038/ajg.2015.22] [Cited by in Crossref: 127] [Cited by in F6Publishing: 110] [Article Influence: 18.1] [Reference Citation Analysis]
40 Golan Y, Epstein L. Safety and efficacy of fidaxomicin in the treatment of Clostridium difficile-associated diarrhea. Therap Adv Gastroenterol 2012;5:395-402. [PMID: 23152733 DOI: 10.1177/1756283X12461294] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
41 Polage CR, Turkiewicz JV, Cohen SH. The never-ending struggle with laboratory testing for Clostridium difficile infection. J Comp Eff Res 2016;5:113-6. [PMID: 26930504 DOI: 10.2217/cer-2016-0001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
42 Ollech JE, Shen NT, Crawford CV, Ringel Y. Use of probiotics in prevention and treatment of patients with Clostridium difficile infection. Best Pract Res Clin Gastroenterol 2016;30:111-8. [PMID: 27048902 DOI: 10.1016/j.bpg.2016.01.002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
43 Rogers DS, Kundrapu S, Sunkesula VC, Donskey CJ. Comparison of perirectal versus rectal swabs for detection of asymptomatic carriers of toxigenic Clostridium difficile. J Clin Microbiol 2013;51:3421-2. [PMID: 23926162 DOI: 10.1128/JCM.01418-13] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
44 Li Y, Shen B. Evaluating pouch problems. Gastroenterol Clin North Am 2012;41:355-78. [PMID: 22500523 DOI: 10.1016/j.gtc.2012.01.013] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
45 Gilligan PH. Contemporary approaches for the laboratory diagnosis of Clostridium difficile infections. Seminars in Colon and Rectal Surgery 2014;25:137-42. [DOI: 10.1053/j.scrs.2014.05.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
46 Masic I, Koluder-Cimic N, Ahmetagic S, Baljic R. On the occasion of the 4th congress of infectiologists of bosnia and herzegovina with international participation. Mater Sociomed 2012;24:20-31. [PMID: 24493992 DOI: 10.5455/msm.2012.24.s20-s31] [Reference Citation Analysis]
47 Kundrapu S, Sunkesula VC, Jury LA, Sethi AK, Donskey CJ. Utility of perirectal swab specimens for diagnosis of Clostridium difficile infection. Clin Infect Dis. 2012;55:1527-1530. [PMID: 22911648 DOI: 10.1093/cid/cis707] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 4.2] [Reference Citation Analysis]
48 Schwenk HT, Graham DA, Sharma TS, Sandora TJ. Vancomycin Use for Pediatric Clostridium difficile Infection Is Increasing and Associated with Specific Patient Characteristics. Antimicrob Agents Chemother 2013;57:4307-13. [PMID: 23796942 DOI: 10.1128/AAC.00661-13] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
49 Jump RL, Olds DM, Seifi N, Kypriotakis G, Jury LA, Peron EP, Hirsch AA, Drawz PE, Watts B, Bonomo RA, Donskey CJ. Effective antimicrobial stewardship in a long-term care facility through an infectious disease consultation service: keeping a LID on antibiotic use. Infect Control Hosp Epidemiol 2012;33:1185-92. [PMID: 23143354 DOI: 10.1086/668429] [Cited by in Crossref: 83] [Cited by in F6Publishing: 81] [Article Influence: 8.3] [Reference Citation Analysis]
50 Thanissery R, Zeng D, Doyle RG, Theriot CM. A Small Molecule-Screening Pipeline to Evaluate the Therapeutic Potential of 2-Aminoimidazole Molecules Against Clostridium difficile. Front Microbiol 2018;9:1206. [PMID: 29928268 DOI: 10.3389/fmicb.2018.01206] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
51 Park KS, Ki CS, Lee NY. Isolation and Identification of Clostridium difficile Using ChromID C. difficile Medium Combined With Gram Staining and PRO Disc Testing: A Proposal for a Simple Culture Process. Ann Lab Med 2015;35:404-9. [PMID: 26131411 DOI: 10.3343/alm.2015.35.4.404] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
52 Pakyz AL, Ozcan YA. Use of Data Envelopment Analysis to Quantify Opportunities for Antibacterial Targets for Reduction of Health Care–Associated Clostridium difficile Infection. Am J Med Qual 2013;29:437-44. [DOI: 10.1177/1062860613502520] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
53 Johnson S, Louie TJ, Gerding DN, Cornely OA, Chasan-Taber S, Fitts D, Gelone SP, Broom C, Davidson DM; Polymer Alternative for CDI Treatment (PACT) investigators. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clin Infect Dis. 2014;59:345-354. [PMID: 24799326 DOI: 10.1093/cid/ciu313] [Cited by in Crossref: 298] [Cited by in F6Publishing: 251] [Article Influence: 37.3] [Reference Citation Analysis]
54 Cruz-rodríguez NC, Hernández-garcía R, Salinas-caballero AG, Pérez-rodríguez E, Garza-gonzález E, Camacho-ortiz A. The effect of pharmacy restriction of clindamycin on Clostridium difficile infection rates in an orthopedics ward. American Journal of Infection Control 2014;42:e71-3. [DOI: 10.1016/j.ajic.2014.02.018] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
55 Thai H, Guerron AD, Bencsath KP, Liu X, Loor M. Fulminant Clostridium difficile enteritis causing abdominal compartment syndrome. Surg Infect (Larchmt) 2014;15:821-5. [PMID: 24824419 DOI: 10.1089/sur.2013.026] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
56 Wei C, Wen-En L, Yang-Ming L, Shan L, Yi-Ming Z. Diagnostic accuracy of loop-mediated isothermal amplification in detection of Clostridium difficile in stool samples: a meta-analysis. Arch Med Sci 2015;11:927-36. [PMID: 26528332 DOI: 10.5114/aoms.2015.54846] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
57 Smith AD, Foss ED, Zhang I, Hastie JL, Giordano NP, Gasparyan L, VinhNguyen LP, Schubert AM, Prasad D, McMichael HL, Sun J, Beger RD, Simonyan V, Cowley SC, Carlson PE Jr. Microbiota of MR1 deficient mice confer resistance against Clostridium difficile infection. PLoS One 2019;14:e0223025. [PMID: 31560732 DOI: 10.1371/journal.pone.0223025] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
58 Nagaraja A, Visintainer P, Haas JP, Menz J, Wormser GP, Montecalvo MA. Clostridium difficile infections before and during use of ultraviolet disinfection. Am J Infect Control 2015;43:940-5. [PMID: 26159499 DOI: 10.1016/j.ajic.2015.05.003] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 5.6] [Reference Citation Analysis]
59 Akahoshi Y, Kimura S, Nakano H, Harada N, Kameda K, Ugai T, Wada H, Yamasaki R, Ishihara Y, Kawamura K, Sakamoto K, Ashizawa M, Sato M, Terasako-Saito K, Nakasone H, Kikuchi M, Yamazaki R, Kanda J, Kako S, Nishida J, Kanda Y. Significance of a positive Clostridium difficile toxin test after hematopoietic stem cell transplantation. Clin Transplant 2016;30:703-8. [PMID: 27019071 DOI: 10.1111/ctr.12737] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
60 Igarashi Y, Tashiro S, Enoki Y, Taguchi K, Matsumoto K, Ohge H, Suzuki H, Nakamura A, Mori N, Morinaga Y, Yamagishi Y, Yoshizawa S, Yanagihara K, Mikamo H, Kunishima H. Oral vancomycin versus metronidazole for the treatment of Clostridioides difficile infection: Meta-analysis of randomized controlled trials. J Infect Chemother 2018;24:907-14. [PMID: 30170735 DOI: 10.1016/j.jiac.2018.08.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
61 Tsutsumi LS, Owusu YB, Hurdle JG, Sun D. Progress in the discovery of treatments for C. difficile infection: A clinical and medicinal chemistry review. Curr Top Med Chem 2014;14:152-75. [PMID: 24236721 DOI: 10.2174/1568026613666131113154753] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
62 Baumgartner LJ, Brown L, Geier C. Hypersensitivity Reaction Following Administration of Low-Dose Oral Vancomycin for the Treatment of Clostridium difficile in a Patient With Normal Renal Function. J Pharm Pract 2017;30:650-2. [PMID: 27630210 DOI: 10.1177/0897190016668437] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
63 Matsuda K, Hashiguchi Y, Tsukamoto M, Ohno K, Okada Y, Yagi T, Fukushima Y, Horiuchi A, Shimada R, Ozawa T, Hayama T, Tsuchiya T, Tamura J, Iinuma H, Nozawa K, Sasajima Y, Kondo F. A case report of successful management of fulminant Clostridium difficile colitis post-ileostomy reversal with administration of vancomycin through a transverse colostomy. Surg Case Rep 2019;5:181. [PMID: 31776700 DOI: 10.1186/s40792-019-0744-0] [Reference Citation Analysis]
64 Martínez-Meléndez A, Camacho-Ortiz A, Morfin-Otero R, Maldonado-Garza HJ, Villarreal-Treviño L, Garza-González E. Current knowledge on the laboratory diagnosis of Clostridium difficile infection. World J Gastroenterol 2017; 23(9): 1552-1567 [PMID: 28321156 DOI: 10.3748/wjg.v23.i9.1552] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 22] [Article Influence: 6.4] [Reference Citation Analysis]
65 King RN, Lager SL. Incidence of Clostridium difficile infections in patients receiving antimicrobial and acid-suppression therapy. Pharmacotherapy. 2011;31:642-648. [PMID: 21923450 DOI: 10.1592/phco.31.7.642] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
66 Hink T, Burnham CA, Dubberke ER. A systematic evaluation of methods to optimize culture-based recovery of Clostridium difficile from stool specimens. Anaerobe 2013;19:39-43. [PMID: 23247066 DOI: 10.1016/j.anaerobe.2012.12.001] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 4.6] [Reference Citation Analysis]
67 Hota SS, Doll M, Bearman G. Preventing Clostridioides difficile infection in hospitals: what is the endgame? BMJ Qual Saf 2020;29:157-60. [PMID: 31582570 DOI: 10.1136/bmjqs-2019-009953] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
68 Cole SA, Stahl TJ. Persistent and Recurrent Clostridium difficile Colitis. Clin Colon Rectal Surg 2015;28:65-9. [PMID: 26034401 DOI: 10.1055/s-0035-1547333] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
69 Lomeli BK, Galbraith H, Schettler J, Saviolakis GA, El-Amin W, Osborn B, Ravel J, Hazleton K, Lozupone CA, Evans RJ, Bell SJ, Ochsner UA, Jarvis TC, Baqar S, Janjic N. Multiple-Ascending-Dose Phase 1 Clinical Study of the Safety, Tolerability, and Pharmacokinetics of CRS3123, a Narrow-Spectrum Agent with Minimal Disruption of Normal Gut Microbiota. Antimicrob Agents Chemother 2019;64:e01395-19. [PMID: 31685472 DOI: 10.1128/AAC.01395-19] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
70 Rutala WA, Gergen MF, Weber DJ. Efficacy of different cleaning and disinfection methods against Clostridium difficile spores: importance of physical removal versus sporicidal inactivation. Infect Control Hosp Epidemiol 2012;33:1255-8. [PMID: 23143366 DOI: 10.1086/668434] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 4.7] [Reference Citation Analysis]
71 Babady NE. Hospital-Associated Infections. Microbiol Spectr 2016;4. [PMID: 27337459 DOI: 10.1128/microbiolspec.DMIH2-0003-2015] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 2.6] [Reference Citation Analysis]
72 Evans ME, Simbartl LA, Kralovic SM, Jain R, Roselle GA. Clostridium difficile Infections in Veterans Health Administration Acute Care Facilities. Infect Control Hosp Epidemiol 2014;35:1037-42. [DOI: 10.1086/677151] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
73 Lee-Tsai YL, Luna-Santiago R, Demichelis-Gómez R, Ponce-de-León A, Ochoa-Hein E, Tamez-Torres KM, Bourlon MT, Bourlon C. Determining the risk factors associated with the development of Clostridium difficile infection in patients with hematological diseases. Blood Res 2019;54:120-4. [PMID: 31309090 DOI: 10.5045/br.2019.54.2.120] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
74 Fehér C, Mensa J. A Comparison of Current Guidelines of Five International Societies on Clostridium difficile Infection Management. Infect Dis Ther 2016;5:207-30. [PMID: 27470257 DOI: 10.1007/s40121-016-0122-1] [Cited by in Crossref: 30] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
75 Vuotto C, Moura I, Barbanti F, Donelli G, Spigaglia P. Subinhibitory concentrations of metronidazole increase biofilm formation in Clostridium difficile strains. Pathog Dis 2016;74:ftv114. [PMID: 26656887 DOI: 10.1093/femspd/ftv114] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 4.1] [Reference Citation Analysis]
76 Ramai D, Zakhia K, Ofosu A, Ofori E, Reddy M. Fecal microbiota transplantation: donor relation, fresh or frozen, delivery methods, cost-effectiveness. Ann Gastroenterol 2019;32:30-8. [PMID: 30598589 DOI: 10.20524/aog.2018.0328] [Cited by in Crossref: 11] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
77 Jiang ZD, Jenq RR, Ajami NJ, Petrosino JF, Alexander AA, Ke S, Iqbal T, DuPont AW, Muldrew K, Shi Y, Peterson C, Do KA, DuPont HL. Safety and preliminary efficacy of orally administered lyophilized fecal microbiota product compared with frozen product given by enema for recurrent Clostridium difficile infection: A randomized clinical trial. PLoS One 2018;13:e0205064. [PMID: 30388112 DOI: 10.1371/journal.pone.0205064] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 9.0] [Reference Citation Analysis]
78 Nosotti M, Tarsia P, Morlacchi LC. Infections after lung transplantation. J Thorac Dis 2018;10:3849-68. [PMID: 30069386 DOI: 10.21037/jtd.2018.05.204] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
79 Ziakas PD, Zacharioudakis IM, Zervou FN, Grigoras C, Pliakos EE, Mylonakis E. Asymptomatic carriers of toxigenic C. difficile in long-term care facilities: a meta-analysis of prevalence and risk factors. PLoS One 2015;10:e0117195. [PMID: 25707002 DOI: 10.1371/journal.pone.0117195] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 6.3] [Reference Citation Analysis]
80 Shen WJ, Deshpande A, Hevener KE, Endres BT, Garey KW, Palmer KL, Hurdle JG. Constitutive expression of the cryptic vanGCd operon promotes vancomycin resistance in Clostridioides difficile clinical isolates. J Antimicrob Chemother 2020;75:859-67. [PMID: 31873741 DOI: 10.1093/jac/dkz513] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
81 Britt NS, Steed ME, Potter EM, Clough LA. Tigecycline for the Treatment of Severe and Severe Complicated Clostridium difficile Infection. Infect Dis Ther 2014;3:321-31. [PMID: 25466443 DOI: 10.1007/s40121-014-0050-x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 3.9] [Reference Citation Analysis]
82 Bhansali SG, Mullane K, Ting LS, Leeds JA, Dabovic K, Praestgaard J, Pertel P. Pharmacokinetics of LFF571 and vancomycin in patients with moderate Clostridium difficile infections. Antimicrob Agents Chemother 2015;59:1441-5. [PMID: 25534724 DOI: 10.1128/AAC.04252-14] [Cited by in Crossref: 22] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
83 Neuendorf M, Guadarrama-Gonzalez R, Lamik B, MacKenzie CR. A prospective study of two isothermal amplification assays compared with real-time PCR, CCNA and toxigenic culture for the diagnosis of Clostridium difficile infection. BMC Microbiol. 2016;16:19. [PMID: 26868647 DOI: 10.1186/s12866-016-0635-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
84 Sammons JS, Toltzis P. Recent trends in the epidemiology and treatment of C. difficile infection in children. Curr Opin Pediatr 2013;25:116-21. [PMID: 23241874 DOI: 10.1097/MOP.0b013e32835bf6c0] [Cited by in Crossref: 25] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
85 Thabit AK, Nicolau DP. Lack of Correlation between Bristol Stool Scale and Quantitative Bacterial Load in Clostridium difficile Infection. Infect Dis (Auckl) 2015;8:1-4. [PMID: 25780339 DOI: 10.4137/IDRT.S23079] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
86 Oman Evans Ii M, Starley B, Galagan JC, Yabes JM, Evans S, Salama JJ. Tea and Recurrent Clostridium difficile Infection. Gastroenterol Res Pract 2016;2016:4514687. [PMID: 27651790 DOI: 10.1155/2016/4514687] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
87 Boone JH, Goodykoontz M, Rhodes SJ, Price K, Smith J, Gearhart KN, Carman RJ, Kerkering TM, Wilkins TD, Lyerly DM. Clostridium difficile prevalence rates in a large healthcare system stratified according to patient population, age, gender, and specimen consistency. Eur J Clin Microbiol Infect Dis 2012;31:1551-9. [PMID: 22167256 DOI: 10.1007/s10096-011-1477-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
88 Ohnishi K, Ainoda Y, Imamura A, Iwabuchi S, Okuda M, Nakano T; Japanese Association for Infectious Disease/Japanese Society of Chemotherapy., JAID/JSC Guide to Clinical Management of Infectious Disease/Guideline-preparing Committee., Intestinal Infections Working Group (WG). JAID/JSC Guidelines for Infection Treatment 2015-Intestinal infections. J Infect Chemother 2018;24:1-17. [PMID: 28986191 DOI: 10.1016/j.jiac.2017.09.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
89 Ciricillo J, Haslam D, Blum S, Kim M, Liu C, Paulsen G, Courter J, Danziger-isakov L. Frequency and risks associated with Clostridium difficile -associated diarrhea after pediatric solid organ transplantation: a single-center retrospective review. Transpl Infect Dis 2016;18:706-13. [DOI: 10.1111/tid.12584] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 3.2] [Reference Citation Analysis]
90 Mcquade R, Roxas B, Viswanathan V, Vedantam G. Clostridium difficile clinical isolates exhibit variable susceptibility and proteome alterations upon exposure to mammalian cationic antimicrobial peptides. Anaerobe 2012;18:614-20. [DOI: 10.1016/j.anaerobe.2012.09.004] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
91 Deshpande A, Pasupuleti V, Thota P, Pant C, Rolston DD, Sferra TJ, Hernandez AV, Donskey CJ. Community-associated Clostridium difficile infection and antibiotics: a meta-analysis. J Antimicrob Chemother 2013;68:1951-61. [PMID: 23620467 DOI: 10.1093/jac/dkt129] [Cited by in Crossref: 241] [Cited by in F6Publishing: 196] [Article Influence: 26.8] [Reference Citation Analysis]
92 Martin JSH, Monaghan TM, Wilcox MH. Clostridium difficile infection: epidemiology, diagnosis and understanding transmission. Nat Rev Gastroenterol Hepatol 2016;13:206-16. [DOI: 10.1038/nrgastro.2016.25] [Cited by in Crossref: 166] [Cited by in F6Publishing: 144] [Article Influence: 27.7] [Reference Citation Analysis]
93 Emmadi R, Boonyaratanakornkit JB, Selvarangan R, Shyamala V, Zimmer BL, Williams L, Bryant B, Schutzbank T, Schoonmaker MM, Amos Wilson JA, Hall L, Pancholi P, Bernard K. Molecular methods and platforms for infectious diseases testing a review of FDA-approved and cleared assays. J Mol Diagn 2011;13:583-604. [PMID: 21871973 DOI: 10.1016/j.jmoldx.2011.05.011] [Cited by in Crossref: 66] [Cited by in F6Publishing: 49] [Article Influence: 6.0] [Reference Citation Analysis]
94 Cecil JA. Clostridium difficile: Changing Epidemiology, Treatment and Infection Prevention Measures. Curr Infect Dis Rep. 2012;14:612-619. [PMID: 23054932 DOI: 10.1007/s11908-012-0298-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
95 Park JH, Romero FA, Taur Y, Sadelain M, Brentjens RJ, Hohl TM, Seo SK. Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells. Clin Infect Dis 2018;67:533-40. [PMID: 29481659 DOI: 10.1093/cid/ciy152] [Cited by in Crossref: 85] [Cited by in F6Publishing: 80] [Article Influence: 28.3] [Reference Citation Analysis]
96 Akiyama S, Yamada A, Komaki Y, Komaki F, Micic D, Sakuraba A. Efficacy and Safety of Monoclonal Antibodies Against Clostridioides difficile Toxins for Prevention of Recurrent Clostridioides difficile Infection: A Systematic Review and Meta-Analysis. J Clin Gastroenterol 2021;55:43-51. [PMID: 32053529 DOI: 10.1097/MCG.0000000000001330] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
97 Wallace BD, Wang H, Lane KT, Scott JE, Orans J, Koo JS, Venkatesh M, Jobin C, Yeh LA, Mani S. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science. 2010;330:831-835. [PMID: 21051639 DOI: 10.1126/science.1191175] [Cited by in Crossref: 509] [Cited by in F6Publishing: 476] [Article Influence: 42.4] [Reference Citation Analysis]
98 Moreno Camacho A, Ruiz Camps I. [Nosocomial infection in patients receiving a solid organ transplant or haematopoietic stem cell transplant]. Enferm Infecc Microbiol Clin 2014;32:386-95. [PMID: 24950613 DOI: 10.1016/j.eimc.2014.05.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
99 Welch HK, Nagel JL, Patel TS, Gandhi TN, Chen B, De Leon J, Chenoweth CE, Washer LL, Rao K, Eschenauer GA. Effect of an antimicrobial stewardship intervention on outcomes for patients with Clostridium difficile infection. Am J Infect Control 2016;44:1539-43. [PMID: 27592160 DOI: 10.1016/j.ajic.2016.05.027] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
100 Dubberke ER, Gerding DN, Kelly CP, Garey KW, Rahav G, Mosley A, Tipping R, Dorr MB. Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of Clostridioides (Clostridium) difficile Infection. Open Forum Infect Dis 2020;7:ofaa157. [PMID: 32523972 DOI: 10.1093/ofid/ofaa157] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
101 Tartof SY, Yu KC, Wei R, Tseng HF, Jacobsen SJ, Rieg GK. Incidence of Polymerase Chain Reaction–Diagnosed Clostridium difficile in a Large High-Risk Cohort, 2011-2012. Mayo Clinic Proceedings 2014;89:1229-38. [DOI: 10.1016/j.mayocp.2014.04.027] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
102 Reigadas E, Muñoz-Pacheco P, Vázquez-Cuesta S, Alcalá L, Marín M, Martin A, Bouza E. Rifaximin-resistant Clostridium difficile strains isolated from symptomatic patients. Anaerobe 2017;48:269-72. [PMID: 28988773 DOI: 10.1016/j.anaerobe.2017.10.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
103 Calderón-Romero P, Castro-Córdova P, Reyes-Ramírez R, Milano-Céspedes M, Guerrero-Araya E, Pizarro-Guajardo M, Olguín-Araneda V, Gil F, Paredes-Sabja D. Clostridium difficile exosporium cysteine-rich proteins are essential for the morphogenesis of the exosporium layer, spore resistance, and affect C. difficile pathogenesis. PLoS Pathog 2018;14:e1007199. [PMID: 30089172 DOI: 10.1371/journal.ppat.1007199] [Cited by in Crossref: 36] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
104 Ulrich RJ, Santhosh K, Mogle JA, Young VB, Rao K. Is Clostridium difficile infection a risk factor for subsequent bloodstream infection? Anaerobe 2017;48:27-33. [PMID: 28669864 DOI: 10.1016/j.anaerobe.2017.06.020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
105 Stallmach A, Katzer K, Reuken P. [Non-severe Clostridioides difficile Infection: Are the data adequate to give up metronidazole?]. Z Gastroenterol 2020;58:778-84. [PMID: 32785914 DOI: 10.1055/a-1190-5735] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
106 Varier RU, Biltaji E, Smith KJ, Roberts MS, Jensen MK, LaFleur J, Nelson RE. Cost-effectiveness analysis of treatment strategies for initial Clostridium difficile infection. Clin Microbiol Infect 2014;20:1343-51. [PMID: 25366338 DOI: 10.1111/1469-0691.12805] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 4.3] [Reference Citation Analysis]
107 Osman MF, Askari R. Infection control in the intensive care unit. Surg Clin North Am 2014;94:1175-94. [PMID: 25440118 DOI: 10.1016/j.suc.2014.08.011] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
108 Hooper MH, Kelly UM, Marik PE. An overview of the diagnosis and management of Clostridium difficile infection. Hosp Pract (1995) 2012;40:119-29. [PMID: 22406887 DOI: 10.3810/hp.2012.02.952] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
109 Younas M, Royer J, Weissman SB, Waites KS, Dash S, Rac H, Bookstaver PB, Justo JA, Bell L, Maki A, Al-hasan MN. Burden of community-associated Clostridioides difficile infection in southeastern United States: a population-based study. Infection 2020;48:129-32. [DOI: 10.1007/s15010-019-01368-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
110 Rao K, Berland D, Young C, Walk ST, Newton DW. The nose knows not: poor predictive value of stool sample odor for detection of Clostridium difficile. Clin Infect Dis. 2013;56:615-616. [PMID: 23166192 DOI: 10.1093/cid/cis974] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
111 Hoffman PS, Bruce AM, Olekhnovich I, Warren CA, Burgess SL, Hontecillas R, Viladomiu M, Bassaganya-Riera J, Guerrant RL, Macdonald TL. Preclinical studies of amixicile, a systemic therapeutic developed for treatment of Clostridium difficile infections that also shows efficacy against Helicobacter pylori. Antimicrob Agents Chemother 2014;58:4703-12. [PMID: 24890599 DOI: 10.1128/AAC.03112-14] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
112 Senok AC, Aldosari KM, Alowaisheq RA, Abid OA, Alsuhaibani KA, Khan MA, Somily AM. Detection of clostridium difficile antigen and toxin in stool specimens: Comparison of the C. difficile quik chek complete enzyme immunoassay and GeneXpert C. difficile polymerase chain reaction assay. Saudi J Gastroenterol 2017;23:259-62. [PMID: 28721981 DOI: 10.4103/sjg.SJG_80_17] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
113 Jarrad AM, Blaskovich MAT, Lyras D, Cooper MA. Clostridium difficile Infection: Current and Emerging Therapeutics. Curr Treat Options Infect Dis 2015;7:317-34. [DOI: 10.1007/s40506-015-0062-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
114 Matthaiou DK, Delga D, Daganou M, Koutsoukou A, Karabela N, Mandragos KE, Kalogeropoulou E, Dimopoulos G. Characteristics, risk factors and outcomes of Clostridium difficile infections in Greek Intensive Care Units. Intensive Crit Care Nurs 2019;53:73-8. [PMID: 30979531 DOI: 10.1016/j.iccn.2019.03.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
115 Tariq R, Singh S, Gupta A, Pardi DS, Khanna S. Association of Gastric Acid Suppression With Recurrent Clostridium difficile Infection: A Systematic Review and Meta-analysis. JAMA Intern Med 2017;177:784-91. [PMID: 28346595 DOI: 10.1001/jamainternmed.2017.0212] [Cited by in Crossref: 73] [Cited by in F6Publishing: 63] [Article Influence: 14.6] [Reference Citation Analysis]
116 Arikan T, Unal A, Kocyigit I, Yurci A, Oymak O. Peritoneal dialysis-related peritonitis triggered by Clostridium difficile-associated colitis. Perit Dial Int 2014;34:139-40. [PMID: 24525609 DOI: 10.3747/pdi.2012.00177] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
117 Blanco N, Walk S, Malani AN, Rickard A, Benn M, Eisenberg M, Zhang M, Foxman B. Clostridium difficile shows no trade-off between toxin and spore production within the human host. J Med Microbiol 2018;67:631-40. [PMID: 29533173 DOI: 10.1099/jmm.0.000719] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
118 Delate T, Albrecht G, Won K, Jackson A. Ambulatory-treated Clostridium difficile infection: a comparison of community-acquired vs . nosocomial infection. Epidemiol Infect 2015;143:1225-35. [DOI: 10.1017/s0950268814001800] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
119 Jiménez A, Araya R, Paniagua D, Camacho-mora Z, Du T, Golding G, Leandro-astorga G, Rodríguez C, Quesada-gómez C. Molecular epidemiology and antimicrobial resistance of Clostridium difficile in a national geriatric hospital in Costa Rica. Journal of Hospital Infection 2018;99:475-80. [DOI: 10.1016/j.jhin.2018.03.027] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
120 Ofosu A. Clostridium difficile infection: a review of current and emerging therapies. Ann Gastroenterol 2016;29:147-54. [PMID: 27065726 DOI: 10.20524/aog.2016.0006] [Cited by in Crossref: 61] [Cited by in F6Publishing: 55] [Article Influence: 10.2] [Reference Citation Analysis]
121 Allegretti JR, Allegretti AS, Phelps E, Xu H, Kassam Z, Fischer M. Asymptomatic Clostridium difficile carriage rate post-fecal microbiota transplant is low: a prospective clinical and stool assessment. Clin Microbiol Infect 2018;24:780.e1-3. [PMID: 29104169 DOI: 10.1016/j.cmi.2017.10.022] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
122 Kwon JH, Reske KA, Hink T, Burnham CA, Dubberke ER. Evaluation of Correlation between Pretest Probability for Clostridium difficile Infection and Clostridium difficile Enzyme Immunoassay Results. J Clin Microbiol 2017;55:596-605. [PMID: 27927930 DOI: 10.1128/JCM.02126-16] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
123 Leibowitz J, Soma VL, Rosen L, Ginocchio CC, Rubin LG. Similar Proportions of Stool Specimens From Hospitalized Children With and Without Diarrhea Test Positive for Clostridium difficile. Pediatric Infectious Disease Journal 2015;34:261-6. [DOI: 10.1097/inf.0000000000000556] [Cited by in Crossref: 31] [Cited by in F6Publishing: 15] [Article Influence: 4.4] [Reference Citation Analysis]
124 Riley TV, Kimura T. The Epidemiology of Clostridium difficile Infection in Japan: A Systematic Review. Infect Dis Ther 2018;7:39-70. [PMID: 29441500 DOI: 10.1007/s40121-018-0186-1] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
125 Olanipekun TO, Salemi JL, Mejia de Grubb MC, Gonzalez SJ, Zoorob RJ. Clostridium difficile infection in patients hospitalized with type 2 diabetes mellitus and its impact on morbidity, mortality, and the costs of inpatient care. Diabetes Res Clin Pract 2016;116:68-79. [PMID: 27321318 DOI: 10.1016/j.diabres.2016.04.021] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
126 Com G, Cetin N, O'Brien CE. Complicated Clostridium difficile colitis in children with cystic fibrosis: association with gastric acid suppression? J Cyst Fibros 2014;13:37-42. [PMID: 23993432 DOI: 10.1016/j.jcf.2013.08.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
127 Bartlett JG. Clostridium difficile Infection. Infect Dis Clin North Am 2017;31:489-95. [PMID: 28779831 DOI: 10.1016/j.idc.2017.05.012] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
128 Lee JT, Whitson BA, Kelly RF, D'Cunha J, Dunitz JM, Hertz MI, Shumway SJ. Calcineurin inhibitors and Clostridium difficile infection in adult lung transplant recipients: the effect of cyclosporine versus tacrolimus. J Surg Res 2013;184:599-604. [PMID: 23566442 DOI: 10.1016/j.jss.2013.03.041] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
129 Li C, Duan J, Liu S, Meng X, Fu C, Zeng C, Wu A. Assessing the risk and disease burden of Clostridium difficile infection among patients with hospital-acquired pneumonia at a University Hospital in Central China. Infection 2017;45:621-8. [PMID: 28497295 DOI: 10.1007/s15010-017-1024-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
130 Rezaizadeh H, Olson E. Specific GI Microbial Infections. In: Wu GY, editor. Pocket Handbook of GI Pharmacotherapeutics. Cham: Springer International Publishing; 2016. pp. 75-109. [DOI: 10.1007/978-3-319-33317-5_7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
131 Marín M, Martín A, Alcalá L, Cercenado E, Iglesias C, Reigadas E, Bouza E. Clostridium difficile isolates with high linezolid MICs harbor the multiresistance gene cfr. Antimicrob Agents Chemother 2015;59:586-9. [PMID: 25385106 DOI: 10.1128/AAC.04082-14] [Cited by in Crossref: 43] [Cited by in F6Publishing: 21] [Article Influence: 5.4] [Reference Citation Analysis]
132 Crobach MJ, Planche T, Eckert C, Barbut F, Terveer EM, Dekkers OM, Wilcox MH, Kuijper EJ. European Society of Clinical Microbiology and Infectious Diseases: update of the diagnostic guidance document for Clostridium difficile infection. Clin Microbiol Infect. 2016;22 Suppl 4:S63-S81. [PMID: 27460910 DOI: 10.1016/j.cmi.2016.03.010] [Cited by in Crossref: 290] [Cited by in F6Publishing: 226] [Article Influence: 48.3] [Reference Citation Analysis]
133 Tang C, Cui L, Xu Y, Xie L, Sun P, Liu C, Xia W, Liu G. The incidence and drug resistance of Clostridium difficile infection in Mainland China: a systematic review and meta-analysis. Sci Rep 2016;6:37865. [PMID: 27897206 DOI: 10.1038/srep37865] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
134 Enoch DA, Murray-Thomas T, Adomakoh N, Dedman D, Georgopali A, Francis NA, Karas A. Risk of complications and mortality following recurrent and non-recurrent Clostridioides difficile infection: a retrospective observational database study in England. J Hosp Infect 2020;106:793-803. [PMID: 32987118 DOI: 10.1016/j.jhin.2020.09.025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
135 Lee JT, Kelly RF, Hertz MI, Dunitz JM, Shumway SJ. Clostridium difficile infection increases mortality risk in lung transplant recipients. The Journal of Heart and Lung Transplantation 2013;32:1020-6. [DOI: 10.1016/j.healun.2013.06.012] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 2.9] [Reference Citation Analysis]
136 Nicholson MR, Crews JD, Starke JR, Jiang ZD, DuPont H, Edwards K. Recurrent Clostridium difficile Infection in Children: Patient Risk Factors and Markers of Intestinal Inflammation. Pediatr Infect Dis J 2017;36:379-83. [PMID: 27977555 DOI: 10.1097/INF.0000000000001450] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
137 White MB, Rajagopalan S, Yoshikawa TT. Infectious Diarrhea: Norovirus and Clostridium difficile in Older Adults. Clin Geriatr Med 2016;32:509-22. [PMID: 27394020 DOI: 10.1016/j.cger.2016.02.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
138 Lalande V, Barrault L, Wadel S, Eckert C, Petit JC, Barbut F. Evaluation of a loop-mediated isothermal amplification assay for diagnosis of Clostridium difficile infections. J Clin Microbiol 2011;49:2714-6. [PMID: 21525213 DOI: 10.1128/JCM.01835-10] [Cited by in Crossref: 70] [Cited by in F6Publishing: 31] [Article Influence: 6.4] [Reference Citation Analysis]
139 Tan X, Verrall A, Jureen R, Riley T, Collins D, Lin R, Balm M, Chan D, Tambyah P. The emergence of community-onset Clostridium difficile infection in a tertiary hospital in Singapore: A cause for concern. International Journal of Antimicrobial Agents 2014;43:47-51. [DOI: 10.1016/j.ijantimicag.2013.09.011] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
140 Shively NR, Buehrle DJ, Clancy CJ, Decker BK. Prevalence of Inappropriate Antibiotic Prescribing in Primary Care Clinics within a Veterans Affairs Health Care System. Antimicrob Agents Chemother 2018;62:e00337-18. [PMID: 29967028 DOI: 10.1128/AAC.00337-18] [Cited by in Crossref: 38] [Cited by in F6Publishing: 21] [Article Influence: 9.5] [Reference Citation Analysis]
141 Hueth KD, Jackson BR, Schmidt RL. An Audit of Repeat Testing at an Academic Medical Center. American Journal of Clinical Pathology 2018;150:27-33. [DOI: 10.1093/ajcp/aqy020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
142 Klatte JM, Myers AL, Livingston RA, Jackson MA. Pediatric physicians' knowledge, attitudes, and beliefs regarding Clostridium difficile-associated disease prevention, testing, and treatment. American Journal of Infection Control 2012;40:577. [DOI: 10.1016/j.ajic.2012.05.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
143 Falcone M, Russo A, Iraci F, Carfagna P, Goldoni P, Vullo V, Venditti M. Risk Factors and Outcomes for Bloodstream Infections Secondary to Clostridium difficile Infection. Antimicrob Agents Chemother 2016;60:252-7. [PMID: 26482315 DOI: 10.1128/AAC.01927-15] [Cited by in Crossref: 26] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
144 Anthouard R, DiRita VJ. Chemical biology applied to the study of bacterial pathogens. Infect Immun 2015;83:456-69. [PMID: 25404026 DOI: 10.1128/IAI.02021-14] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
145 Aljafel NA, Al-Shaikhy HH, Alnahdi MA, Thabit AK. Incidence of Clostridioides difficile infection at a Saudi Tertiary Academic Medical Center and compliance with IDSA/SHEA, ACG, and ESCMID guidelines for treatment over a 10-year period. J Infect Public Health 2020;13:1156-60. [PMID: 32276872 DOI: 10.1016/j.jiph.2020.03.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
146 Rauseo AM, Olsen MA, Reske KA, Dubberke ER. Strategies to prevent adverse outcomes following Clostridioides difficile infection in the elderly. Expert Rev Anti Infect Ther 2020;18:203-17. [PMID: 31976779 DOI: 10.1080/14787210.2020.1717950] [Reference Citation Analysis]
147 Goldstein EJ, Johnson S, Maziade PJ, McFarland LV, Trick W, Dresser L, Millette M, Mazloum H, Low DE. Pathway to Prevention of Nosocomial Clostridium difficile Infection. Clin Infect Dis. 2015;60 Suppl 2:S148-S158. [PMID: 25922401 DOI: 10.1093/cid/civ142] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 7.5] [Reference Citation Analysis]
148 Kim YK, Song SA, Lee JN, Oh M, Jo KM, Kim HJ, Lee JH, Park J, Jang HJ, Kim HK, Kiem S. Clinical factors predicting persistent carriage of Klebsiella pneumoniae carbapenemase-producing carbapenem-resistant Enterobacteriaceae among patients with known carriage. J Hosp Infect 2018;99:405-12. [PMID: 29111353 DOI: 10.1016/j.jhin.2017.10.017] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
149 Appaneal HJ, Caffrey AR, Beganovic M, Avramovic S, LaPlante KL. Predictors of Clostridioides difficile recurrence across a national cohort of veterans in outpatient, acute, and long-term care settings. Am J Health Syst Pharm 2019;76:581-90. [PMID: 31361830 DOI: 10.1093/ajhp/zxz032] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
150 Ong GK, Reidy TJ, Huk MD, Lane FR. Clostridium difficile colitis: A clinical review. Am J Surg 2017;213:565-71. [PMID: 28131326 DOI: 10.1016/j.amjsurg.2016.10.035] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 5.6] [Reference Citation Analysis]
151 Li Y, Figler RA, Kolling G, Bracken TC, Rieger J, Stevenson RW, Linden J, Guerrant RL, Warren CA. Adenosine A2A receptor activation reduces recurrence and mortality from Clostridium difficile infection in mice following vancomycin treatment. BMC Infect Dis 2012;12:342. [PMID: 23217055 DOI: 10.1186/1471-2334-12-342] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
152 Appaneal HJ, Caffrey AR, Beganovic M, Avramovic S, LaPlante KL. Predictors of Mortality Among a National Cohort of Veterans With Recurrent Clostridium difficile Infection. Open Forum Infect Dis 2018;5:ofy175. [PMID: 30327788 DOI: 10.1093/ofid/ofy175] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
153 Daniel A, Rapose A. The evaluation of Clostridium difficile infection (CDI) in a community hospital. J Infect Public Health 2015;8:155-60. [PMID: 25301221 DOI: 10.1016/j.jiph.2014.08.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
154 Alhazzani W, Guyatt G, Marshall JC, Hall R, Muscedere J, Lauzier F, Thabane L, Alshahrani M, English SW, Arabi YM, Deane AM, Karachi T, Rochwerg B, Finfer S, Daneman N, Zytaruk N, Heel-Ansdell D, Cook D, Of OB. Re-evaluating the Inhibition of Stress Erosions (REVISE): a protocol for pilot randomized controlled trial. Ann Saudi Med 2016;36:427-33. [PMID: 27920416 DOI: 10.5144/0256-4947.2016.427] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
155 Landry ML, Ferguson D, Topal J. Comparison of Simplexa universal direct PCR with cytotoxicity assay for diagnosis of Clostridium difficile infection: performance, cost, and correlation with disease. J Clin Microbiol 2014;52:275-80. [PMID: 24226924 DOI: 10.1128/JCM.02545-13] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
156 Hill DM, Sinclair SE, Hickerson WL. Rational Selection and Use of Antimicrobials in Patients with Burn Injuries. Clinics in Plastic Surgery 2017;44:521-34. [DOI: 10.1016/j.cps.2017.02.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
157 Thabit AK, Nicolau DP. Impact of vancomycin faecal concentrations on clinical and microbiological outcomes in Clostridium difficile infection. Int J Antimicrob Agents 2015;46:205-8. [PMID: 26055927 DOI: 10.1016/j.ijantimicag.2015.03.016] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
158 Seah D, De Cruz P. Review article: the practical management of acute severe ulcerative colitis. Aliment Pharmacol Ther. 2016;43:482-513. [PMID: 26725569 DOI: 10.1111/apt.13491] [Cited by in Crossref: 50] [Cited by in F6Publishing: 42] [Article Influence: 8.3] [Reference Citation Analysis]
159 Taur Y, Pamer EG. Harnessing microbiota to kill a pathogen: Fixing the microbiota to treat Clostridium difficile infections. Nat Med 2014;20:246-7. [PMID: 24603796 DOI: 10.1038/nm.3492] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
160 Boyanton BL Jr, Sural P, Loomis CR, Pesta C, Gonzalez-Krellwitz L, Robinson-Dunn B, Riska P. Loop-mediated isothermal amplification compared to real-time PCR and enzyme immunoassay for toxigenic Clostridium difficile detection. J Clin Microbiol 2012;50:640-5. [PMID: 22189114 DOI: 10.1128/JCM.01014-11] [Cited by in Crossref: 43] [Cited by in F6Publishing: 18] [Article Influence: 3.9] [Reference Citation Analysis]
161 Paparella AS, Aboulache BL, Harijan RK, Potts KS, Tyler PC, Schramm VL. Inhibition of Clostridium difficile TcdA and TcdB toxins with transition state analogues. Nat Commun 2021;12:6285. [PMID: 34725358 DOI: 10.1038/s41467-021-26580-6] [Reference Citation Analysis]
162 Leeds JA. Antibacterials Developed to Target a Single Organism: Mechanisms and Frequencies of Reduced Susceptibility to the Novel Anti-Clostridium difficile Compounds Fidaxomicin and LFF571. Cold Spring Harb Perspect Med 2016;6:a025445. [PMID: 26834162 DOI: 10.1101/cshperspect.a025445] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
163 Korayem GB, Eljaaly K, Matthias KR, Zangeneh TT. Oral Vancomycin Monotherapy Versus Combination Therapy in Solid Organ Transplant Recipients With Uncomplicated Clostridium difficile Infection: A Retrospective Cohort Study. Transplant Proc 2018;50:137-41. [PMID: 29407296 DOI: 10.1016/j.transproceed.2017.11.016] [Reference Citation Analysis]
164 Thiemann S, Smit N, Strowig T. Antibiotics and the Intestinal Microbiome : Individual Responses, Resilience of the Ecosystem, and the Susceptibility to Infections. Curr Top Microbiol Immunol 2016;398:123-46. [PMID: 27738912 DOI: 10.1007/82_2016_504] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
165 Drekonja DM. Vancomycin “telephone”. Clin Infect Dis. 2011;53:211-212. [PMID: 21690636 DOI: 10.1093/cid/cir311] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
166 Eckert C, Jones G, Barbut F. Diagnosis of Clostridium difficile infection: the molecular approach. Future Microbiol. 2013;8:1587-1598. [PMID: 24266358 DOI: 10.2217/fmb.13.129] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
167 Vaishnavi C, Gupta PK, Sharma M, Kochhar R. Pancreatic disease patients are at higher risk for Clostridium difficile infection compared to those with other co-morbidities. Gut Pathog 2019;11:17. [PMID: 31044014 DOI: 10.1186/s13099-019-0300-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
168 Neemann K, Freifeld A. Clostridium difficile –Associated Diarrhea in the Oncology Patient. JOP 2017;13:25-30. [DOI: 10.1200/jop.2016.018614] [Cited by in Crossref: 22] [Cited by in F6Publishing: 7] [Article Influence: 4.4] [Reference Citation Analysis]
169 Kundrapu S, Sunkesula V, Jury LA, Sitzlar BM, Donskey CJ. Daily disinfection of high-touch surfaces in isolation rooms to reduce contamination of healthcare workers' hands. Infect Control Hosp Epidemiol 2012;33:1039-42. [PMID: 22961024 DOI: 10.1086/667730] [Cited by in Crossref: 62] [Cited by in F6Publishing: 58] [Article Influence: 6.2] [Reference Citation Analysis]
170 Carignan A, Poulin S, Martin P, Labbé AC, Valiquette L, Al-Bachari H, Montpetit LP, Pépin J. Efficacy of Secondary Prophylaxis With Vancomycin for Preventing Recurrent Clostridium difficile Infections. Am J Gastroenterol 2016;111:1834-40. [PMID: 27619835 DOI: 10.1038/ajg.2016.417] [Cited by in Crossref: 54] [Cited by in F6Publishing: 46] [Article Influence: 9.0] [Reference Citation Analysis]
171 Karyal C, Hughes J, Kelly ML, Luckett JC, Kaye PV, Cockayne A, Minton NP, Griffin R. Colonisation Factor CD0873, an Attractive Oral Vaccine Candidate against Clostridioides difficile. Microorganisms 2021;9:306. [PMID: 33540694 DOI: 10.3390/microorganisms9020306] [Reference Citation Analysis]
172 Bader MS, Hawboldt J, Main C, Mertz D, Loeb M, Farrell A, Joyce J. Review of high dose vancomycin in the treatment of Clostridioides difficile infection. Infect Dis (Lond) 2020;52:847-57. [PMID: 32744879 DOI: 10.1080/23744235.2020.1800080] [Reference Citation Analysis]
173 Vickers RJ, Tillotson G, Goldstein EJ, Citron DM, Garey KW, Wilcox MH. Ridinilazole: a novel therapy for Clostridium difficile infection. Int J Antimicrob Agents 2016;48:137-43. [PMID: 27283730 DOI: 10.1016/j.ijantimicag.2016.04.026] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 4.2] [Reference Citation Analysis]
174 Hong KL, Maher E, Williams RM, Sooter LJ. In Vitro Selection of a Single-Stranded DNA Molecular Recognition Element against Clostridium difficile Toxin B and Sensitive Detection in Human Fecal Matter. J Nucleic Acids 2015;2015:808495. [PMID: 25734010 DOI: 10.1155/2015/808495] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
175 Yang Z, Huang Q, Qin J, Zhang X, Jian Y, Lv H, Liu Q, Li M. Molecular Epidemiology and Risk Factors of Clostridium difficile ST81 Infection in a Teaching Hospital in Eastern China. Front Cell Infect Microbiol 2020;10:578098. [PMID: 33425775 DOI: 10.3389/fcimb.2020.578098] [Reference Citation Analysis]
176 Murphy CR, Avery TR, Dubberke ER, Huang SS. Frequent hospital readmissions for Clostridium difficile infection and the impact on estimates of hospital-associated C. difficile burden. Infect Control Hosp Epidemiol 2012;33:20-8. [PMID: 22173518 DOI: 10.1086/663209] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 4.0] [Reference Citation Analysis]
177 Vernaya M, McAdam J, Hampton MD. Effectiveness of probiotics in reducing the incidence of Clostridium difficile-associated diarrhea in elderly patients: a systematic review. JBI Database System Rev Implement Rep 2017;15:140-64. [PMID: 28085732 DOI: 10.11124/JBISRIR-2016-003234] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 5.3] [Reference Citation Analysis]
178 Leal J, Ronksley P, Henderson EA, Conly J, Manns B. Predictors of mortality and length of stay in patients with hospital-acquired Clostridioides difficile infection: a population-based study in Alberta, Canada. J Hosp Infect 2019;103:85-91. [PMID: 30991081 DOI: 10.1016/j.jhin.2019.04.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
179 Markovic S, Jankovic M, Kalaba A, Zogovic B, Sreckovic SS. Infliximab Rescue in Acute Severe Ulcerative Colitis Complicated by Clostridium Difficile Infection: A Case Series. Cureus 2021;13:e19019. [PMID: 34824934 DOI: 10.7759/cureus.19019] [Reference Citation Analysis]
180 Weissman JS, Coyle W. Stool transplants: ready for prime time? Curr Gastroenterol Rep. 2012;14:313-316. [PMID: 22585070 DOI: 10.1007/s11894-012-0263-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
181 Sammons JS, Localio R, Xiao R, Coffin SE, Zaoutis T. Clostridium difficile infection is associated with increased risk of death and prolonged hospitalization in children. Clin Infect Dis 2013;57:1-8. [PMID: 23532470 DOI: 10.1093/cid/cit155] [Cited by in Crossref: 74] [Cited by in F6Publishing: 65] [Article Influence: 8.2] [Reference Citation Analysis]
182 Novak A, Spigaglia P, Barbanti F, Goic-Barisic I, Tonkic M. First clinical and microbiological characterization of Clostridium difficile infection in a Croatian University Hospital. Anaerobe. 2014;30:18-23. [PMID: 25079669 DOI: 10.1016/j.anaerobe.2014.07.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
183 Choi B, Wong KK, Dunn AN, Butler R, Fraser TG, Procop GW, Richter SS, Isada CM, Deshpande A. Real-time polymerase chain reaction (PCR) cycle threshold and Clostridioides difficile infection outcomes. Infect Control Hosp Epidemiol 2021;:1-7. [PMID: 33622425 DOI: 10.1017/ice.2020.1405] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
184 Eyre DW, Cule ML, Griffiths D, Crook DW, Peto TE, Walker AS, Wilson DJ. Detection of mixed infection from bacterial whole genome sequence data allows assessment of its role in Clostridium difficile transmission. PLoS Comput Biol 2013;9:e1003059. [PMID: 23658511 DOI: 10.1371/journal.pcbi.1003059] [Cited by in Crossref: 64] [Cited by in F6Publishing: 54] [Article Influence: 7.1] [Reference Citation Analysis]
185 Mittal C, Hassan S, Arshad S, Jeepalyam S, Bruni S, Miceli M, Jacobsen G, Abouljoud M, Bajjoka I, Ramesh M, Alangaden G. Clostridium difficile Infection in Liver Transplant Recipients: A Retrospective Study of Rates, Risk Factors and Outcomes: Clostridium difficile Infections in Liver Transplant Recipients. American Journal of Transplantation 2014;14:1901-7. [DOI: 10.1111/ajt.12798] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
186 Archbald-Pannone LR, McMurry TL, Guerrant RL, Warren CA. Delirium and other clinical factors with Clostridium difficile infection that predict mortality in hospitalized patients. Am J Infect Control 2015;43:690-3. [PMID: 25920706 DOI: 10.1016/j.ajic.2015.03.017] [Cited by in F6Publishing: 14] [Reference Citation Analysis]
187 Li Z, Lee K, Rajyaguru U, Jones CH, Janezic S, Rupnik M, Anderson AS, Liberator P. Ribotype Classification of Clostridioides difficile Isolates Is Not Predictive of the Amino Acid Sequence Diversity of the Toxin Virulence Factors TcdA and TcdB. Front Microbiol 2020;11:1310. [PMID: 32636819 DOI: 10.3389/fmicb.2020.01310] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
188 Barker A, Duster M, Valentine S, Archbald-Pannone L, Guerrant R, Safdar N. Probiotics for Clostridium difficile infection in adults (PICO): Study protocol for a double-blind, randomized controlled trial. Contemp Clin Trials 2015;44:26-32. [PMID: 26210512 DOI: 10.1016/j.cct.2015.07.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
189 Hikone M, Ainoda Y, Tago S, Fujita T, Hirai Y, Takeuchi K, Totsuka K. Risk factors for recurrent hospital-acquired Clostridium difficile infection in a Japanese university hospital. Clin Exp Gastroenterol 2015;8:191-6. [PMID: 26203270 DOI: 10.2147/CEG.S85007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.1] [Reference Citation Analysis]
190 Wenisch JM, Schmid D, Kuo HW, Allerberger F, Michl V, Tesik P, Tucek G, Laferl H, Wenisch C. Prospective observational study comparing three different treatment regimes in patients with Clostridium difficile infection. Antimicrob Agents Chemother 2012;56:1974-8. [PMID: 22252830 DOI: 10.1128/AAC.05647-11] [Cited by in Crossref: 26] [Cited by in F6Publishing: 7] [Article Influence: 2.6] [Reference Citation Analysis]
191 Brown AWW, Wilson RB. Clostridium difficile colitis and zoonotic origins-a narrative review. Gastroenterol Rep (Oxf) 2018;6:157-66. [PMID: 30151199 DOI: 10.1093/gastro/goy016] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
192 Callejas-díaz A, Gea-banacloche JC. Clostridium difficile: Deleterious Impact on Hematopoietic Stem Cell Transplantation. Curr Hematol Malig Rep 2014;9:85-90. [DOI: 10.1007/s11899-013-0193-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
193 Boseiwaqa LV, Foster NF, Thean SK, Squire MM, Riley TV, Carson KC. Comparison of ChromID C. difficile agar and cycloserine-cefoxitin-fructose agar for the recovery of Clostridium difficile. Pathology 2013;45:495-500. [DOI: 10.1097/pat.0b013e3283632680] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
194 Singh S, Khardori NM. Intra-abdominal and Pelvic Emergencies. Medical Clinics of North America 2012;96:1171-91. [DOI: 10.1016/j.mcna.2012.09.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
195 Chapin K. Discrepancies in testing recommendations for Clostridium difficile infection: updated review favors amplification test systems. Expert Review of Molecular Diagnostics 2014;12:223-6. [DOI: 10.1586/erm.12.13] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
196 Early CR, Park JM, Dorsch MP, Pogue KT, Hanigan SM. Effect of metronidazole use on tacrolimus concentrations in transplant patients treated for Clostridium difficile. Transpl Infect Dis 2016;18:714-20. [PMID: 27501504 DOI: 10.1111/tid.12588] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
197 Bamba S, Nishida A, Imaeda H, Inatomi O, Sasaki M, Sugimoto M, Andoh A. Successful treatment by fecal microbiota transplantation for Japanese patients with refractory Clostridium difficile infection: A prospective case series. J Microbiol Immunol Infect 2019;52:663-6. [PMID: 29158082 DOI: 10.1016/j.jmii.2017.08.027] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
198 Halaweish I, Alam HB. Surgical Management of Severe Colitis in the Intensive Care Unit. J Intensive Care Med 2015;30:451-61. [DOI: 10.1177/0885066614534941] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
199 Shin JH, Warren CA. Collateral damage during antibiotic treatment of C. difficile infection in the aged host: Insights into why recurrent disease happens. Gut Microbes 2017;8:504-10. [PMID: 28453386 DOI: 10.1080/19490976.2017.1323616] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
200 Khanafer N, Voirin N, Barbut F, Kuijper E, Vanhems P. Hospital management of Clostridium difficile infection: a review of the literature. Journal of Hospital Infection 2015;90:91-101. [DOI: 10.1016/j.jhin.2015.02.015] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
201 Cunha BA, Sessa J, Blum S. Enhanced Efficacy of High Dose Oral Vancomycin Therapy in Clostridium difficile Diarrhea for Hospitalized Adults Not Responsive to Conventional Oral Vancomycin Therapy: Antibiotic Stewardship Implications. J Clin Med 2018;7:E75. [PMID: 29642570 DOI: 10.3390/jcm7040075] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
202 Hammond DA, Hughes CA, Painter JT, Pennick RE, Chatterjee K, Boye B, Meena N. Impact of Targeted Educational Interventions on Clostridium difficile Infection Treatment in Critically Ill Adults. Hosp Pharm 2016;51:901-6. [PMID: 28057949 DOI: 10.1310/hpj5111-901] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
203 Guarner J, Kraft CS. Need for clinicopathologic correlation of Clostridium difficile colitis in view of molecular diagnosis. Clin Infect Dis 2012;54:156. [PMID: 22187416 DOI: 10.1093/cid/cir713] [Reference Citation Analysis]
204 Humphries RM, Uslan DZ, Rubin Z. Performance of Clostridium difficile toxin enzyme immunoassay and nucleic acid amplification tests stratified by patient disease severity. J Clin Microbiol 2013;51:869-73. [PMID: 23269736 DOI: 10.1128/JCM.02970-12] [Cited by in Crossref: 73] [Cited by in F6Publishing: 35] [Article Influence: 7.3] [Reference Citation Analysis]
205 Wang S, Deng W, Li F, Chen YE, Wang PU. Blockade of T helper 17 cell function ameliorates recurrent Clostridioides difficile infection in mice. Acta Biochim Biophys Sin (Shanghai) 2021:gmab107. [PMID: 34379099 DOI: 10.1093/abbs/gmab107] [Reference Citation Analysis]
206 Warren CA, van Opstal EJ, Riggins MS, Li Y, Moore JH, Kolling GL, Guerrant RL, Hoffman PS. Vancomycin treatment's association with delayed intestinal tissue injury, clostridial overgrowth, and recurrence of Clostridium difficile infection in mice. Antimicrob Agents Chemother 2013;57:689-96. [PMID: 23147742 DOI: 10.1128/AAC.00877-12] [Cited by in Crossref: 39] [Cited by in F6Publishing: 29] [Article Influence: 3.9] [Reference Citation Analysis]
207 Abrahamian FM, Talan DA, Krishnadasan A, Citron DM, Paulick AL, Anderson LJ, Goldstein EJ, Moran GJ, Abrahamian F, Moore J, Femling J, Chiang W, Lovecchio F, Jui J, Garg M, Steele M, Sullivan D, Rothman R. Clostridium difficile Infection Among US Emergency Department Patients With Diarrhea and No Vomiting. Annals of Emergency Medicine 2017;70:19-27.e4. [DOI: 10.1016/j.annemergmed.2016.12.013] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
208 Bruminhent J, Cawcutt KA, Thongprayoon C, Petterson TM, Kremers WK, Razonable RR. Epidemiology, risk factors, and outcome of Clostridium difficile infection in heart and heart-lung transplant recipients. Clin Transplant 2017;31. [PMID: 28314071 DOI: 10.1111/ctr.12968] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
209 Reigadas E, Alcalá L, Marín M, Martín A, Iglesias C, Bouza E. Role of binary toxin in the outcome of Clostridium difficile infection in a non-027 ribotype setting. Epidemiol Infect 2016;144:268-73. [PMID: 26119775 DOI: 10.1017/S095026881500148X] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
210 Pop-vicas A, Shaban E, Letourneau C, Pechie A. Empirical Antimicrobial Prescriptions in Patients with Clostridium difficile Infection at Hospital Admission and Impact on Clinical Outcome. Infect Control Hosp Epidemiol 2012;33:1101-6. [DOI: 10.1086/668015] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
211 Bowman KA, Broussard EK, Surawicz CM. Fecal microbiota transplantation: current clinical efficacy and future prospects. Clin Exp Gastroenterol. 2015;8:285-291. [PMID: 26566371 DOI: 10.2147/ceg.s61305] [Cited by in Crossref: 6] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
212 Gabriel V, Grigorian A, Phillips JL, Schubl SD, Barrios C, Pejcinovska M, Won E, Nahmias J. A Propensity Score Analysis of Clostridium difficile Infection among Adult Trauma Patients. Surgical Infections 2018;19:661-6. [DOI: 10.1089/sur.2018.110] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
213 Tieu JD, Williams RJ, Skrepnek GH, Gentry CA. Clinical outcomes of fidaxomicin vs oral vancomycin in recurrent Clostridium difficile infection. J Clin Pharm Ther 2019;44:220-8. [DOI: 10.1111/jcpt.12771] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
214 Hourigan SK, Chirumamilla SR, Ross T, Golub JE, Rabizadeh S, Saeed SA, Elson CO, Kelly CP, Carroll KC, Oliva-Hemker M, Sears C. Clostridium difficile carriage and serum antitoxin responses in children with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:2744-2752. [PMID: 24145927 DOI: 10.1097/01.mib.0000435434.53871.36] [Cited by in Crossref: 48] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
215 Choi HY, Park SY, Kim YA, Yoon TY, Choi JM, Choe BK, Ahn SH, Yoon SJ, Lee YR, Oh IH. The epidemiology and economic burden of Clostridium difficile infection in Korea. Biomed Res Int 2015;2015:510386. [PMID: 25821807 DOI: 10.1155/2015/510386] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
216 Pallis A, Jazayeri J, Ward P, Dimovski K, Svobodova S. Rapid detection of Clostridium difficile toxins from stool samples using real-time multiplex PCR. Journal of Medical Microbiology 2013;62:1350-6. [DOI: 10.1099/jmm.0.058339-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
217 Fakih MG, Greene MT, Kennedy EH, Meddings JA, Krein SL, Olmsted RN, Saint S. Introducing a population-based outcome measure to evaluate the effect of interventions to reduce catheter-associated urinary tract infection. Am J Infect Control 2012;40:359-64. [PMID: 21868133 DOI: 10.1016/j.ajic.2011.05.012] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 3.9] [Reference Citation Analysis]
218 Eyre DW, Walker AS, Wyllie D, Dingle KE, Griffiths D, Finney J, O’Connor L, Vaughan A, Crook DW, Wilcox MH. Predictors of first recurrence of Clostridium difficile infection: implications for initial management. Clin Infect Dis. 2012;55 Suppl 2:S77-S87. [PMID: 22752869 DOI: 10.1093/cid/cis356] [Cited by in Crossref: 139] [Cited by in F6Publishing: 135] [Article Influence: 13.9] [Reference Citation Analysis]
219 Guerrero D, Becker J, Eckstein E, Kundrapu S, Deshpande A, Sethi A, Donskey C. Asymptomatic carriage of toxigenic Clostridium difficile by hospitalized patients. Journal of Hospital Infection 2013;85:155-8. [DOI: 10.1016/j.jhin.2013.07.002] [Cited by in Crossref: 56] [Cited by in F6Publishing: 47] [Article Influence: 6.2] [Reference Citation Analysis]
220 Mamic P, Heidenreich PA, Hedlin H, Tennakoon L, Staudenmayer KL. Hospitalized Patients with Heart Failure and Common Bacterial Infections: A Nationwide Analysis of Concomitant Clostridium Difficile Infection Rates and In-Hospital Mortality. J Card Fail 2016;22:891-900. [PMID: 27317844 DOI: 10.1016/j.cardfail.2016.06.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
221 Tenover FC, Baron EJ, Peterson LR, Persing DH. Laboratory diagnosis of Clostridium difficile infection can molecular amplification methods move us out of uncertainty? J Mol Diagn 2011;13:573-82. [PMID: 21854871 DOI: 10.1016/j.jmoldx.2011.06.001] [Cited by in Crossref: 69] [Cited by in F6Publishing: 61] [Article Influence: 6.3] [Reference Citation Analysis]
222 Shin JH, Chaves-Olarte E, Warren CA. Clostridium difficile Infection. Microbiol Spectr 2016;4. [PMID: 27337475 DOI: 10.1128/microbiolspec.EI10-0007-2015] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
223 Johnson SW, Kanatani M, Humphries RM, Uslan DZ. Clinical impact of switching conventional enzyme immunoassay with nucleic acid amplification test for suspected Clostridium difficile-associated diarrhea. Am J Infect Control 2013;41:373-5. [PMID: 23040489 DOI: 10.1016/j.ajic.2012.04.329] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
224 Kim HH, Kim YS, Han DS, Kim Y, Kim WH, Kim JS, Kim H, Kim H, Park Y, Song HJ, Shin SJ, Yang S, Ye BD, Eun CS, Lee K, Lee SH, Jang B, Jung S, Cheon JH, Choi CH, Huh K; IBD Study Group of the Korean Association for the Study of Intestinal Diseases. Clinical differences in Clostridium difficile infection based on age: A multicenter study. Scandinavian Journal of Infectious Diseases 2013;46:46-51. [DOI: 10.3109/00365548.2013.840918] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
225 Carlson TJ, Gonzales-Luna AJ, Nebo K, Chan HY, Tran NT, Antony S, Lancaster C, Alam MJ, Begum K, Garey KW. Assessment of Kidney Injury as a Severity Criteria for Clostridioides Difficile Infection. Open Forum Infect Dis 2020;7:ofaa476. [PMID: 33209956 DOI: 10.1093/ofid/ofaa476] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
226 Malamood M, Nellis E, Ehrlich AC, Friedenberg FK. Vancomycin Enemas as Adjunctive Therapy for Clostridium difficile Infection. J Clin Med Res 2015;7:422-7. [PMID: 25883704 DOI: 10.14740/jocmr2117w] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
227 Legendre P, Lalande V, Eckert C, Barbut F, Fardet L, Meynard J, Surgers L. Clostridium difficile associated reactive arthritis: Case report and literature review. Anaerobe 2016;38:76-80. [DOI: 10.1016/j.anaerobe.2015.12.011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
228 Wenzler E, Mulugeta SG, Danziger LH. The Antimicrobial Stewardship Approach to Combating Clostridium Difficile. Antibiotics (Basel) 2015;4:198-215. [PMID: 27025621 DOI: 10.3390/antibiotics4020198] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
229 Stuart RL, Marshall C. Clostridium difficile infection: a new threat on our doorstep. Medical Journal of Australia 2011;194:331-2. [DOI: 10.5694/j.1326-5377.2011.tb02998.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
230 Whang DH, Joo SY. Evaluation of the diagnostic performance of the xpert Clostridium difficile assay and its comparison with the toxin A/B enzyme-linked fluorescent assay and in-house real-time PCR assay used for the detection of toxigenic C. difficile. J Clin Lab Anal 2014;28:124-9. [PMID: 24395702 DOI: 10.1002/jcla.21655] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
231 Brown KA, Fisman DN, Moineddin R, Daneman N. The magnitude and duration of Clostridium difficile infection risk associated with antibiotic therapy: a hospital cohort study. PLoS One 2014;9:e105454. [PMID: 25157757 DOI: 10.1371/journal.pone.0105454] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 5.1] [Reference Citation Analysis]
232 Santos CAQ, Rhee Y, Czapka MT, Kazi AS, Proia LA. Make Sure You Have a Safety Net: Updates in the Prevention and Management of Infectious Complications in Stem Cell Transplant Recipients. J Clin Med 2020;9:E865. [PMID: 32245201 DOI: 10.3390/jcm9030865] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
233 Howerton A, Seymour CO, Murugapiran SK, Liao Z, Phan JR, Estrada A, Wagner AJ, Mefferd CC, Hedlund BP, Abel-Santos E. Effect of the Synthetic Bile Salt Analog CamSA on the Hamster Model of Clostridium difficile Infection. Antimicrob Agents Chemother 2018;62:e02251-17. [PMID: 30012758 DOI: 10.1128/AAC.02251-17] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
234 Bartsch SM, Curry SR, Harrison LH, Lee BY. The potential economic value of screening hospital admissions for Clostridium difficile. Eur J Clin Microbiol Infect Dis 2012;31:3163-71. [PMID: 22752150 DOI: 10.1007/s10096-012-1681-z] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 2.7] [Reference Citation Analysis]
235 Vargo CA, Bauer KA, Mangino JE, Johnston JE, Goff DA. An Antimicrobial Stewardship Program's Real-World Experience with Fidaxomicin for Treatment of Clostridium difficile Infection: A Case Series. Pharmacotherapy 2014;34:901-9. [DOI: 10.1002/phar.1451] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
236 Xu X, Luo Y, Chen H, Song X, Bian Q, Wang X, Liang Q, Zhao J, Li C, Song G, Yang J, Sun L, Jiang J, Wang H, Zhu B, Ye G, Chen L, Tang YW, Jin D. Genomic evolution and virulence association of Clostridioides difficile sequence type 37 (ribotype 017) in China. Emerg Microbes Infect 2021;10:1331-45. [PMID: 34125660 DOI: 10.1080/22221751.2021.1943538] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
237 Dubberke ER, Olsen MA, Stwalley D, Kelly CP, Gerding DN, Young-Xu Y, Mahé C. Identification of Medicare Recipients at Highest Risk for Clostridium difficile Infection in the US by Population Attributable Risk Analysis. PLoS One 2016;11:e0146822. [PMID: 26859403 DOI: 10.1371/journal.pone.0146822] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
238 Spinler JK, Ross CL, Savidge TC. Probiotics as adjunctive therapy for preventing Clostridium difficile infection - What are we waiting for? Anaerobe 2016;41:51-7. [PMID: 27180657 DOI: 10.1016/j.anaerobe.2016.05.007] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 4.3] [Reference Citation Analysis]
239 Battaglia CC, Hale K. Hospital-Acquired Infections in Critically Ill Patients With Cancer. J Intensive Care Med 2019;34:523-36. [PMID: 30012057 DOI: 10.1177/0885066618788019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
240 Seekatz AM, Aas J, Gessert CE, Rubin TA, Saman DM, Bakken JS, Young VB. Recovery of the gut microbiome following fecal microbiota transplantation. mBio. 2014;5:e00893-e00814. [PMID: 24939885 DOI: 10.1128/mbio.00893-14] [Cited by in Crossref: 201] [Cited by in F6Publishing: 117] [Article Influence: 25.1] [Reference Citation Analysis]
241 Madden GR, Weinstein RA, Sifri CD. Diagnostic Stewardship for Healthcare-Associated Infections: Opportunities and Challenges to Safely Reduce Test Use. Infect Control Hosp Epidemiol 2018;39:214-8. [PMID: 29331159 DOI: 10.1017/ice.2017.278] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
242 Liu NW, Shatagopam K, Monn MF, Kaimakliotis HZ, Cary C, Boris RS, Mellon MJ, Masterson TA, Foster RS, Gardner TA, Bihrle R, House MG, Koch MO. Risk for Clostridium difficile infection after radical cystectomy for bladder cancer: Analysis of a contemporary series. Urol Oncol 2015;33:503.e17-22. [PMID: 26278363 DOI: 10.1016/j.urolonc.2015.07.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
243 Mergenhagen KA, Wojciechowski AL, Paladino JA. A Review of the Economics of Treating Clostridium difficile Infection. PharmacoEconomics 2014;32:639-50. [DOI: 10.1007/s40273-014-0161-y] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
244 Waltz P, Zuckerbraun B. Novel therapies for severe Clostridium difficile colitis. Curr Opin Crit Care 2016;22:167-73. [PMID: 26771898 DOI: 10.1097/MCC.0000000000000282] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
245 Eyre DW, Cule ML, Wilson DJ, Griffiths D, Vaughan A, O’Connor L, Ip CL, Golubchik T, Batty EM, Finney JM. Diverse sources of C. difficile infection identified on whole-genome sequencing. N Engl J Med. 2013;369:1195-1205. [PMID: 24066741 DOI: 10.1056/nejmoa1216064] [Cited by in Crossref: 442] [Cited by in F6Publishing: 243] [Article Influence: 49.1] [Reference Citation Analysis]
246 Villafuerte Gálvez JA, Kelly CP. Bezlotoxumab: anti-toxin B monoclonal antibody to prevent recurrence of Clostridium difficile infection. Expert Review of Gastroenterology & Hepatology 2017;11:611-22. [DOI: 10.1080/17474124.2017.1344551] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
247 Netland PJ, Brochardt SM, Koo JM, Lo TS, Krenz T. A Retrospective Analysis of Risk Factors and Therapeutic Outcomes for Clostridium difficile Infection. Hosp Pharm 2011;46:336-40. [DOI: 10.1310/hpj4605-336] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
248 Allegretti JR, Allegretti AS, Phelps E, Xu H, Fischer M, Kassam Z. Classifying Fecal Microbiota Transplantation Failure: An Observational Study Examining Timing and Characteristics of Fecal Microbiota Transplantation Failures. Clin Gastroenterol Hepatol 2018;16:1832-3. [PMID: 29104129 DOI: 10.1016/j.cgh.2017.10.031] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
249 Stripling J, Rodriguez M. Current Evidence in Delivery and Therapeutic Uses of Fecal Microbiota Transplantation in Human Diseases-Clostridium difficile Disease and Beyond. Am J Med Sci 2018;356:424-32. [PMID: 30384951 DOI: 10.1016/j.amjms.2018.08.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
250 Rivkin A, Gim S. Rifaximin: new therapeutic indication and future directions. Clin Ther. 2011;33:812-827. [PMID: 21741091 DOI: 10.1016/j.clinthera.2011.06.007] [Cited by in Crossref: 45] [Cited by in F6Publishing: 34] [Article Influence: 4.1] [Reference Citation Analysis]
251 Nicholson MR, Thomsen IP, Slaughter JC, Creech CB, Edwards KM. Novel risk factors for recurrent Clostridium difficile infection in children. J Pediatr Gastroenterol Nutr. 2015;60:18-22. [PMID: 25199038 DOI: 10.1097/mpg.0000000000000553] [Cited by in Crossref: 43] [Cited by in F6Publishing: 23] [Article Influence: 6.1] [Reference Citation Analysis]
252 Singhal T, Shah S, Tejam R, Thakkar P. Incidence, epidemiology and control of Clostridium difficile infection in a tertiary care private hospital in India. Indian J Med Microbiol 2018;36:381-4. [PMID: 30429391 DOI: 10.4103/ijmm.IJMM_18_340] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
253 Guo CLT, Kwong TNY, Mak JWY, Zhang L, Lui GCY, Wong GLH, Ip M, Yu J, Sung JJY, Wu WKK, Wong SH. Trends in Incidence and Clinical Outcomes of Clostridioides difficile Infection, Hong Kong. Emerg Infect Dis 2021;27. [PMID: 34812719 DOI: 10.3201/eid2712.203769] [Reference Citation Analysis]
254 Sammons JS, Toltzis P. Pitfalls in Diagnosis of Pediatric Clostridium difficile Infection. Infect Dis Clin North Am 2015;29:465-76. [PMID: 26188603 DOI: 10.1016/j.idc.2015.05.010] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
255 Khanna S, Pardi DS, Aronson SL, Kammer PP, Orenstein R, St Sauver JL, Harmsen WS, Zinsmeister AR. The epidemiology of community-acquired Clostridium difficile infection: a population-based study. Am J Gastroenterol. 2012;107:89-95. [PMID: 22108454 DOI: 10.1038/ajg.2011.398] [Cited by in Crossref: 395] [Cited by in F6Publishing: 362] [Article Influence: 35.9] [Reference Citation Analysis]
256 Sizemore EN, Rivas KM, Valdes J, Caballero J. Enteral vancomycin and probiotic use for methicillin-resistant Staphylococcus aureus antibiotic-associated diarrhoea. BMJ Case Rep 2012;2012:bcr2012006366. [PMID: 22847566 DOI: 10.1136/bcr-2012-006366] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
257 Issa MM, Nejem RM, Shanab AMA, Shaat NT. Kinetic spectrophotometric H-point standard addition method for the simultaneous determination of diloxanide furoate and metronidazole in binary mixtures and biological fluids. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy 2013;114:592-8. [DOI: 10.1016/j.saa.2013.05.062] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
258 Murad YM, Perez J, Ybazeta G, Mavin S, Lefebvre S, Weese JS, Rousseau J, Diaz-Mitoma F, Nokhbeh R. False Negative Results in Clostridium difficile Testing. BMC Infect Dis 2016;16:430. [PMID: 27543102 DOI: 10.1186/s12879-016-1741-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
259 Kodadek LM, Lipsett PA. Prevention and Treatment of Clostridium difficile Enterocolitis. Adv Surg 2018;52:29-42. [PMID: 30098619 DOI: 10.1016/j.yasu.2018.04.001] [Reference Citation Analysis]
260 Moore JH 2nd, van Opstal E, Kolling GL, Shin JH, Bogatcheva E, Nikonenko B, Einck L, Phipps AJ, Guerrant RL, Protopopova M, Warren CA. Treatment of Clostridium difficile infection using SQ641, a capuramycin analogue, increases post-treatment survival and improves clinical measures of disease in a murine model. J Antimicrob Chemother 2016;71:1300-6. [PMID: 26832756 DOI: 10.1093/jac/dkv479] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
261 Roldan GA, Cui AX, Pollock NR. Assessing the Burden of Clostridium difficile Infection in Low- and Middle-Income Countries. J Clin Microbiol 2018;56:e01747-17. [PMID: 29305541 DOI: 10.1128/JCM.01747-17] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
262 Varkonyi I, Rakoczi E, Misak O, Komaromi E, Kardos L, Lampe Z, Szilvassy Z. Findings of a hospital surveillance-based outcome evaluation study for Clostridium difficile-associated colitis. Clinical Microbiology and Infection 2014;20:1085-90. [DOI: 10.1111/1469-0691.12652] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
263 Tsapepas DS, Martin ST, Miao J, Shah SA, Scheffert J, Fester K, Ma K, Lat A, Egan R, McKeen JT. Clostridium difficile infection, a descriptive analysis of solid organ transplant recipients at a single center. Diagn Microbiol Infect Dis 2015;81:299-304. [PMID: 25586932 DOI: 10.1016/j.diagmicrobio.2014.11.018] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
264 Chung MS, Kim J, Kang JO, Pai H. Impact of malignancy on Clostridium difficile infection. Eur J Clin Microbiol Infect Dis 2016;35:1771-6. [DOI: 10.1007/s10096-016-2725-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
265 Ochsner UA, Katilius E, Janjic N. Detection of Clostridium difficile toxins A, B and binary toxin with slow off-rate modified aptamers. Diagn Microbiol Infect Dis 2013;76:278-85. [PMID: 23680240 DOI: 10.1016/j.diagmicrobio.2013.03.029] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
266 Charilaou P, Devani K, John F, Kanna S, Ahlawat S, Young M, Khanna S, Reddy C. Acute kidney injury impact on inpatient mortality in Clostridium difficile infection: A national propensity-matched study: AKI in Clostridium difficile Infection. Journal of Gastroenterology and Hepatology 2018;33:1227-33. [DOI: 10.1111/jgh.14064] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
267 Garcia RA, Spitzer ED, Kranz B, Barnes S. A national survey of interventions and practices in the prevention of blood culture contamination and associated adverse health care events. American Journal of Infection Control 2018;46:571-6. [DOI: 10.1016/j.ajic.2017.11.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
268 Chiang SR, Lai CC, Ho CH, Chen CM, Chao CM, Wang JJ, Cheng KC. Prolonged Mechanical Ventilation Assistance Interacts Synergistically with Carbapenem for Clostridium difficile Infection in Critically Ill Patients. J Clin Med 2018;7:E224. [PMID: 30127264 DOI: 10.3390/jcm7080224] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
269 Lee JT, Hertz MI, Dunitz JM, Kelly RF, D'Cunha J, Whitson BA, Shumway SJ. The rise of Clostridium difficile infection in lung transplant recipients in the modern era. Clin Transplant 2013;27:303-10. [PMID: 23316931 DOI: 10.1111/ctr.12064] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
270 Soriano MM, Liao S, Danziger LH. Fidaxomicin: a minimally absorbed macrocyclic antibiotic for the treatment of Clostridium difficile infections. Expert Rev Anti Infect Ther 2013;11:767-76. [PMID: 23977933 DOI: 10.1586/14787210.2013.814767] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
271 Portela F, Lago P. Fulminant colitis. Best Practice & Research Clinical Gastroenterology 2013;27:771-82. [DOI: 10.1016/j.bpg.2013.08.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
272 Buckman SA, Turnbull IR, Mazuski JE. Empiric Antibiotics for Sepsis. Surg Infect (Larchmt). 2018;19:147-154. [PMID: 29341844 DOI: 10.1089/sur.2017.282] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
273 Kulaylat AS, Kassam Z, Hollenbeak CS, Stewart DB. A Surgical Clostridium-Associated Risk of Death Score Predicts Mortality After Colectomy for Clostridium difficile. Diseases of the Colon & Rectum 2017;60:1285-90. [DOI: 10.1097/dcr.0000000000000920] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
274 Kucharzik T, Ellul P, Greuter T, Rahier JF, Verstockt B, Abreu C, Albuquerque A, Allocca M, Esteve M, Farraye FA, Gordon H, Karmiris K, Kopylov U, Kirchgesner J, MacMahon E, Magro F, Maaser C, de Ridder L, Taxonera C, Toruner M, Tremblay L, Scharl M, Viget N, Zabana Y, Vavricka S. ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease. J Crohns Colitis 2021;15:879-913. [PMID: 33730753 DOI: 10.1093/ecco-jcc/jjab052] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
275 Andersen KK, Strokappe NM, Hultberg A, Truusalu K, Smidt I, Mikelsaar RH, Mikelsaar M, Verrips T, Hammarström L, Marcotte H. Neutralization of Clostridium difficile Toxin B Mediated by Engineered Lactobacilli That Produce Single-Domain Antibodies. Infect Immun 2016;84:395-406. [PMID: 26573738 DOI: 10.1128/IAI.00870-15] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
276 Korać M, Rupnik M, Nikolić N, Jovanović M, Tošić T, Malinić J, Mitrović N, Marković M, Vujović A, Peruničić S, Bojović K, Djordjević V, Barać A, Milošević I. Clostridioides difficile ribotype distribution in a large teaching hospital in Serbia. Gut Pathog 2020;12:26. [PMID: 32477428 DOI: 10.1186/s13099-020-00364-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
277 Chopra T, Chandrasekar P, Salimnia H, Heilbrun LK, Smith D, Alangaden GJ. Recent epidemiology of Clostridium difficile infection during hematopoietic stem cell transplantation. Clin Transplant. 2011;25:E82-E87. [PMID: 20973823 DOI: 10.1111/j.1399-0012.2010.01331.x] [Cited by in Crossref: 77] [Cited by in F6Publishing: 71] [Article Influence: 6.4] [Reference Citation Analysis]
278 Catanzaro M, Cirone J. Real-time polymerase chain reaction testing for Clostridium difficile reduces isolation time and improves patient management in a small community hospital. American Journal of Infection Control 2012;40:663-6. [DOI: 10.1016/j.ajic.2011.09.005] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 3.2] [Reference Citation Analysis]
279 Kurti Z, Lovasz BD, Mandel MD, Csima Z, Golovics PA, Csako BD, Mohas A, Gönczi L, Gecse KB, Kiss LS, Szathmari M, Lakatos PL. Burden of Clostridium difficile infection between 2010 and 2013: Trends and outcomes from an academic center in Eastern Europe. World J Gastroenterol 2015; 21(21): 6728-6735 [PMID: 26074711 DOI: 10.3748/wjg.v21.i21.6728] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
280 Manian FA, Griesnauer S, Bryant A. Implementation of hospital-wide enhanced terminal cleaning of targeted patient rooms and its impact on endemic Clostridium difficile infection rates. Am J Infect Control 2013;41:537-41. [PMID: 23219675 DOI: 10.1016/j.ajic.2012.06.014] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 4.5] [Reference Citation Analysis]
281 Leuzzi R, Adamo R, Scarselli M. Vaccines against Clostridium difficile. Hum Vaccin Immunother 2014;10:1466-77. [PMID: 24637887 DOI: 10.4161/hv.28428] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 4.6] [Reference Citation Analysis]
282 Shivashankar R, Khanna S, Kammer PP, Harmsen WS, Zinsmeister AR, Baddour LM, Pardi DS. Clinical factors associated with development of severe-complicated Clostridium difficile infection. Clin Gastroenterol Hepatol. 2013;11:1466-1471. [PMID: 23702192 DOI: 10.1016/j.cgh.2013.04.050] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 4.6] [Reference Citation Analysis]
283 Shields K, Araujo-Castillo RV, Theethira TG, Alonso CD, Kelly CP. Recurrent Clostridium difficile infection: From colonization to cure. Anaerobe 2015;34:59-73. [PMID: 25930686 DOI: 10.1016/j.anaerobe.2015.04.012] [Cited by in Crossref: 54] [Cited by in F6Publishing: 52] [Article Influence: 7.7] [Reference Citation Analysis]
284 Hu C, Sunday R, Bruminhent J, Bobik B, Wagner J, Weiss M, Flomenberg P, Wang Z. Investigation of a Clostridium difficile cluster by multilocus sequence typing in a bone marrow transplant unit. American Journal of Infection Control 2014;42:691-3. [DOI: 10.1016/j.ajic.2014.02.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
285 Cook DJ, Johnstone J, Marshall JC, Lauzier F, Thabane L, Mehta S, Dodek PM, McIntyre L, Pagliarello J, Henderson W, Taylor RW, Cartin-Ceba R, Golan E, Herridge M, Wood G, Ovakim D, Karachi T, Surette MG, Bowdish DM, Lamarche D, Verschoor CP, Duan EH, Heels-Ansdell D, Arabi Y, Meade M; PROSPECT Investigators and the Canadian Critical Care Trials Group. Probiotics: Prevention of Severe Pneumonia and Endotracheal Colonization Trial-PROSPECT: a pilot trial. Trials 2016;17:377. [PMID: 27480757 DOI: 10.1186/s13063-016-1495-x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
286 Lanzas C, Dubberke ER, Lu Z, Reske KA, Gröhn YT. Epidemiological model for Clostridium difficile transmission in healthcare settings. Infect Control Hosp Epidemiol 2011;32:553-61. [PMID: 21558767 DOI: 10.1086/660013] [Cited by in Crossref: 68] [Cited by in F6Publishing: 63] [Article Influence: 6.2] [Reference Citation Analysis]
287 Han S, Soylu MC, Kirimli CE, Wu W, Sen B, Joshi SG, Emery CL, Au G, Niu X, Hamilton R, Krevolin K, Shih WH, Shih WY. Rapid, label-free genetic detection of enteropathogens in stool without genetic isolation or amplification. Biosens Bioelectron 2019;130:73-80. [PMID: 30731348 DOI: 10.1016/j.bios.2019.01.025] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
288 Kleger A, Schnell J, Essig A, Wagner M, Bommer M, Seufferlein T, Härter G. Fecal transplant in refractory Clostridium difficile colitis. Dtsch Arztebl Int. 2013;110:108-115. [PMID: 23468820 DOI: 10.3238/arztebl.2013.0108] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
289 Gualtero SM, Abril LA, Camelo N, Sanchez SD, Davila FA, Arias G, Silva E, Bustos IG, Josa DF, Torres IC, Zambrano LC, Pareja MJ. Characteristics of Clostridium difficile infection in a high complexity hospital and report of the circulation of the NAP1/027 hypervirulent strain in Colombia. biomedica 2017;37:466. [DOI: 10.7705/biomedica.v37i4.3244] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
290 Alp S, Akova M. Antibacterial Resistance in Patients with Hematopoietic Stem Cell Transplantation. Mediterr J Hematol Infect Dis 2017;9:e2017002. [PMID: 28101308 DOI: 10.4084/MJHID.2017.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
291 Blocker O, Abdulkadir U, Roberts P. Clostridium difficile-associated diarrhoea in primary joint arthroplasty in Aneurin Bevan University Health Board South. Ann R Coll Surg Engl 2016;98:222-5. [PMID: 26836055 DOI: 10.1308/rcsann.2016.0066] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
292 Sydnor ER, Lenhart A, Trollinger B, Avdic E, Maragakis LL, Carroll KC, Cosgrove SE. Antimicrobial prescribing practices in response to different Clostridium difficile diagnostic methodologies. Infect Control Hosp Epidemiol 2011;32:1133-6. [PMID: 22011545 DOI: 10.1086/662381] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
293 Gerry CJ, Schreiber SL. Chemical probes and drug leads from advances in synthetic planning and methodology. Nat Rev Drug Discov 2018;17:333-52. [PMID: 29651105 DOI: 10.1038/nrd.2018.53] [Cited by in Crossref: 95] [Cited by in F6Publishing: 71] [Article Influence: 23.8] [Reference Citation Analysis]
294 Khanafer N, Vanhems P, Bennia S, Martin-Gaujard G, Juillard L, Rimmelé T, Argaud L, Martin O, Huriaux L, Marcotte G, Hernu R, Floccard B, Cassier P, Group S. Factors Associated with Clostridioides (Clostridium) Difficile Infection and Colonization: Ongoing Prospective Cohort Study in a French University Hospital. Int J Environ Res Public Health 2021;18:7528. [PMID: 34299978 DOI: 10.3390/ijerph18147528] [Reference Citation Analysis]
295 Asensio A, Di Bella S, Lo Vecchio A, Grau S, Hart WM, Isidoro B, Scotto R, Petrosillo N, Watt M, Nazir J. The impact of Clostridium difficile infection on resource use and costs in hospitals in Spain and Italy: a matched cohort study. Int J Infect Dis. 2015;36:31-38. [PMID: 26003403 DOI: 10.1016/j.ijid.2015.05.013] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
296 Shah K, Pass LA, Cox M, Lanham M, Arnold FW. Evaluating contemporary antibiotics as a risk factor for Clostridium difficile infection in surgical trauma patients. J Trauma Acute Care Surg 2012;72:691-5. [PMID: 22491554 DOI: 10.1097/TA.0b013e31823c5637] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
297 Jiang ZD, Hoang LN, Lasco TM, Garey KW, Dupont HL. Physician attitudes toward the use of fecal transplantation for recurrent Clostridium difficile infection in a metropolitan area. Clin Infect Dis 2013;56:1059-60. [PMID: 23223589 DOI: 10.1093/cid/cis1025] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
298 Postma N, Kiers D, Pickkers P. The challenge of Clostridium difficile infection: Overview of clinical manifestations, diagnostic tools and therapeutic options. International Journal of Antimicrobial Agents 2015;46:S47-50. [DOI: 10.1016/j.ijantimicag.2015.11.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
299 Anikst VE, Gaur RL, Schroeder LF, Banaei N. Organism burden, toxin concentration, and lactoferrin concentration do not distinguish between clinically significant and nonsignificant diarrhea in patients with Clostridium difficile. Diagnostic Microbiology and Infectious Disease 2016;84:343-6. [DOI: 10.1016/j.diagmicrobio.2015.11.022] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
300 Barbut F, Le Monnier A, Eckert C. Infections à Clostridium difficile : aspects cliniques épidémiologiques et thérapeutiques. Réanimation 2012;21:373-83. [DOI: 10.1007/s13546-011-0341-4] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
301 Karmali S, Laffin M, de Gara C. CAGS Clinical Practice Committee report: the science of Clostridium difficile and surgery. Can J Surg 2013;56:367-71. [PMID: 24284142 DOI: 10.1503/cjs.018413] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
302 Bakken JS. Staggered and tapered antibiotic withdrawal with administration of kefir for recurrent Clostridium difficile infection. Clin Infect Dis. 2014;59:858-861. [PMID: 24917658 DOI: 10.1093/cid/ciu429] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
303 Su WY, Mercer J, Van Hal SJ, Maley M. Clostridium difficile testing: have we got it right? J Clin Microbiol 2013;51:377-8. [PMID: 23100357 DOI: 10.1128/JCM.02189-12] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
304 Cho S, Spencer E, Hirten R, Grinspan A, Dubinsky MC. Fecal Microbiota Transplant for Recurrent Clostridium difficile Infection in Pediatric Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology & Nutrition 2019;68:343-7. [DOI: 10.1097/mpg.0000000000002172] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
305 Fang WJ, Jing DZ, Luo Y, Fu CY, Zhao P, Qian J, Tian BR, Chen XG, Zheng YL, Zheng Y, Deng J, Zou WH, Feng XR, Liu FL, Mou XZ, Zheng SS. Clostridium difficile carriage in hospitalized cancer patients: a prospective investigation in eastern China. BMC Infect Dis 2014;14:523. [PMID: 25267108 DOI: 10.1186/1471-2334-14-523] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
306 Kachrimanidou M, Tsachouridou O, Ziogas IA, Christaki E, Protonotariou E, Metallidis S, Skoura L, Kuijper E. Clostridium difficile infections in a university hospital in Greece are mainly associated with PCR ribotypes 017 and 126. J Med Microbiol 2017;66:1774-81. [PMID: 29087273 DOI: 10.1099/jmm.0.000623] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
307 Sathyendran V, McAuliffe GN, Swager T, Freeman JT, Taylor SL, Roberts SA. Clostridium difficile as a cause of healthcare-associated diarrhoea among children in Auckland, New Zealand: clinical and molecular epidemiology. Eur J Clin Microbiol Infect Dis. 2014;33:1741-1747. [PMID: 24810967 DOI: 10.1007/s10096-014-2139-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
308 Li Z, Liu X, Zhao J, Xu K, Tian T, Yang J, Qiang C, Shi D, Wei H, Sun S, Cui Q, Li R, Niu Y, Huang B. Comparison of a newly developed binary typing with ribotyping and multilocus sequence typing methods for Clostridium difficile. Journal of Microbiological Methods 2018;147:50-5. [DOI: 10.1016/j.mimet.2018.02.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
309 Hundt AS, Ngam C, Carayon P, Haun N, Safdar N. Work System Barriers and Facilitators to Compliance with Infection Prevention Intervention: Initial Findings Regarding Hand Hygiene from Three Target Roles. Proceedings of the Human Factors and Ergonomics Society Annual Meeting 2016;60:546-50. [DOI: 10.1177/1541931213601126] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
310 Carmo J, Marques S, Chapim I, Túlio MA, Rodrigues JP, Bispo M, Chagas C. Leaping Forward in the Treatment of Clostridium Difficile Infection: Update in 2015. GE Port J Gastroenterol 2015;22:259-67. [PMID: 28868417 DOI: 10.1016/j.jpge.2015.07.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
311 Kulaylat AS, Buonomo EL, Stewart DB. Interest of Eosinophil Count in Bacterial Infections to Predict Antimicrobial Therapy Efficacy-Reply. JAMA Surg 2019;154:464-5. [PMID: 30758488 DOI: 10.1001/jamasurg.2018.5596] [Reference Citation Analysis]
312 Waye A, Atkins K, Kao D. Cost Averted With Timely Fecal Microbiota Transplantation in the Management of Recurrent Clostridium difficile Infection in Alberta, Canada. J Clin Gastroenterol 2016;50:747-53. [PMID: 26890327 DOI: 10.1097/MCG.0000000000000494] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
313 Seekatz AM, Wolfrum E, DeWald CM, Putler RKB, Vendrov KC, Rao K, Young VB. Presence of multiple Clostridium difficile strains at primary infection is associated with development of recurrent disease. Anaerobe 2018;53:74-81. [PMID: 29859301 DOI: 10.1016/j.anaerobe.2018.05.017] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
314 Cózar A, Ramos-Martínez A, Merino E, Martínez-García C, Shaw E, Marrodán T, Calbo E, Bereciartúa E, Sánchez-Muñoz LA, Salavert M, Pérez-Rodríguez MT, García D, Bravo-Ferrer JM, Gálvez-Acebal J, Henríquez C, Cuquet J, Gil-Campesino H, Torres L, Sánchez-Porto A, Royuela A, Cobo J; Study group. High delayed mortality after the first episode of Clostridium difficile infection. Anaerobe 2019;57:93-8. [PMID: 30959165 DOI: 10.1016/j.anaerobe.2019.04.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
315 Sell J, Dolan B. Common Gastrointestinal Infections. Prim Care 2018;45:519-32. [PMID: 30115338 DOI: 10.1016/j.pop.2018.05.008] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
316 Katz KC, Golding GR, Choi KB, Pelude L, Amaratunga KR, Taljaard M, Alexandre S, Collet JC, Davis I, Du T, Evans GA, Frenette C, Gravel D, Hota S, Kibsey P, Langley JM, Lee BE, Lemieux C, Longtin Y, Mertz D, Mieusement LMD, Minion J, Moore DL, Mulvey MR, Richardson S, Science M, Simor AE, Stagg P, Suh KN, Taylor G, Wong A, Thampi N; Canadian Nosocomial Infection Surveillance Program. The evolving epidemiology of Clostridium difficile infection in Canadian hospitals during a postepidemic period (2009-2015). CMAJ 2018;190:E758-65. [PMID: 29941432 DOI: 10.1503/cmaj.180013] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 9.3] [Reference Citation Analysis]
317 Rodrigues R, Barber GE, Ananthakrishnan AN. A Comprehensive Study of Costs Associated With Recurrent Clostridium difficile Infection. Infect Control Hosp Epidemiol 2017;38:196-202. [PMID: 27817758 DOI: 10.1017/ice.2016.246] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
318 Gould CV, File TM Jr, McDonald LC. Causes, Burden, and Prevention of Clostridium difficile Infection. Infect Dis Clin Pract (Baltim Md) 2015;23:281-8. [PMID: 31048951 DOI: 10.1097/IPC.0000000000000331] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.9] [Reference Citation Analysis]
319 Siegfried J, Dubrovskaya Y, Flagiello T, Scipione MR, Phillips M, Papadopoulos J, Chen D, Safdar A. Initial Therapy for Mild to Moderate Clostridium difficile Infection: Exploring the Role of Oral Metronidazole Versus Vancomycin in 168 Hospitalized Patients. Infect Dis Clin Pract 2016;24:210-6. [DOI: 10.1097/ipc.0000000000000375] [Cited by in Crossref: 17] [Article Influence: 2.8] [Reference Citation Analysis]
320 Turner NA, Warren BG, Gergen-Teague MF, Addison RM, Addison B, Rutala WA, Weber DJ, Sexton DJ, Anderson DJ. Impact of Oral Metronidazole, Vancomycin, and Fidaxomicin on Host Shedding and Environmental Contamination with Clostridioides difficile. Clin Infect Dis 2021:ciab473. [PMID: 34017999 DOI: 10.1093/cid/ciab473] [Reference Citation Analysis]
321 Rodriguez C, Fernandez J, Van Broeck J, Taminiau B, Avesani V, Boga JA, Vazquez F, Delmée M, Daube G. Clostridium difficile presence in Spanish and Belgian hospitals. Microb Pathog 2016;100:141-8. [PMID: 27616443 DOI: 10.1016/j.micpath.2016.09.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
322 Schmidt-Hieber M, Bierwirth J, Buchheidt D, Cornely OA, Hentrich M, Maschmeyer G, Schalk E, Vehreschild JJ, Vehreschild MJGT; AGIHO Working Group. Diagnosis and management of gastrointestinal complications in adult cancer patients: 2017 updated evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Hematol 2018;97:31-49. [PMID: 29177551 DOI: 10.1007/s00277-017-3183-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
323 Kong LY, Dendukuri N, Schiller I, Bourgault AM, Brassard P, Poirier L, Lamothe F, Béliveau C, Michaud S, Turgeon N, Toye B, Frost EH, Gilca R, Dascal A, Loo VG. Predictors of asymptomatic Clostridium difficile colonization on hospital admission. Am J Infect Control 2015;43:248-53. [PMID: 25728150 DOI: 10.1016/j.ajic.2014.11.024] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 4.1] [Reference Citation Analysis]
324 Petrof EO, Gloor GB, Vanner SJ, Weese SJ, Carter D, Daigneault MC, Brown EM, Schroeter K, Allen-Vercoe E. Stool substitute transplant therapy for the eradication of Clostridium difficile infection: 'RePOOPulating' the gut. Microbiome 2013;1:3. [PMID: 24467987 DOI: 10.1186/2049-2618-1-3] [Cited by in Crossref: 462] [Cited by in F6Publishing: 404] [Article Influence: 51.3] [Reference Citation Analysis]
325 Indra A, Schmid D, Huhulescu S, Simons E, Hell M, Stickler K, Allerberger F; Austrian C. difficile Study Group. Clostridium difficile ribotypes in Austria: a multicenter, hospital-based survey. Wien Klin Wochenschr 2015;127:587-93. [PMID: 26156942 DOI: 10.1007/s00508-015-0808-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
326 Barbut F, Monot M, Rousseau A, Cavelot S, Simon T, Burghoffer B, Lalande V, Tankovic J, Petit JC, Dupuy B. Rapid diagnosis of Clostridium difficile infection by multiplex real-time PCR. Eur J Clin Microbiol Infect Dis. 2011;30:1279-1285. [PMID: 21487764 DOI: 10.1007/s10096-011-1224-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
327 Postigo R, Kim JH. Colonoscopic versus nasogastric fecal transplantation for the treatment of Clostridium difficile infection: a review and pooled analysis. Infection 2012;40:643-8. [PMID: 22847629 DOI: 10.1007/s15010-012-0307-9] [Cited by in Crossref: 76] [Cited by in F6Publishing: 65] [Article Influence: 7.6] [Reference Citation Analysis]
328 Khanna S, Pardi DS, Aronson SL, Kammer PP, Baddour LM. Outcomes in community-acquired Clostridium difficile infection. Aliment Pharmacol Ther. 2012;35:613-618. [PMID: 22229532 DOI: 10.1111/j.1365-2036.2011.04984.x] [Cited by in Crossref: 54] [Cited by in F6Publishing: 53] [Article Influence: 5.4] [Reference Citation Analysis]
329 Le Monnier A, Zahar J, Barbut F. Update on Clostridium difficile infections. Médecine et Maladies Infectieuses 2014;44:354-65. [DOI: 10.1016/j.medmal.2014.04.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
330 Humphries RM, Linscott AJ. Practical Guidance for Clinical Microbiology Laboratories: Diagnosis of Bacterial Gastroenteritis. Clin Microbiol Rev 2015;28:3-31. [PMID: 25567220 DOI: 10.1128/CMR.00073-14] [Cited by in Crossref: 91] [Cited by in F6Publishing: 49] [Article Influence: 13.0] [Reference Citation Analysis]
331 Polivkova S, Krutova M, Petrlova K, Benes J, Nyc O. Clostridium difficile ribotype 176 - A predictor for high mortality and risk of nosocomial spread? Anaerobe 2016;40:35-40. [PMID: 27155489 DOI: 10.1016/j.anaerobe.2016.05.002] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
332 Prohaska L, Mahmoudjafari Z, Shune L, Singh A, Lin T, Abhyankar S, Ganguly S, Grauer D, McGuirk J, Clough L. Retrospective evaluation of fidaxomicin versus oral vancomycin for treatment of Clostridium difficile infections in allogeneic stem cell transplant. Hematol Oncol Stem Cell Ther 2018;11:233-40. [PMID: 29928848 DOI: 10.1016/j.hemonc.2018.05.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
333 Louie TJ, Miller MA, Crook DW, Lentnek A, Bernard L, High KP, Shue YK, Gorbach SL. Effect of age on treatment outcomes in Clostridium difficile infection. J Am Geriatr Soc. 2013;61:222-230. [PMID: 23379974 DOI: 10.1111/jgs.12090] [Cited by in Crossref: 52] [Cited by in F6Publishing: 49] [Article Influence: 5.8] [Reference Citation Analysis]
334 Ena J, Afonso-carrillo RG, Bou-collado M, Galian-nicolas V, Reyes-jara MD, Martínez-peinado C, Gomez-alonso B, Arjona-zaragozi F. Epidemiology of Severe Acute Diarrhea in Patients Requiring Hospital Admission. The Journal of Emergency Medicine 2019;57:290-8. [DOI: 10.1016/j.jemermed.2019.06.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
335 Nathwani D, Cornely OA, Van Engen AK, Odufowora-Sita O, Retsa P, Odeyemi IA. Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection. J Antimicrob Chemother 2014;69:2901-12. [PMID: 25096079 DOI: 10.1093/jac/dku257] [Cited by in Crossref: 47] [Cited by in F6Publishing: 53] [Article Influence: 5.9] [Reference Citation Analysis]
336 Tschudin-sutter S, Tamma PD, Milstone AM, Perl TM. Predictors of First Recurrence of Clostridium difficile Infections in Children. Pediatric Infectious Disease Journal 2014;33:414-6. [DOI: 10.1097/inf.0000000000000108] [Cited by in Crossref: 23] [Cited by in F6Publishing: 9] [Article Influence: 2.9] [Reference Citation Analysis]
337 Tariq R, Khanna S. Clostridium difficile infection: Updates in management. Indian J Gastroenterol 2017;36:3-10. [DOI: 10.1007/s12664-016-0719-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
338 Meehan AM, Tariq R, Khanna S. Challenges in management of recurrent and refractory Clostridium difficile infection. World J Clin Infect Dis 2016; 6(3): 28-36 [DOI: 10.5495/wjcid.v6.i3.28] [Reference Citation Analysis]
339 Blanco N, Foxman B, Malani AN, Zhang M, Walk S, Rickard AH, Eisenberg MC. An in silico evaluation of treatment regimens for recurrent Clostridium difficile infection. PLoS One 2017;12:e0182815. [PMID: 28800598 DOI: 10.1371/journal.pone.0182815] [Reference Citation Analysis]
340 Sullivan T, Weinberg A, Rana M, Patel G, Huprikar S. The Epidemiology and Clinical Features of Clostridium difficile Infection in Liver Transplant Recipients. Transplantation. 2016;100:1939-1943. [PMID: 27379554 DOI: 10.1097/tp.0000000000001309] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 2.8] [Reference Citation Analysis]
341 De Leon LM, Watson JB, Kelly CR. Transient flare of ulcerative colitis after fecal microbiota transplantation for recurrent Clostridium difficile infection. Clin Gastroenterol Hepatol. 2013;11:1036-1038. [PMID: 23669309 DOI: 10.1016/j.cgh.2013.04.045] [Cited by in Crossref: 136] [Cited by in F6Publishing: 122] [Article Influence: 15.1] [Reference Citation Analysis]
342 Al-Tawfiq JA, Abed MS. Clostridium difficile-associated disease among patients in Dhahran, Saudi Arabia. Travel Med Infect Dis 2010;8:373-6. [PMID: 21030314 DOI: 10.1016/j.tmaid.2010.10.003] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
343 Awali RA, Kandipalli D, Pervaiz A, Narukonda S, Qazi U, Trehan N, Chopra T. Risk factors associated with interfacility transfers among patients with Clostridium difficile infection. Am J Infect Control 2016;44:1027-31. [PMID: 27207161 DOI: 10.1016/j.ajic.2016.03.037] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
344 Esmaily-fard A, Tverdek FP, Crowther DM, Ghantoji SS, Adachi JA, Chemaly RF. The Use of Fidaxomicin for Treatment of Relapsed Clostridium difficile Infections in Patients with Cancer. Pharmacotherapy 2014;34:1220-5. [DOI: 10.1002/phar.1479] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
345 Jain S, Clezy K, Mclaws M. Modified glove use for contact precautions: Health care workers’ perceptions and acceptance. American Journal of Infection Control 2019;47:938-44. [DOI: 10.1016/j.ajic.2019.01.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
346 Hickson M. Probiotics in the prevention of antibiotic-associated diarrhoea and Clostridium difficile infection. Therap Adv Gastroenterol. 2011;4:185-197. [PMID: 21694803 DOI: 10.1177/1756283x11399115] [Cited by in Crossref: 95] [Cited by in F6Publishing: 32] [Article Influence: 8.6] [Reference Citation Analysis]
347 Vigvári S, Sipos D, Solt J, Vincze Á, Kocsis B, Nemes Z, Kappéter Á, Feiszt Z, Kovács B, Péterfi Z. Faecal microbiota transplantation for Clostridium difficile infection using a lyophilized inoculum from non-related donors: A case series involving 19 patients. Acta Microbiol Immunol Hung 2019;66:69-78. [PMID: 29239198 DOI: 10.1556/030.64.2017.042] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
348 Ferguson JK, Cheng AC, Gilbert GL, Gottlieb T, Korman T, Mcgregor A, Richards M, Roberts S, Robson J, Gessel HV, Riley TV. Clostridium difficile laboratory testing in Australia and New Zealand: national survey results and Australasian Society for Infectious Diseases recommendations for best practice. Pathology 2011;43:482-7. [DOI: 10.1097/pat.0b013e328348c9b4] [Cited by in Crossref: 27] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
349 Bandelj P, Logar K, Usenik AM, Vengust M, Ocepek M. An improved qPCR protocol for rapid detection and quantification of Clostridium difficile in cattle feces. FEMS Microbiol Lett 2013;341:115-21. [DOI: 10.1111/1574-6968.12102] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
350 Akoghlanian G, Lakshmi S. The difficile in Clostridium difficile infection. Int J Infect Dis 2018;77:14-5. [PMID: 30025934 DOI: 10.1016/j.ijid.2018.07.006] [Reference Citation Analysis]
351 Stites S, Cooblall C, Aronovitz J, Singletary S, Micklow K, Sjeime M. The tipping point: patients predisposed to Clostridium difficile infection and a hospital antimicrobial stewardship programme. Journal of Hospital Infection 2016;94:242-8. [DOI: 10.1016/j.jhin.2016.07.022] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
352 Golembiewski J. Antimicrobial prophylaxis for surgery--2014 update. J Perianesth Nurs 2014;29:155-8. [PMID: 24661487 DOI: 10.1016/j.jopan.2014.01.001] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
353 Stevens VW, Khader K, Echevarria K, Nelson RE, Zhang Y, Jones M, Timbrook TT, Samore MH, Rubin MA. Use of Oral Vancomycin for Clostridioides difficile Infection and the Risk of Vancomycin-Resistant Enterococci. Clinical Infectious Diseases 2020;71:645-51. [DOI: 10.1093/cid/ciz871] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
354 Pollack LA, Gould CV, Srinivasan A. If not now, when? Seizing the moment for antibiotic stewardship. Infect Control Hosp Epidemiol 2013;34:117-8. [PMID: 23295555 DOI: 10.1086/669228] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
355 Jiang Y, Sarpong EM, Sears P, Obi EN. Budget Impact Analysis of Fidaxomicin Versus Vancomycin for the Treatment of Clostridioides difficile Infection in the United States. Infect Dis Ther 2021. [PMID: 34292496 DOI: 10.1007/s40121-021-00480-0] [Reference Citation Analysis]
356 Lee CH, Belanger JE, Kassam Z, Smieja M, Higgins D, Broukhanski G, Kim PT. The outcome and long-term follow-up of 94 patients with recurrent and refractory Clostridium difficile infection using single to multiple fecal microbiota transplantation via retention enema. Eur J Clin Microbiol Infect Dis. 2014;33:1425-1428. [PMID: 24627239 DOI: 10.1007/s10096-014-2088-9] [Cited by in Crossref: 77] [Cited by in F6Publishing: 64] [Article Influence: 9.6] [Reference Citation Analysis]
357 Rao K, Santhosh K, Mogle JA, Higgins PD, Young VB. Elevated fecal calprotectin associates with adverse outcomes from Clostridium difficile infection in older adults. Infect Dis (Lond). 2016;48:663-669. [PMID: 27206404 DOI: 10.1080/23744235.2016.1186832] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
358 Pechal A, Lin K, Allen S, Reveles K. National age group trends in Clostridium difficile infection incidence and health outcomes in United States Community Hospitals. BMC Infect Dis 2016;16:682. [PMID: 27855653 DOI: 10.1186/s12879-016-2027-8] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
359 Leekha S, Aronhalt KC, Sloan LM, Patel R, Orenstein R. Asymptomatic Clostridium difficile colonization in a tertiary care hospital: admission prevalence and risk factors. Am J Infect Control. 2013;41:390-393. [PMID: 23622704 DOI: 10.1016/j.ajic.2012.09.023] [Cited by in Crossref: 72] [Cited by in F6Publishing: 68] [Article Influence: 8.0] [Reference Citation Analysis]
360 Berg AM, Kelly CP, Farraye FA. Clostridium difficile infection in the inflammatory bowel disease patient. Inflamm Bowel Dis 2013;19:194-204. [PMID: 22508484 DOI: 10.1002/ibd.22964] [Cited by in Crossref: 87] [Cited by in F6Publishing: 75] [Article Influence: 9.7] [Reference Citation Analysis]
361 Mejia-Chew C, Dubberke ER. Clostridium difficile control measures: current and future methods for prevention. Expert Rev Anti Infect Ther 2018;16:121-31. [PMID: 29353504 DOI: 10.1080/14787210.2018.1429911] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
362 Khanna R, Chande N, Nelson RL. Treatment of an initial infection with clostridium difficile in patients with inflammatory bowel disease. Inflamm Bowel Dis 2013;19:2223-6. [PMID: 23929262 DOI: 10.1097/MIB.0b013e31829b3e1d] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
363 Rafiullah F, Kanwal S, Majeed UM, Korsten MA, Cheema FH, Luthra M, Sohail MR. Successful use of nitazoxanide in the treatment of recurrent Clostridium difficile infection. BMJ Case Rep 2011;2011:bcr0420114123. [PMID: 22674696 DOI: 10.1136/bcr.04.2011.4123] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
364 Yogo N, Shihadeh K, Young H, Calcaterra SL, Knepper BC, Burman WJ, Mehler PS, Jenkins TC. Intervention to Reduce Broad-Spectrum Antibiotics and Treatment Durations Prescribed at the Time of Hospital Discharge: A Novel Stewardship Approach. Infect Control Hosp Epidemiol 2017;38:534-41. [PMID: 28260538 DOI: 10.1017/ice.2017.10] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
365 Grein JD, Ochner M, Hoang H, Jin A, Morgan MA, Murthy AR. Comparison of testing approaches for Clostridium difficile infection at a large community hospital. Clin Microbiol Infect 2014;20:65-9. [PMID: 23521523 DOI: 10.1111/1469-0691.12198] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
366 Pépin J, Gonzales M, Valiquette L. Risk of secondary cases of Clostridium difficile infection among household contacts of index cases. J Infect 2012;64:387-90. [PMID: 22227466 DOI: 10.1016/j.jinf.2011.12.011] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
367 Liu M, Yin Q, Brennan JD, Li Y. Selection and characterization of DNA aptamers for detection of glutamate dehydrogenase from Clostridium difficile. Biochimie 2018;145:151-7. [PMID: 28882627 DOI: 10.1016/j.biochi.2017.08.015] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
368 Barbut F, Guery B, Eckert C. Comment traiter une infection digestive à Clostridium difficile en 2014 ? Réanimation 2014;23:284-97. [DOI: 10.1007/s13546-014-0867-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
369 Evans ME, Kralovic SM, Simbartl LA, Jain R, Roselle GA. Effect of a Clostridium difficile Infection Prevention Initiative in Veterans Affairs Acute Care Facilities. Infect Control Hosp Epidemiol 2016;37:720-2. [PMID: 26864803 DOI: 10.1017/ice.2016.27] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 4.3] [Reference Citation Analysis]
370 Psoinos CM, Collins CE, Ayturk MD, Anderson FA, Santry HP. Post-hospitalization Treatment Regimen and Readmission for C. difficile Colitis in Medicare Beneficiaries. World J Surg 2018;42:246-53. [PMID: 28744593 DOI: 10.1007/s00268-017-4139-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
371 Olsen MA, Young-Xu Y, Stwalley D, Kelly CP, Gerding DN, Saeed MJ, Mahé C, Dubberke ER. The burden of clostridium difficile infection: estimates of the incidence of CDI from U.S. Administrative databases. BMC Infect Dis 2016;16:177. [PMID: 27102582 DOI: 10.1186/s12879-016-1501-7] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 4.5] [Reference Citation Analysis]
372 Dinh A, Bouchand F, Le Monnier A. Actualités épidémiologiques et thérapeutiques des infections à Clostridium difficile. La Revue de Médecine Interne 2015;36:596-602. [DOI: 10.1016/j.revmed.2015.02.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
373 Housman ST, Banevicius MA, Lamb LM, Nicolau DP. Isolation and quantitation of Clostridium difficile in aqueous and fecal matter using two types of selective media. J Microbiol Immunol Infect 2016;49:445-7. [PMID: 26198865 DOI: 10.1016/j.jmii.2015.05.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
374 Ford DC, Schroeder MC, Ince D, Ernst EJ. Cost-effectiveness analysis of initial treatment strategies for mild-to-moderate Clostridium difficile infection in hospitalized patients. American Journal of Health-System Pharmacy 2018;75:1110-21. [DOI: 10.2146/ajhp170554] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
375 Zilberberg MD, Shorr AF, Wang L, Baser O, Yu H. Development and Validation of a Risk Score for Clostridium difficile Infection in Medicare Beneficiaries: A Population‐Based Cohort Study. J Am Geriatr Soc 2016;64:1690-5. [DOI: 10.1111/jgs.14236] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
376 Heslop OD, Roye-Green K, Coard K, Mulvey MR. A unique strain of community-acquired Clostridium difficile in severe complicated infection and death of a young adult. BMC Infect Dis 2013;13:299. [PMID: 23815405 DOI: 10.1186/1471-2334-13-299] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
377 Reigadas E, Alcalá L, Gómez J, Marín M, Martin A, Onori R, Muñoz P, Bouza E. Breakthrough Clostridium difficile Infection in Cirrhotic Patients Receiving Rifaximin. Clinical Infectious Diseases 2018;66:1086-91. [DOI: 10.1093/cid/cix918] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
378 Howerton A, Patra M, Abel-Santos E. Fate of ingested Clostridium difficile spores in mice. PLoS One 2013;8:e72620. [PMID: 24023628 DOI: 10.1371/journal.pone.0072620] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
379 Cho SH, Chon JW, Seo KH, Kim YK, Kim JB, Bak YS, Jung WW, Kim CH, Choi JT. Characterization of Clostridium difficile Strains Isolated from Patients with C. difficile-associated Disease in Korea. Osong Public Health Res Perspect 2017;8:325-31. [PMID: 29164044 DOI: 10.24171/j.phrp.2017.8.5.06] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
380 Qu H, Jiang Z. Clostridium difficile infection in diabetes. Diabetes Research and Clinical Practice 2014;105:285-94. [DOI: 10.1016/j.diabres.2014.06.002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
381 Dow DE, Seed PC. Clostridium difficile cure with fecal microbiota transplantation in a child with Pompe disease: a case report. J Med Case Rep 2018;12:112. [PMID: 29703246 DOI: 10.1186/s13256-018-1659-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
382 Honda H, Dubberke ER. The changing epidemiology of Clostridium difficile infection. Curr Opin Gastroenterol. 2014;30:54-62. [PMID: 24285002 DOI: 10.1097/mog.0000000000000018] [Cited by in Crossref: 38] [Cited by in F6Publishing: 14] [Article Influence: 4.8] [Reference Citation Analysis]
383 Davido B, de Truchis P, Dinh A. Interest of Eosinophil Count in Bacterial Infections to Predict Antimicrobial Therapy Efficacy. JAMA Surg 2019;154:464. [PMID: 30758492 DOI: 10.1001/jamasurg.2018.5578] [Reference Citation Analysis]
384 Lam TS, Yuk MT, Tsang NC, Wong MH, Chuang SK. Clostridium difficile infection outbreak in a male rehabilitation ward, Hong Kong Special Administrative Region (China), 2011. Western Pac Surveill Response J. 2012;3:59-60. [PMID: 23908942 DOI: 10.5365/wpsar.2012.3.4.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
385 Rimawi RH, Mazer MA, Siraj DS, Gooch M, Cook PP. Impact of regular collaboration between infectious diseases and critical care practitioners on antimicrobial utilization and patient outcome. Crit Care Med. 2013;41:2099-2107. [PMID: 23873275 DOI: 10.1097/ccm.0b013e31828e9863] [Cited by in Crossref: 74] [Cited by in F6Publishing: 25] [Article Influence: 8.2] [Reference Citation Analysis]
386 Martin J, Wilcox M. New and emerging therapies for Clostridium difficile infection: . Current Opinion in Infectious Diseases 2016;29:546-54. [DOI: 10.1097/qco.0000000000000320] [Cited by in Crossref: 34] [Cited by in F6Publishing: 21] [Article Influence: 5.7] [Reference Citation Analysis]
387 de Jong E, de Jong AS, Bartels CJ, van der Rijt-van den Biggelaar C, Melchers WJ, Sturm PD. Clinical and laboratory evaluation of a real-time PCR for Clostridium difficile toxin A and B genes. Eur J Clin Microbiol Infect Dis 2012;31:2219-25. [PMID: 22327373 DOI: 10.1007/s10096-012-1558-1] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 3.9] [Reference Citation Analysis]
388 Vargas E, Apewokin S, Madan R. Role of the leukocyte response in normal and immunocompromised host after Clostridium difficile infection. Anaerobe 2017;45:101-5. [PMID: 28223256 DOI: 10.1016/j.anaerobe.2017.02.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
389 El Feghaly RE, Bangar H, Haslam DB. The molecular basis of Clostridium difficile disease and host response. Curr Opin Gastroenterol 2015;31:24-9. [PMID: 25394235 DOI: 10.1097/MOG.0000000000000131] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
390 Gens KD, Elshaboury RH, Holt JS. Fecal microbiota transplantation and emerging treatments for Clostridium difficile infection. J Pharm Pract 2013;26:498-505. [PMID: 23966282 DOI: 10.1177/0897190013499527] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
391 Garg S, Mirza YR, Girotra M, Kumar V, Yoselevitz S, Segon A, Dutta SK. Epidemiology of Clostridium difficile-associated disease (CDAD): a shift from hospital-acquired infection to long-term care facility-based infection. Dig Dis Sci. 2013;58:3407-3412. [PMID: 24154638 DOI: 10.1007/s10620-013-2848-x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 3.2] [Reference Citation Analysis]
392 Wiland HO, Procop GW, Goldblum JR, Tuohy M, Rybicki L, Patil DT. Interobserver Variability and Feasibility of Polymerase Chain Reaction–Based Assay in Distinguishing Ischemic Colitis From Clostridium difficile Colitis in Endoscopic Mucosal Biopsies. Am J Clin Pathol 2013;139:730-5. [DOI: 10.1309/ajcpg8ayn9muwjxv] [Cited by in Crossref: 5] [Article Influence: 0.6] [Reference Citation Analysis]
393 Dulęba K, Pawłowska M, Wietlicka-Piszcz M. Clostridium difficile infection in children hospitalized due to diarrhea. Eur J Clin Microbiol Infect Dis 2014;33:201-9. [PMID: 24213847 DOI: 10.1007/s10096-013-1946-1] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
394 Luk S, To WK, Ng TK, Hui WT, Lee WK, Lau F, Ching AM. A cost-effective approach for detection of toxigenic Clostridium difficile: toxigenic culture using ChromID Clostridium difficile agar. J Clin Microbiol 2014;52:671-3. [PMID: 24478510 DOI: 10.1128/JCM.03113-13] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
395 Jump RLP, Crnich CJ, Mody L, Bradley SF, Nicolle LE, Yoshikawa TT. Infectious Diseases in Older Adults of Long-Term Care Facilities: Update on Approach to Diagnosis and Management. J Am Geriatr Soc 2018;66:789-803. [PMID: 29667186 DOI: 10.1111/jgs.15248] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 10.0] [Reference Citation Analysis]
396 Pérez-Cobas AE, Artacho A, Ott SJ, Moya A, Gosalbes MJ, Latorre A. Structural and functional changes in the gut microbiota associated to Clostridium difficile infection. Front Microbiol 2014;5:335. [PMID: 25309515 DOI: 10.3389/fmicb.2014.00335] [Cited by in Crossref: 31] [Cited by in F6Publishing: 49] [Article Influence: 3.9] [Reference Citation Analysis]
397 Eldin C, Raffetin A, Bouiller K, Hansmann Y, Roblot F, Raoult D, Parola P. Review of European and American guidelines for the diagnosis of Lyme borreliosis. Med Mal Infect 2019;49:121-32. [PMID: 30528068 DOI: 10.1016/j.medmal.2018.11.011] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 8.5] [Reference Citation Analysis]
398 Gutiérrez RL, Riddle MS, Porter CK. Increased risk of functional gastrointestinal sequelae after Clostridium difficile infection among active duty United States military personnel (1998-2010). Gastroenterology 2015;149:1408-14. [PMID: 26255560 DOI: 10.1053/j.gastro.2015.07.059] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
399 Donskey CJ. Does improving surface cleaning and disinfection reduce health care-associated infections? American Journal of Infection Control 2013;41:S12-9. [DOI: 10.1016/j.ajic.2012.12.010] [Cited by in Crossref: 156] [Cited by in F6Publishing: 132] [Article Influence: 17.3] [Reference Citation Analysis]
400 Ruiter-Ligeti J, Vincent S, Czuzoj-Shulman N, Abenhaim HA. Risk Factors, Incidence, and Morbidity Associated With Obstetric Clostridium difficile Infection. Obstet Gynecol. 2018;131:387-391. [PMID: 29324599 DOI: 10.1097/aog.0000000000002422] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
401 Saffouri G, Gupta A, Loftus EV Jr, Baddour LM, Pardi DS, Khanna S. The incidence and outcomes from Clostridium difficile infection in hospitalized adults with inflammatory bowel disease. Scand J Gastroenterol 2017;52:1240-7. [PMID: 28782372 DOI: 10.1080/00365521.2017.1362466] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
402 Janssen I, Cooper P, Gunka K, Rupnik M, Wetzel D, Zimmermann O, Groß U. High prevalence of nontoxigenic Clostridium difficile isolated from hospitalized and non-hospitalized individuals in rural Ghana. Int J Med Microbiol 2016;306:652-6. [PMID: 27693000 DOI: 10.1016/j.ijmm.2016.09.004] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
403 Endres BT, Bassères E, Alam MJ, Garey KW. Cadazolid for the treatment of Clostridium difficile. Expert Opin Investig Drugs 2017;26:509-14. [PMID: 28286992 DOI: 10.1080/13543784.2017.1304538] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
404 Banerjee R, Komarow L, Virk A, Rajapakse N, Schuetz AN, Dylla B, Earley M, Lok J, Kohner P, Ihde S, Cole N, Hines L, Reed K, Garner OB, Chandrasekaran S, de St Maurice A, Kanatani M, Curello J, Arias R, Swearingen W, Doernberg SB, Patel R. Randomized Trial Evaluating Clinical Impact of RAPid IDentification and Susceptibility Testing for Gram-negative Bacteremia: RAPIDS-GN. Clin Infect Dis 2021;73:e39-46. [PMID: 32374822 DOI: 10.1093/cid/ciaa528] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
405 Svensson AM. Pathology Consultation on Detection of Clostridium difficile. Am J Clin Pathol 2012;137:10-5. [DOI: 10.1309/ajcp62wezhlfijkh] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
406 Han A, Jump RL. Discrepancies between surveillance definition and the clinical incidence of Clostridium difficile infection in a Veterans Affairs long-term care facility. Infect Control Hosp Epidemiol 2014;35:1435-6. [PMID: 25333446 DOI: 10.1086/678434] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
407 Cocanour CS. Best strategies in recurrent or persistent Clostridium difficile infection. Surg Infect (Larchmt). 2011;12:235-239. [PMID: 21767157 DOI: 10.1089/sur.2010.080] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 2.9] [Reference Citation Analysis]
408 Salavert M, Cobo J, Pascual Á, Aragón B, Maratia S, Jiang Y, Aceituno S, Grau S. Cost-Effectiveness Analysis of Bezlotoxumab Added to Standard of Care Versus Standard of Care Alone for the Prevention of Recurrent Clostridium difficile Infection in High-Risk Patients in Spain. Adv Ther 2018;35:1920-34. [PMID: 30328061 DOI: 10.1007/s12325-018-0813-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
409 Venugopal AA, Johnson S. Current state of Clostridium difficile treatment options. Clin Infect Dis 2012;55 Suppl 2:S71-6. [PMID: 22752868 DOI: 10.1093/cid/cis355] [Cited by in Crossref: 48] [Cited by in F6Publishing: 39] [Article Influence: 4.8] [Reference Citation Analysis]
410 Guillemin I, Marrel A, Lambert J, Beriot-mathiot A, Doucet C, Kazoglou O, Luxemburger C, Reygrobellet C, Arnould B. Patients’ Experience and Perception of Hospital-Treated Clostridium difficile Infections: a Qualitative Study. Patient 2014;7:97-105. [DOI: 10.1007/s40271-013-0043-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
411 Wieczorkiewicz S, Zatarski R. Adherence to and Outcomes Associated with a Clostridium difficile Guideline at a Large Teaching Institution. Hosp Pharm 2015;50:42-50. [PMID: 25684800 DOI: 10.1310/hjp5001-042] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
412 Lewis PO, Lundberg TS, Tharp JL, Runnels CW. Implementation of Global Strategies to Prevent Hospital-Onset Clostridium difficile Infection: Targeting Proton Pump Inhibitors and Probiotics. Ann Pharmacother 2017;51:848-54. [DOI: 10.1177/1060028017694050] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
413 Kundrapu S, Sunkesula V, Tomas M, Donskey CJ. Skin and Environmental Contamination in Patients Diagnosed With Clostridium difficile Infection but Not Meeting Clinical Criteria for Testing. Infect Control Hosp Epidemiol 2015;36:1348-50. [PMID: 26315659 DOI: 10.1017/ice.2015.191] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
414 Feuerstein JD, Gifford AE, Akbari M, Goldman J, Leffler DA, Sheth SG, Cheifetz AS. Systematic Analysis Underlying the Quality of the Scientific Evidence and Conflicts of Interest in Gastroenterology Practice Guidelines. American Journal of Gastroenterology 2013;108:1686-93. [DOI: 10.1038/ajg.2013.150] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
415 Dunwoody R, Steel A, Landy J, Simmonds N. Clostridium difficile and cystic fibrosis: management strategies and the role of faecal transplantation. Paediatr Respir Rev 2018;26:16-8. [PMID: 28411069 DOI: 10.1016/j.prrv.2017.03.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
416 Sauberan JB, Bradley JS. Antimicrobial Agents. Principles and Practice of Pediatric Infectious Diseases. Elsevier; 2018. pp. 1499-1531.e3. [DOI: 10.1016/b978-0-323-40181-4.00292-9] [Cited by in Crossref: 4] [Article Influence: 1.0] [Reference Citation Analysis]
417 Kachrimanidou M, Sarmourli T, Skoura L, Metallidis S, Malisiovas N. Clostridium difficile infection: New insights into therapeutic options. Crit Rev Microbiol 2016;42:773-9. [PMID: 25955884 DOI: 10.3109/1040841X.2015.1027171] [Reference Citation Analysis]
418 Mulherin DW, Hutchison AM, Thomas GJ, Hansen RA, Childress DT. Concordance of the SHEA-IDSA severity classification for Clostridium difficile infection and the ATLAS bedside scoring system in hospitalized adult patients. Infection 2014;42:999-1005. [PMID: 25129565 DOI: 10.1007/s15010-014-0671-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
419 Jia H, Du P, Yang H, Zhang Y, Wang J, Zhang W, Han G, Han N, Yao Z, Wang H, Zhang J, Wang Z, Ding Q, Qiang Y, Barbut F, Gao GF, Cao Y, Cheng Y, Chen C. Nosocomial transmission of Clostridium difficile ribotype 027 in a Chinese hospital, 2012-2014, traced by whole genome sequencing. BMC Genomics 2016;17:405. [PMID: 27411304 DOI: 10.1186/s12864-016-2708-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
420 Darkoh C, Odo C, DuPont HL. Accessory Gene Regulator-1 Locus Is Essential for Virulence and Pathogenesis of Clostridium difficile. mBio 2016;7:e01237-16. [PMID: 27531912 DOI: 10.1128/mBio.01237-16] [Cited by in Crossref: 30] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
421 Khanna S, Pardi DS, Aronson SL, Kammer PP, Orenstein R, St Sauver JL, Harmsen WS, Zinsmeister AR. The epidemiology of community-acquired Clostridium difficile infection: a population-based study. Am J Gastroenterol. 2012;107:89-95. [PMID: 22108454 DOI: 10.1038/ajg.2011.398ajg2011398] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
422 Álvarez-Hernández DA, González-Chávez AM, González-Hermosillo-Cornejo D, Franyuti-Kelly GA, Díaz-Girón-Gidi A, Vázquez-López R. Present and past perspectives on Clostridium difficile infection. Rev Gastroenterol Mex (Engl Ed) 2018;83:41-50. [PMID: 28684034 DOI: 10.1016/j.rgmx.2017.03.004] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
423 Kawsar HI, Gopal KV, Shahnewaz J, Daw HA. Constipation in Clostridium difficile infection. BMJ Case Rep 2012;2012:bcr0220125938. [PMID: 22761206 DOI: 10.1136/bcr.02.2012.5938] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
424 Bogaty C, Lévesque S, Garenc C, Frenette C, Bolduc D, Galarneau L, Lalancette C, Loo V, Tremblay C, Trudeau M, Vachon J, Dionne M, Villeneuve J, Longtin J, Longtin Y. Trends in the use of laboratory tests for the diagnosis of Clostridium difficile infection and association with incidence rates in Quebec, Canada, 2010-2014. American Journal of Infection Control 2017;45:964-8. [DOI: 10.1016/j.ajic.2017.04.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
425 Reeves JS, Evans ME, Simbartl LA, Kralovic SM, Kelly AA, Jain R, Roselle GA. Clostridium difficile Infections in Veterans Health Administration Long-Term Care Facilities. Infect Control Hosp Epidemiol 2016;37:295-300. [PMID: 26686361 DOI: 10.1017/ice.2015.309] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
426 Bassères E, Endres BT, Khaleduzzaman M, Miraftabi F, Alam MJ, Vickers RJ, Garey KW. Impact on toxin production and cell morphology in Clostridium difficile by ridinilazole (SMT19969), a novel treatment for C. difficile infection. J Antimicrob Chemother 2016;71:1245-51. [PMID: 26895772 DOI: 10.1093/jac/dkv498] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 6.0] [Reference Citation Analysis]
427 Rutala WA, Weber DJ. Role of the hospital environment in disease transmission, with a focus on Clostridium difficile. Healthcare infection 2013;18:14-22. [DOI: 10.1071/hi12057] [Cited by in Crossref: 9] [Article Influence: 1.0] [Reference Citation Analysis]
428 Katzman M. Antibiotic therapy for Clostridium difficile infection. Seminars in Colon and Rectal Surgery 2014;25:143-9. [DOI: 10.1053/j.scrs.2014.05.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
429 Bowman JA, Utter GH. Evolving Strategies to Manage Clostridium difficile Colitis. J Gastrointest Surg 2020;24:484-91. [PMID: 31768834 DOI: 10.1007/s11605-019-04478-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
430 Rodriguez C, Van Broeck J, Taminiau B, Delmée M, Daube G. Clostridium difficile infection: Early history, diagnosis and molecular strain typing methods. Microb Pathog 2016;97:59-78. [PMID: 27238460 DOI: 10.1016/j.micpath.2016.05.018] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
431 Ferm S, Varadi N, Fisher C, Gutkin E. Serum-Derived Bovine Immunoglobulin as Novel Adjunct in Complicated Clostridium difficile Colitis Treatment. ACG Case Rep J 2017;4:e64. [PMID: 28516109 DOI: 10.14309/crj.2017.64] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
432 Sadahiro S, Suzuki T, Tanaka A, Okada K, Kamata H, Ozaki T, Koga Y. Comparison between oral antibiotics and probiotics as bowel preparation for elective colon cancer surgery to prevent infection: prospective randomized trial. Surgery. 2014;155:493-503. [PMID: 24524389 DOI: 10.1016/j.surg.2013.06.002] [Cited by in Crossref: 75] [Cited by in F6Publishing: 58] [Article Influence: 9.4] [Reference Citation Analysis]
433 Di Bella S, Paglia MG, Johnson E, Petrosillo N. Clostridium difficile 027 infection in Central Italy. BMC Infect Dis 2012;12:370. [PMID: 23259814 DOI: 10.1186/1471-2334-12-370] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
434 Martin J, Mawer D, Wilcox MH. Clostridium difficile: biological therapies. Curr Opin Infect Dis 2013;26:454-60. [PMID: 23982236 DOI: 10.1097/01.qco.0000433319.82618.8f] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
435 Søgaard KK, Ejlertsen T, Schønheyder HC. Clostridium difficile 027-associated pseudomembranous colitis after short-term treatment with cefuroxime and cephalexin in an elderly orthopedic patient: a case report. BMC Res Notes 2012;5:609. [PMID: 23113897 DOI: 10.1186/1756-0500-5-609] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
436 Zipursky JS, Sidorsky TI, Freedman CA, Sidorsky MN, Kirkland KB. Physician attitudes toward the use of fecal microbiota transplantation for the treatment of recurrent Clostridium difficile infection. Can J Gastroenterol Hepatol 2014;28:319-24. [PMID: 24719899 DOI: 10.1155/2014/403828] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
437 Black SR, Weaver KN, Weinstein RA, Hayden MK, Lin MY, Lavin MA, Gerber SI. Regional infection control assessment of antibiotic resistance knowledge and practice. Infect Control Hosp Epidemiol 2015;36:381-6. [PMID: 25782891 DOI: 10.1017/ice.2014.78] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
438 Mutai WC, Mureithi MW, Anzala O, Revathi G, Kullin B, Burugu M, Kyany'a C, Odoyo E, Otieno P, Musila L. High Prevalence of Multidrug-Resistant Clostridioides difficile Following Extensive Use of Antimicrobials in Hospitalized Patients in Kenya. Front Cell Infect Microbiol 2020;10:604986. [PMID: 33628744 DOI: 10.3389/fcimb.2020.604986] [Reference Citation Analysis]
439 Reigadas E, Alcalá L, Valerio M, Marín M, Martin A, Bouza E. Toxin B PCR cycle threshold as a predictor of poor outcome of Clostridium difficile infection: a derivation and validation cohort study. J Antimicrob Chemother 2016;71:1380-5. [PMID: 26869691 DOI: 10.1093/jac/dkv497] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 5.3] [Reference Citation Analysis]
440 Oleastro M, Coelho M, Gião M, Coutinho S, Mota S, Santos A, Rodrigues J, Faria D. Outbreak of Clostridium difficile PCR ribotype 027--the recent experience of a regional hospital. BMC Infect Dis 2014;14:209. [PMID: 24739945 DOI: 10.1186/1471-2334-14-209] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
441 Chiang HY, Huang HC, Chung CW, Yeh YC, Chen YC, Tien N, Lin HS, Ho MW, Kuo CC. Risk prediction for 30-day mortality among patients with Clostridium difficile infections: a retrospective cohort study. Antimicrob Resist Infect Control 2019;8:175. [PMID: 31749963 DOI: 10.1186/s13756-019-0642-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
442 D’Aoust J, Battat R, Bessissow T. Management of inflammatory bowel disease with Clostridium difficile infection. World J Gastroenterol 2017; 23(27): 4986-5003 [PMID: 28785153 DOI: 10.3748/wjg.v23.i27.4986] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
443 Crowell KT, Julian KG, Katzman M, Berg AS, Tinsley A, Williams ED, Koltun WA, Messaris E. Compliance with Clostridium difficile treatment guidelines: effect on patient outcomes. Epidemiol Infect 2017;145:2185-92. [PMID: 28578710 DOI: 10.1017/S0950268817000644] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 3.4] [Reference Citation Analysis]
444 Jansen JW. Fecal Microbiota Transplant vs Oral Vancomycin Taper: Important Undiscussed Limitations. Clinical Infectious Diseases 2017;64:1292-3. [DOI: 10.1093/cid/cix093] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
445 Samuel BP, Crumb TL, Duba MM. What nurses need to know about fecal microbiota transplantation: education, assessment, and care for children and young adults. J Pediatr Nurs 2014;29:354-61. [PMID: 24582649 DOI: 10.1016/j.pedn.2014.01.013] [Cited by in Crossref: 4] [Article Influence: 0.5] [Reference Citation Analysis]
446 Levy AR, Szabo SM, Lozano-Ortega G, Lloyd-Smith E, Leung V, Lawrence R, Romney MG. Incidence and Costs of Clostridium difficile Infections in Canada. Open Forum Infect Dis 2015;2:ofv076. [PMID: 26191534 DOI: 10.1093/ofid/ofv076] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 4.7] [Reference Citation Analysis]
447 Ley RE. Harnessing microbiota to kill a pathogen: the sweet tooth of Clostridium difficile. Nat Med 2014;20:248-9. [PMID: 24603797 DOI: 10.1038/nm.3494] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
448 Kuon C, Wannier R, Sterken D, Fang MC, Wolf J, Prasad PA. Are Antimotility Agents Safe for Use in Clostridioides difficile Infections? Results From an Observational Study in Malignant Hematology Patients. Mayo Clin Proc Innov Qual Outcomes 2020;4:792-800. [PMID: 33367215 DOI: 10.1016/j.mayocpiqo.2020.06.005] [Reference Citation Analysis]
449 Manthey C, Eckmann L, Fuhrmann V. Therapy for Clostridium difficile infection – any news beyond Metronidazole and Vancomycin? Expert Review of Clinical Pharmacology 2017;10:1239-50. [DOI: 10.1080/17512433.2017.1362978] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
450 Yeung SS, Yeung JK, Lau TT, Forrester LA, Steiner TS, Bowie WR, Bryce EA. Evaluation of a Clostridium difficile infection management policy with clinical pharmacy and medical microbiology involvement at a major Canadian teaching hospital. J Clin Pharm Ther 2015;40:655-60. [PMID: 26547905 DOI: 10.1111/jcpt.12329] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
451 Cristina ML, Spagnolo AM, Sartini M, Panatto D, Perdelli F. Clostridium difficile infections: an emerging problem in healthcare facilities. Reviews in Medical Microbiology 2012;23:67-75. [DOI: 10.1097/mrm.0b013e3283573643] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
452 Katzer KC, Hagel S, Reuken PA, Bruns T, Stallmach A. Development and validation of a simple and robust model to predict 30-day mortality in patients with Clostridioides difficile-associated enterocolitis. BMJ Open Gastroenterol 2020;7:e000468. [PMID: 32912845 DOI: 10.1136/bmjgast-2020-000468] [Reference Citation Analysis]
453 Knight EM, Schiller DS, Fulman MK, Rastogi R. Long-Term Efficacy of Oral Vancomycin Prophylaxis for the Prevention of Clostridium difficile Recurrence. J Pharm Pract 2020;33:633-9. [PMID: 30744479 DOI: 10.1177/0897190019825994] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
454 Schwab EM, Wilkes J, Korgenski K, Hersh AL, Pavia AT, Stevens VW. Risk Factors for Recurrent Clostridium difficile Infection in Pediatric Inpatients. Hosp Pediatr 2016;6:339-44. [PMID: 27146969 DOI: 10.1542/hpeds.2015-0170] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
455 Ananthakrishnan AN, Guzman-Perez R, Gainer V, Cai T, Churchill S, Kohane I, Plenge RM, Murphy S. Predictors of severe outcomes associated with Clostridium difficile infection in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2012;35:789-795. [PMID: 22360370 DOI: 10.1111/j.1365-2036.2012.05022.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 51] [Article Influence: 4.9] [Reference Citation Analysis]
456 Han SH, Yi J, Kim JH, Lee S, Moon HW. Composition of gut microbiota in patients with toxigenic Clostridioides (Clostridium) difficile: Comparison between subgroups according to clinical criteria and toxin gene load. PLoS One 2019;14:e0212626. [PMID: 30785932 DOI: 10.1371/journal.pone.0212626] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 6.3] [Reference Citation Analysis]
457 Piper GL, Kaplan LJ. Antibiotic heterogeneity optimizes antimicrobial prescription and enables resistant pathogen control in the intensive care unit. Surg Infect (Larchmt). 2012;13:194-202. [PMID: 22913313 DOI: 10.1089/sur.2012.121] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
458 Sclar DA, Robison LM, Oganov AM, Schmidt JM, Bowen KA, Castillo LV. Fidaxomicin for Clostridium difficile-associated diarrhoea: epidemiological method for estimation of warranted price. Clin Drug Investig 2012;32:e17-24. [PMID: 22708825 DOI: 10.1007/BF03261906] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
459 Tschudin-Sutter S, Widmer AF, Perl TM. Clostridium difficile: novel insights on an incessantly challenging disease. Curr Opin Infect Dis. 2012;25:405-411. [PMID: 22614522 DOI: 10.1097/qco.0b013e32835533a2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
460 Daly SM, Joyner JA, Triplett KD, Elmore BO, Pokhrel S, Frietze KM, Peabody DS, Chackerian B, Hall PR. VLP-based vaccine induces immune control of Staphylococcus aureus virulence regulation. Sci Rep 2017;7:637. [PMID: 28377579 DOI: 10.1038/s41598-017-00753-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
461 Kang CY, Huang IH, Chou CC, Wu TY, Chang JC, Hsiao YY, Cheng CH, Tsai WJ, Hsu KC, Wang S. Functional analysis of Clostridium difficile sortase B reveals key residues for catalytic activity and substrate specificity. J Biol Chem 2020;295:3734-45. [PMID: 32005667 DOI: 10.1074/jbc.RA119.011322] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
462 Tomas ME, Mana TSC, Wilson BM, Nerandzic MM, Joussef-Piña S, Quiñones-Mateu ME, Donskey CJ. Tapering Courses of Oral Vancomycin Induce Persistent Disruption of the Microbiota That Provide Colonization Resistance to Clostridium difficile and Vancomycin-Resistant Enterococci in Mice. Antimicrob Agents Chemother 2018;62:e02237-17. [PMID: 29530853 DOI: 10.1128/AAC.02237-17] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
463 Okouchi R, E S, Yamamoto K, Ota T, Seki K, Imai M, Ota R, Asayama Y, Nakashima A, Suzuki K, Tsuduki T. Simultaneous Intake of Euglena gracilis and Vegetables Exerts Synergistic Anti-Obesity and Anti-Inflammatory Effects by Modulating the Gut Microbiota in Diet-Induced Obese Mice. Nutrients 2019;11:E204. [PMID: 30669573 DOI: 10.3390/nu11010204] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
464 Furuya-Kanamori L, Marquess J, Yakob L, Riley TV, Paterson DL, Foster NF, Huber CA, Clements AC. Asymptomatic Clostridium difficile colonization: epidemiology and clinical implications. BMC Infect Dis 2015;15:516. [PMID: 26573915 DOI: 10.1186/s12879-015-1258-4] [Cited by in Crossref: 114] [Cited by in F6Publishing: 84] [Article Influence: 16.3] [Reference Citation Analysis]
465 Albarrak AA, Romana BS, Uraz S, Yousef MH, Juboori AA, Tahan V. Clostridium Difficile Infection in Inflammatory Bowel Disease Patients. Endocr Metab Immune Disord Drug Targets 2019;19:929-35. [PMID: 30827274 DOI: 10.2174/1871530319666190301120558] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
466 Watt M, Dinh A, Le Monnier A, Tilleul P. Cost-effectiveness analysis on the use of fidaxomicin and vancomycin to treat Clostridium difficile infection in France. Journal of Medical Economics 2017;20:678-86. [DOI: 10.1080/13696998.2017.1302946] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
467 Datta R, Brown S, Nguyen VQ, Cao C, Billimek J, Avery T, Lee BY, Huang SS. Quantifying the Exposure to Antibiotic-Resistant Pathogens Among Patients Discharged From a Single Hospital Across All California Healthcare Facilities. Infect Control Hosp Epidemiol 2015;36:1275-82. [PMID: 26387690 DOI: 10.1017/ice.2015.181] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
468 Drekonja DM. Clostridium difficile infection: current, forgotten and emerging treatment options. J Comp Eff Res 2014;3:547-57. [PMID: 25350805 DOI: 10.2217/cer.14.36] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
469 O’Horo JC, Jones A, Sternke M, Harper C, Safdar N. Molecular techniques for diagnosis of Clostridium difficile infection: systematic review and meta-analysis. Mayo Clin Proc. 2012;87:643-651. [PMID: 22766084 DOI: 10.1016/j.mayocp.2012.02.024] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 5.2] [Reference Citation Analysis]
470 Barberio B, Facchin S, Mele E, D'Incà R, Sturniolo GC, Farinati F, Zingone F, Quagliariello A, Ghisa M, Massimi D, Casadei C, Savarino EV. Faecal microbiota transplantation in Clostridioides difficile infection: real-life experience from an academic Italian hospital. Therap Adv Gastroenterol 2020;13:1756284820934315. [PMID: 32774464 DOI: 10.1177/1756284820934315] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
471 Horwitz E, Tal-Gan Y, Temper V, Shapiro M, Gilon C, Hoffman A. Chemical trapping of vancomycin: a potential strategy for preventing selection of vancomycin-resistant Enterococci. Microb Drug Resist 2012;18:109-15. [PMID: 22088148 DOI: 10.1089/mdr.2011.0057] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
472 Cheng AC, Ferguson JK, Richards MJ, Robson JM, Gilbert GL, Mcgregor A, Roberts S, Korman TM, Riley TV. Australasian Society for Infectious Diseases guidelines for the diagnosis and treatment of Clostridium difficile infection. Medical Journal of Australia 2011;194:353-8. [DOI: 10.5694/j.1326-5377.2011.tb03006.x] [Cited by in Crossref: 59] [Cited by in F6Publishing: 48] [Article Influence: 5.4] [Reference Citation Analysis]
473 Tam J, Beilhartz GL, Auger A, Gupta P, Therien AG, Melnyk RA. Small molecule inhibitors of Clostridium difficile toxin B-induced cellular damage. Chem Biol 2015;22:175-85. [PMID: 25619932 DOI: 10.1016/j.chembiol.2014.12.010] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 6.9] [Reference Citation Analysis]
474 Peng Z, Jin D, Kim HB, Stratton CW, Wu B, Tang YW, Sun X. Update on Antimicrobial Resistance in Clostridium difficile: Resistance Mechanisms and Antimicrobial Susceptibility Testing. J Clin Microbiol 2017;55:1998-2008. [PMID: 28404671 DOI: 10.1128/JCM.02250-16] [Cited by in Crossref: 95] [Cited by in F6Publishing: 57] [Article Influence: 19.0] [Reference Citation Analysis]
475 Madden GR, German Mesner I, Cox HL, Mathers AJ, Lyman JA, Sifri CD, Enfield KB. Reduced Clostridium difficile Tests and Laboratory-Identified Events With a Computerized Clinical Decision Support Tool and Financial Incentive. Infect Control Hosp Epidemiol 2018;39:737-40. [PMID: 29644943 DOI: 10.1017/ice.2018.53] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 9.5] [Reference Citation Analysis]
476 Appel-da-Silva MC, Narvaez GA, Perez LRR, Drehmer L, Lewgoy J. Saccharomyces cerevisiae var. boulardii fungemia following probiotic treatment. Med Mycol Case Rep 2017;18:15-7. [PMID: 28794958 DOI: 10.1016/j.mmcr.2017.07.007] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
477 Gavaldà J, Vidal E, Lumbreras C. Infection prevention in solid organ transplantation. Enfermedades Infecciosas y Microbiología Clínica 2012;30:27-33. [DOI: 10.1016/s0213-005x(12)70079-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
478 Hui ML, Tan LT, Letchumanan V, He YW, Fang CM, Chan KG, Law JW, Lee LH. The Extremophilic Actinobacteria: From Microbes to Medicine. Antibiotics (Basel) 2021;10:682. [PMID: 34201133 DOI: 10.3390/antibiotics10060682] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
479 Draper K, Ley C, Parsonnet J. Probiotic guidelines and physician practice: a cross-sectional survey and overview of the literature. Beneficial Microbes 2017;8:507-19. [DOI: 10.3920/bm2016.0146] [Cited by in Crossref: 24] [Cited by in F6Publishing: 10] [Article Influence: 4.8] [Reference Citation Analysis]
480 Antoon JW, Hall M, Metropulos D, Steiner MJ, Jhaveri R, Lohr JA. A Prospective Pilot Study on the Systemic Absorption of Oral Vancomycin in Children With Colitis. J Pediatr Pharmacol Ther 2016;21:426-31. [PMID: 27877096 DOI: 10.5863/1551-6776-21.5.426] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
481 Lin YC, Huang YT, Lee TF, Lee NY, Liao CH, Lin SY, Ko WC, Hsueh PR. Characteristics of patients with Clostridium difficile infection in Taiwan. Epidemiol Infect. 2013;141:2031-2038. [PMID: 23218131 DOI: 10.1017/s0950268812002749] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
482 Niven DJ, Laupland KB. Pyrexia: aetiology in the ICU. Crit Care. 2016;20:247. [PMID: 27581757 DOI: 10.1186/s13054-016-1406-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
483 Mendo-Lopez R, Villafuerte-Gálvez J, White N, Mahoney MV, Kelly CP, Alonso CD. Recent developments in the management of recurrent Clostridioides difficile infection. Anaerobe 2020;62:102108. [PMID: 31606481 DOI: 10.1016/j.anaerobe.2019.102108] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
484 You E, Song H, Cho J, Lee J. Reduction in the incidence of hospital-acquired Clostridium difficile infection through infection control interventions other than the restriction of antimicrobial use. Int J Infect Dis. 2014;22:9-10. [PMID: 24583565 DOI: 10.1016/j.ijid.2014.01.011] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
485 Sartelli M, Di Bella S, McFarland LV, Khanna S, Furuya-Kanamori L, Abuzeid N, Abu-Zidan FM, Ansaloni L, Augustin G, Bala M, Ben-Ishay O, Biffl WL, Brecher SM, Camacho-Ortiz A, Caínzos MA, Chan S, Cherry-Bukowiec JR, Clanton J, Coccolini F, Cocuz ME, Coimbra R, Cortese F, Cui Y, Czepiel J, Demetrashvili Z, Di Carlo I, Di Saverio S, Dumitru IM, Eckmann C, Eiland EH, Forrester JD, Fraga GP, Frossard JL, Fry DE, Galeiras R, Ghnnam W, Gomes CA, Griffiths EA, Guirao X, Ahmed MH, Herzog T, Kim JI, Iqbal T, Isik A, Itani KMF, Labricciosa FM, Lee YY, Juang P, Karamarkovic A, Kim PK, Kluger Y, Leppaniemi A, Lohsiriwat V, Machain GM, Marwah S, Mazuski JE, Metan G, Moore EE, Moore FA, Ordoñez CA, Pagani L, Petrosillo N, Portela F, Rasa K, Rems M, Sakakushev BE, Segovia-Lohse H, Sganga G, Shelat VG, Spigaglia P, Tattevin P, Tranà C, Urbánek L, Ulrych J, Viale P, Baiocchi GL, Catena F. 2019 update of the WSES guidelines for management of Clostridioides (Clostridium) difficile infection in surgical patients. World J Emerg Surg 2019;14:8. [PMID: 30858872 DOI: 10.1186/s13017-019-0228-3] [Cited by in Crossref: 47] [Cited by in F6Publishing: 33] [Article Influence: 15.7] [Reference Citation Analysis]
486 Lo Vecchio A, Zacur GM. Clostridium difficile infection: an update on epidemiology, risk factors, and therapeutic options. Curr Opin Gastroenterol. 2012;28:1-9. [PMID: 22134217 DOI: 10.1097/mog.0b013e32834bc9a9] [Cited by in Crossref: 143] [Cited by in F6Publishing: 55] [Article Influence: 14.3] [Reference Citation Analysis]
487 Hostler CJ, Chen LF. Fidaxomicin for treatment of clostridium difficile-associated diarrhea and its potential role for prophylaxis. Expert Opinion on Pharmacotherapy 2013;14:1529-36. [DOI: 10.1517/14656566.2013.802307] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
488 Bloomfield LE, Riley TV. Epidemiology and Risk Factors for Community-Associated Clostridium difficile Infection: A Narrative Review. Infect Dis Ther 2016;5:231-51. [PMID: 27370914 DOI: 10.1007/s40121-016-0117-y] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 6.8] [Reference Citation Analysis]
489 Aronoff DM. Building a Better Crystal Ball for Predicting Complications of Clostridium difficile Infection. Clin Infect Dis 2015;61:1789-91. [PMID: 26338793 DOI: 10.1093/cid/civ751] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
490 Shahinas D, Silverman M, Sittler T, Chiu C, Kim P, Allen-Vercoe E, Weese S, Wong A, Low DE, Pillai DR. Toward an understanding of changes in diversity associated with fecal microbiome transplantation based on 16S rRNA gene deep sequencing. MBio. 2012;3:pii: e00338-12. [PMID: 23093385 DOI: 10.1128/mbio.00338-12] [Cited by in Crossref: 119] [Cited by in F6Publishing: 71] [Article Influence: 11.9] [Reference Citation Analysis]
491 Ananthakrishnan AN. Detecting and treating Clostridium difficile infections in patients with inflammatory bowel disease. Gastroenterol Clin North Am. 2012;41:339-353. [PMID: 22500522 DOI: 10.1016/j.gtc.2012.01.003] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
492 Khanna S. Management of Clostridioides difficile infection in patients with inflammatory bowel disease. Intest Res 2021;19:265-74. [PMID: 32806873 DOI: 10.5217/ir.2020.00045] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
493 Scappaticci GB, Perissinotti AJ, Nagel JL, Bixby DL, Marini BL. Risk factors and impact of Clostridium difficile recurrence on haematology patients. Journal of Antimicrobial Chemotherapy 2017;72:1488-95. [DOI: 10.1093/jac/dkx005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
494 Soriano MM, Johnson S. Treatment of Clostridium difficile Infections. Infectious Disease Clinics of North America 2015;29:93-108. [DOI: 10.1016/j.idc.2014.11.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
495 Lee H, Patel K, Singam V, Rastogi S, Silverberg J. Associations of cutaneous and extracutaneous infections with hidradenitis suppurativa in U.S. children and adults. Br J Dermatol 2020;182:327-34. [DOI: 10.1111/bjd.18093] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
496 Huttunen R, Vuento R, Syrjänen J, Tissari P, Aittoniemi J. Case fatality associated with a hypervirulent strain in patients with culture-positive Clostridium difficile infection: a retrospective population-based study. International Journal of Infectious Diseases 2012;16:e532-5. [DOI: 10.1016/j.ijid.2012.02.019] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
497 Press A, Ku BS, McCullagh L, Rosen L, Richardson S, McGinn T. Developing a Clinical Prediction Rule for First Hospital-Onset Clostridium difficile Infections: A Retrospective Observational Study. Infect Control Hosp Epidemiol 2016;37:896-900. [PMID: 27123975 DOI: 10.1017/ice.2016.97] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
498 Xing P, Shi Y, Dong C, Liu H, Cheng Y, Sun J, Li D, Li M, Sun K, Feng D. Colon-Targeted Delivery of IgY Against Clostridium difficile Toxin A and B by Encapsulation in Chitosan-Ca Pectinate Microbeads. AAPS PharmSciTech 2017;18:1095-103. [PMID: 27826799 DOI: 10.1208/s12249-016-0656-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
499 Mullane K, Lee C, Bressler A, Buitrago M, Weiss K, Dabovic K, Praestgaard J, Leeds JA, Blais J, Pertel P. Multicenter, randomized clinical trial to compare the safety and efficacy of LFF571 and vancomycin for Clostridium difficile infections. Antimicrob Agents Chemother 2015;59:1435-40. [PMID: 25534727 DOI: 10.1128/AAC.04251-14] [Cited by in Crossref: 61] [Cited by in F6Publishing: 25] [Article Influence: 7.6] [Reference Citation Analysis]
500 Petrof EO, Khoruts A. From stool transplants to next-generation microbiota therapeutics. Gastroenterology. 2014;146:1573-1582. [PMID: 24412527 DOI: 10.1053/j.gastro.2014.01.004] [Cited by in Crossref: 125] [Cited by in F6Publishing: 108] [Article Influence: 15.6] [Reference Citation Analysis]
501 Karczewski J, Zorman J, Wang S, Miezeiewski M, Xie J, Soring K, Petrescu I, Rogers I, Thiriot DS, Cook JC, Chamberlin M, Xoconostle RF, Nahas DD, Joyce JG, Bodmer J, Heinrichs JH, Secore S. Development of a recombinant toxin fragment vaccine for Clostridium difficile infection. Vaccine 2014;32:2812-8. [DOI: 10.1016/j.vaccine.2014.02.026] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
502 Foglia G, Shah S, Luxemburger C, Pietrobon PJ. Clostridium difficile: development of a novel candidate vaccine. Vaccine. 2012;30:4307-4309. [PMID: 22682287 DOI: 10.1016/j.vaccine.2012.01.056] [Cited by in Crossref: 79] [Cited by in F6Publishing: 68] [Article Influence: 7.9] [Reference Citation Analysis]
503 van Prehn J, Reigadas E, Vogelzang EH, Bouza E, Hristea A, Guery B, Krutova M, Norén T, Allerberger F, Coia J, Goorhuis A, van Rossen TM, Ooijevaar RE, Burns K, Scharvik Olesen BR, Tschudin-Sutter S, Wilcox MH, Vehreschild M, Fitzpatrick F, Kuijper EJ; guideline committee of the European Study Group on Clostridioides difficile. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults. Clin Microbiol Infect 2021:S1198-743X(21)00568-1. [PMID: 34678515 DOI: 10.1016/j.cmi.2021.09.038] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
504 Shin JH, High KP, Warren CA. Older Is Not Wiser, Immunologically Speaking: Effect of Aging on Host Response to Clostridium difficile Infections. J Gerontol A Biol Sci Med Sci 2016;71:916-22. [PMID: 26809495 DOI: 10.1093/gerona/glv229] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
505 Gentry CA, Nguyen PK, Thind S, Kurdgelashvili G, Skrepnek GH, Williams RJ 2nd. Fidaxomicin versus oral vancomycin for severe Clostridium difficile infection: a retrospective cohort study. Clin Microbiol Infect 2019;25:987-93. [PMID: 30583055 DOI: 10.1016/j.cmi.2018.12.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
506 Kelly BJ, Tebas P. Clinical Practice and Infrastructure Review of Fecal Microbiota Transplantation for Clostridium difficile Infection. Chest. 2018;153:266-277. [PMID: 28923757 DOI: 10.1016/j.chest.2017.09.002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 4.2] [Reference Citation Analysis]
507 Gergely Szabo B, Kadar B, Szidonia Lenart K, Dezsenyi B, Kunovszki P, Fried K, Kamotsay K, Nikolova R, Prinz G. Use of intravenous tigecycline in patients with severe Clostridium difficile infection: a retrospective observational cohort study. Clinical Microbiology and Infection 2016;22:990-5. [DOI: 10.1016/j.cmi.2016.08.017] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
508 Przybylo M, Peel A, Cooke R, Guleri A. UK laboratory diagnosis of Clostridium difficile infection: in a state of transition, confusion, or both? Journal of Hospital Infection 2012;80:273-4. [DOI: 10.1016/j.jhin.2012.01.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
509 Fuchs BB, Tharmalingam N, Mylonakis E. Vulnerability of long-term care facility residents to Clostridium difficile infection due to microbiome disruptions. Future Microbiol 2018;13:1537-47. [PMID: 30311778 DOI: 10.2217/fmb-2018-0157] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
510 Kennedy C, Waldron C, Skally M, Gaughan L, Magee C, Burns K, Fitzpatrick F. The epidemiology of Clostridium difficile infection in a national kidney transplant center. Clin Transplant 2017;31:e12962. [DOI: 10.1111/ctr.12962] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
511 Verhoeven PO, Carricajo A, Pillet S, Ros A, Fonsale N, Botelho-nevers E, Lucht F, Berthelot P, Pozzetto B, Grattard F. Evaluation of the new CE-IVD marked BD MAX Cdiff Assay for the detection of toxigenic Clostridium difficile harboring the tcdB gene from clinical stool samples. Journal of Microbiological Methods 2013;94:58-60. [DOI: 10.1016/j.mimet.2013.04.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
512 Carson KC, Boseiwaqa LV, Thean SK, Foster NF, Riley TV. Isolation of Clostridium difficile from faecal specimens--a comparison of chromID C. difficile agar and cycloserine-cefoxitin-fructose agar. J Med Microbiol. 2013;62:1423-1427. [PMID: 23579394 DOI: 10.1099/jmm.0.056515-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
513 Knight DR, Elliott B, Chang BJ, Perkins TT, Riley TV. Diversity and Evolution in the Genome of Clostridium difficile. Clin Microbiol Rev 2015;28:721-41. [PMID: 26085550 DOI: 10.1128/CMR.00127-14] [Cited by in Crossref: 146] [Cited by in F6Publishing: 84] [Article Influence: 20.9] [Reference Citation Analysis]
514 Howerton A, Patra M, Abel-Santos E. A new strategy for the prevention of Clostridium difficile infection. J Infect Dis. 2013;207:1498-1504. [PMID: 23420906 DOI: 10.1093/infdis/jit068] [Cited by in Crossref: 54] [Cited by in F6Publishing: 46] [Article Influence: 6.0] [Reference Citation Analysis]
515 Campbell CT, Poisson MO, Hand EO. An Updated Review of Clostridium difficile Treatment in Pediatrics. J Pediatr Pharmacol Ther 2019;24:90-8. [PMID: 31019401 DOI: 10.5863/1551-6776-24.2.90] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
516 Kociolek LK, Bovee M, Carter D, Ciolino JD, Patel R, O'Donnell A, Rupp AH, Zheng X, Shulman ST, Patel SJ. Impact of a Healthcare Provider Educational Intervention on Frequency of Clostridium difficile Polymerase Chain Reaction Testing in Children: A Segmented Regression Analysis. J Pediatric Infect Dis Soc 2017;6:142-8. [PMID: 27190172 DOI: 10.1093/jpids/piw027] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
517 Granato PA, Hansen G, Herding E, Chaudhuri S, Tang S, Garg SK, Rowell CR, Sickler JJ. Performance comparison of the cobas Liat and Cepheid GeneXpert systems for Clostridium difficile detection. PLoS One 2018;13:e0200498. [PMID: 30040852 DOI: 10.1371/journal.pone.0200498] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
518 Shah DN, Chan FS, Kachru N, Garcia KP, Balcer HE, Dyer AP, Emanuel JE, Jordan MD, Lusardi KT, Naymick G, Polisetty RS, Sieman L, Tyler AM, Johnson ML, Garey KW. A multi-center study of fidaxomicin use for Clostridium difficile infection. Springerplus 2016;5:1224. [PMID: 27536508 DOI: 10.1186/s40064-016-2825-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
519 Alonso-fernández P, Wu Lai T, García-salmones M, Saavedra-cervera B, García-salguero C, Merino P. Clostridium difficile, ¿están todos los que son? Revista de Calidad Asistencial 2015;30:79-85. [DOI: 10.1016/j.cali.2015.01.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
520 Gordon D, Young L, Reddy S, Bergman C, Young J. Incidence of Clostridium difficile infection in patients receiving high-risk antibiotics with or without a proton pump inhibitor. Journal of Hospital Infection 2016;92:173-7. [DOI: 10.1016/j.jhin.2015.10.009] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]
521 Vindigni SM, Surawicz CM. Cirrhosis and C. difficile: A Deadly Duo? Dig Dis Sci 2015;60:2865-7. [DOI: 10.1007/s10620-015-3777-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
522 Adler A, Schwartzberg Y, Samra Z, Schwartz O, Carmeli Y, Schwaber M. Trends and changes in Clostridium difficile diagnostic policies and their impact on the proportion of positive samples: a national survey. Clinical Microbiology and Infection 2014;20:O904-10. [DOI: 10.1111/1469-0691.12634] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
523 Yang Z, Ramsey J, Hamza T, Zhang Y, Li S, Yfantis HG, Lee D, Hernandez LD, Seghezzi W, Furneisen JM, Davis NM, Therien AG, Feng H. Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab. Infect Immun 2015;83:822-31. [PMID: 25486992 DOI: 10.1128/IAI.02897-14] [Cited by in Crossref: 63] [Cited by in F6Publishing: 33] [Article Influence: 7.9] [Reference Citation Analysis]
524 Anderson PA, Bernatz J, Safdar N. Clostridium difficile Infection: An Orthopaedic Surgeon's Guide to Epidemiology, Management, and Prevention. J Am Acad Orthop Surg 2017;25:214-23. [PMID: 28134674 DOI: 10.5435/JAAOS-D-15-00470] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.4] [Reference Citation Analysis]
525 Bartlett JG. A call to arms: the imperative for antimicrobial stewardship. Clin Infect Dis. 2011;53 Suppl 1:S4-S7. [PMID: 21795727 DOI: 10.1093/cid/cir362] [Cited by in Crossref: 80] [Cited by in F6Publishing: 73] [Article Influence: 7.3] [Reference Citation Analysis]
526 Walker AS, Eyre DW, Wyllie DH, Dingle KE, Griffiths D, Shine B, Oakley S, O'Connor L, Finney J, Vaughan A, Crook DW, Wilcox MH, Peto TE; Infections in Oxfordshire Research Database. Relationship between bacterial strain type, host biomarkers, and mortality in Clostridium difficile infection. Clin Infect Dis 2013;56:1589-600. [PMID: 23463640 DOI: 10.1093/cid/cit127] [Cited by in Crossref: 164] [Cited by in F6Publishing: 156] [Article Influence: 18.2] [Reference Citation Analysis]
527 Napolitano LM, Edmiston CE. Clostridium difficile disease: Diagnosis, pathogenesis, and treatment update. Surgery 2017;162:325-48. [DOI: 10.1016/j.surg.2017.01.018] [Cited by in Crossref: 61] [Cited by in F6Publishing: 48] [Article Influence: 12.2] [Reference Citation Analysis]
528 Na X, Kelly C. Probiotics in clostridium difficile Infection. J Clin Gastroenterol 2011;45 Suppl:S154-8. [PMID: 21992956 DOI: 10.1097/MCG.0b013e31822ec787] [Cited by in Crossref: 47] [Cited by in F6Publishing: 18] [Article Influence: 4.7] [Reference Citation Analysis]
529 Keddis MT, Khanna S, Noheria A, Baddour LM, Pardi DS, Qian Q. Clostridium difficile infection in patients with chronic kidney disease. Mayo Clin Proc 2012;87:1046-53. [PMID: 23127731 DOI: 10.1016/j.mayocp.2012.05.025] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 5.1] [Reference Citation Analysis]
530 Stahlmann J, Schönberg M, Herrmann M, von Müller L. Detection of nosocomial Clostridium difficile infections with toxigenic strains despite negative toxin A and B testing on stool samples. Clin Microbiol Infect 2014;20:O590-2. [PMID: 24450741 DOI: 10.1111/1469-0691.12558] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
531 Song L, Zhao M, Duffy DC, Hansen J, Shields K, Wungjiranirun M, Chen X, Xu H, Leffler DA, Sambol SP, Gerding DN, Kelly CP, Pollock NR. Development and Validation of Digital Enzyme-Linked Immunosorbent Assays for Ultrasensitive Detection and Quantification of Clostridium difficile Toxins in Stool. J Clin Microbiol 2015;53:3204-12. [PMID: 26202120 DOI: 10.1128/JCM.01334-15] [Cited by in Crossref: 34] [Cited by in F6Publishing: 18] [Article Influence: 4.9] [Reference Citation Analysis]
532 Eyre DW, Griffiths D, Vaughan A, Golubchik T, Acharya M, O’Connor L, Crook DW, Walker AS, Peto TE. Asymptomatic Clostridium difficile colonisation and onward transmission. PLoS One. 2013;8:e78445. [PMID: 24265690 DOI: 10.1371/journal.pone.0078445] [Cited by in Crossref: 87] [Cited by in F6Publishing: 79] [Article Influence: 9.7] [Reference Citation Analysis]
533 Nerandzic MM, Rackaityte E, Jury LA, Eckart K, Donskey CJ. Novel strategies for enhanced removal of persistent Bacillus anthracis surrogates and Clostridium difficile spores from skin. PLoS One 2013;8:e68706. [PMID: 23844234 DOI: 10.1371/journal.pone.0068706] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
534 Rao K, Young VB, Aronoff DM. Reply to Planche et al. Clin Infect Dis 2015;61:1211-2. [PMID: 26092487 DOI: 10.1093/cid/civ480] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
535 Mansour NM, Elkhatib WF, Aboshanab KM, Bahr MMA. Inhibition of Clostridium difficile in Mice Using a Mixture of Potential Probiotic Strains Enterococcus faecalis NM815, E. faecalis NM915, and E. faecium NM1015: Novel Candidates to Control C. difficile Infection (CDI). Probiotics Antimicrob Proteins 2018;10:511-22. [PMID: 28497217 DOI: 10.1007/s12602-017-9285-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
536 Strauss R, Neurath MF. [Clostridium difficile infections - still a major challenge]. MMW Fortschr Med 2013;155:57-9. [PMID: 23668179 DOI: 10.1007/s15006-013-0436-9] [Reference Citation Analysis]
537 Abe K, Shiba H, Furukawa K, Sakamoto T, Ishida Y, Yanaga K. Repeated Clostridium difficile infection after living donor liver transplantation. Clin J Gastroenterol 2018;11:309-11. [DOI: 10.1007/s12328-018-0840-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
538 Furuya-Kanamori L, Riley TV, Paterson DL, Foster NF, Huber CA, Hong S, Harris-Brown T, Robson J, Clements AC. Comparison of Clostridium difficile Ribotypes Circulating in Australian Hospitals and Communities. J Clin Microbiol 2017;55:216-25. [PMID: 27807147 DOI: 10.1128/JCM.01779-16] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
539 Yu S, Abdelkarim A, Nawras A, Hinch BT, Mbaso C, Valavoor S, Safi F, Hammersley J, Tang J, Assaly R. Fecal Transplant for Treatment of Toxic Megacolon Associated With Clostridium Difficile Colitis in a Patient With Duchenne Muscular Dystrophy. American Journal of Therapeutics 2016;23:e609-13. [DOI: 10.1097/mjt.0000000000000062] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
540 Ng QX, Loke W, Foo NX, Mo Y, Yeo W, Soh AYS. A systematic review of the use of rifaximin for Clostridium difficile infections. Anaerobe 2019;55:35-9. [DOI: 10.1016/j.anaerobe.2018.10.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
541 Tousseeva A, Jackson JD, Redell M, Henry T, Hui M, Capurso S, DeRyke CA. Stability and recovery of DIFICID(®) (Fidaxomicin) 200-mg crushed tablet preparations from three delivery vehicles, and administration of an aqueous dispersion via nasogastric tube. Drugs R D 2014;14:309-14. [PMID: 25424419 DOI: 10.1007/s40268-014-0067-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
542 Schechner V, Carmeli Y, Leshno M. A mathematical model of Clostridium difficile transmission in medical wards and a cost-effectiveness analysis comparing different strategies for laboratory diagnosis and patient isolation. PLoS One 2017;12:e0171327. [PMID: 28187144 DOI: 10.1371/journal.pone.0171327] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
543 Tay HL, Chow A, Ng TM, Lye DC. Risk factors and treatment outcomes of severe Clostridioides difficile infection in Singapore. Sci Rep 2019;9:13440. [PMID: 31530847 DOI: 10.1038/s41598-019-49794-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
544 Katz S, Surawicz C, Pardi DS. Management of the Elderly Patients with Inflammatory Bowel Disease: Practical Considerations. Inflammatory Bowel Diseases 2013;19:2257-72. [DOI: 10.1097/mib.0b013e31828c8536] [Cited by in Crossref: 19] [Cited by in F6Publishing: 4] [Article Influence: 2.1] [Reference Citation Analysis]
545 Beck ET, Buchan BW, Riebe KM, Alkins BR, Pancholi P, Granato PA, Ledeboer NA. Multicenter evaluation of the Quidel Lyra Direct C. difficile nucleic acid amplification assay. J Clin Microbiol. 2014;52:1998-2002. [PMID: 24671790 DOI: 10.1128/jcm.03089-13] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
546 Kaltsas A, Simon M, Unruh LH, Son C, Wroblewski D, Musser KA, Sepkowitz K, Babady NE, Kamboj M. Clinical and laboratory characteristics of Clostridium difficile infection in patients with discordant diagnostic test results. J Clin Microbiol 2012;50:1303-7. [PMID: 22238444 DOI: 10.1128/JCM.05711-11] [Cited by in Crossref: 49] [Cited by in F6Publishing: 30] [Article Influence: 4.9] [Reference Citation Analysis]
547 Penit A, Bemer P, Besson J, Cazet L, Bourigault C, Juvin ME, Fix MH, Bruley des Varannes S, Boutoille D, Batard E, Lepelletier D. Community-acquired Clostridium difficile infections. Med Mal Infect 2016;46:131-9. [PMID: 27039068 DOI: 10.1016/j.medmal.2016.01.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
548 El Feghaly RE, Tarr PI. Editorial Commentary: Clostridium difficile in Children: Colonization and Consequences. Clinical Infectious Diseases 2013;57:9-12. [DOI: 10.1093/cid/cit160] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
549 Giancola SE, Williams RJ, Gentry CA. Evaluation of fidaxomicin usage patterns and outcomes for Clostridium difficile infection across the United States Veterans Health Administration. J Clin Pharm Ther 2018;43:353-8. [DOI: 10.1111/jcpt.12663] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
550 Zhao R, Wang Y, Huang Y, Cui Y, Xia L, Rao Z, Zhou Y, Wu X. Effects of fiber and probiotics on diarrhea associated with enteral nutrition in gastric cancer patients: A prospective randomized and controlled trial. Medicine (Baltimore) 2017;96:e8418. [PMID: 29069041 DOI: 10.1097/MD.0000000000008418] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
551 Reigadas E, Alcalá L, Marín M, Burillo A, Muñoz P, Bouza E. Missed diagnosis of Clostridium difficile infection; a prospective evaluation of unselected stool samples. J Infect 2015;70:264-72. [PMID: 25452039 DOI: 10.1016/j.jinf.2014.10.013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
552 Lv Z, Peng GL, Su JR. Factors associated with Clostridium difficile diarrhea in a hospital in Beijing, China. Braz J Med Biol Res 2014;47:1085-90. [PMID: 25387676 [PMID: 25387676 DOI: 10.1590/1414-431x20143520] [Cited by in Crossref: 5] [Article Influence: 0.6] [Reference Citation Analysis]
553 Lamps L. PCR vs "PCAren't": limitations of PCR-based assays performed on formalin-fixed, paraffin-embedded mucosal biopsy specimens. Am J Clin Pathol 2013;139:705-7. [PMID: 23690111 DOI: 10.1309/AJCPWFN9D0EGDEUK] [Reference Citation Analysis]
554 Scaria J, Suzuki H, Ptak CP, Chen JW, Zhu Y, Guo XK, Chang YF. Comparative genomic and phenomic analysis of Clostridium difficile and Clostridium sordellii, two related pathogens with differing host tissue preference. BMC Genomics 2015;16:448. [PMID: 26059449 DOI: 10.1186/s12864-015-1663-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
555 Alrabaa S, Jariwala R, Zeitler K, Montero J. Fecal microbiota transplantation outcomes in immunocompetent and immunocompromised patients: A single-center experience. Transpl Infect Dis 2017;19:e12726. [DOI: 10.1111/tid.12726] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
556 Galdys AL, Curry SR, Harrison LH. Asymptomatic Clostridium difficile colonization as a reservoir for Clostridium difficile infection. Expert Review of Anti-infective Therapy 2014;12:967-80. [DOI: 10.1586/14787210.2014.920252] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
557 Furuya-Kanamori L, Robson J, Soares Magalhães RJ, Yakob L, McKenzie SJ, Paterson DL, Riley TV, Clements AC. A population-based spatio-temporal analysis of Clostridium difficile infection in Queensland, Australia over a 10-year period. J Infect 2014;69:447-55. [PMID: 24984276 DOI: 10.1016/j.jinf.2014.06.014] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
558 Passaretti CL, Otter JA, Reich NG, Myers J, Shepard J, Ross T, Carroll KC, Lipsett P, Perl TM. An Evaluation of Environmental Decontamination With Hydrogen Peroxide Vapor for Reducing the Risk of Patient Acquisition of Multidrug-Resistant Organisms. Clinical Infectious Diseases 2013;56:27-35. [DOI: 10.1093/cid/cis839] [Cited by in Crossref: 141] [Cited by in F6Publishing: 119] [Article Influence: 14.1] [Reference Citation Analysis]
559 Malani AN, Richards PG, Kapila S, Otto MH, Czerwinski J, Singal B. Clinical and economic outcomes from a community hospital's antimicrobial stewardship program. Am J Infect Control 2013;41:145-8. [PMID: 22579261 DOI: 10.1016/j.ajic.2012.02.021] [Cited by in Crossref: 104] [Cited by in F6Publishing: 92] [Article Influence: 10.4] [Reference Citation Analysis]
560 Rodriguez C, Hakimi D, Vanleyssem R, Taminiau B, Van Broeck J, Delmée M, Korsak N, Daube G. Clostridium difficile in beef cattle farms, farmers and their environment: Assessing the spread of the bacterium. Veterinary Microbiology 2017;210:183-7. [DOI: 10.1016/j.vetmic.2017.09.010] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
561 Issa I, Moucari R. Probiotics for antibiotic-associated diarrhea: Do we have a verdict? World J Gastroenterol 2014; 20(47): 17788-17795 [PMID: 25548477 DOI: 10.3748/wjg.v20.i47.17788] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 20] [Article Influence: 4.3] [Reference Citation Analysis]
562 Reigadas E, Alcalá L, Marín M, Pelaéz T, Martin A, Iglesias C, Bouza E. In vitro activity of surotomycin against contemporary clinical isolates of toxigenic Clostridium difficile strains obtained in Spain. J Antimicrob Chemother 2015;70:2311-5. [PMID: 25876881 DOI: 10.1093/jac/dkv092] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
563 Joyce NR, Mylonakis E, Mor V. Effect of Clostridium difficile Prevalence in Hospitals and Nursing Homes on Risk of Infection. J Am Geriatr Soc 2017;65:1527-34. [PMID: 28394408 DOI: 10.1111/jgs.14838] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
564 Kaiser AM, Hogen R, Bordeianou L, Alavi K, Wise PE, Sudan R; On behalf of the CME Committee of the SSAT. Clostridium Difficile Infection from a Surgical Perspective. J Gastrointest Surg 2015;19:1363-77. [DOI: 10.1007/s11605-015-2785-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 3.1] [Reference Citation Analysis]
565 Dupont HL. Diagnosis and management of Clostridium difficile infection. Clin Gastroenterol Hepatol 2013;11:1216-23; quiz e73. [PMID: 23542332 DOI: 10.1016/j.cgh.2013.03.016] [Cited by in Crossref: 45] [Cited by in F6Publishing: 32] [Article Influence: 5.0] [Reference Citation Analysis]
566 Thabit AK, Alsolami MH, Baghlaf NA, Alsharekh RM, Almazmumi HA, Alselami AS, Alsubhi FA. Comparison of three current Clostridioides difficile infection guidelines: IDSA/SHEA, ESCMID, and ACG guidelines. Infection 2019;47:899-909. [PMID: 31428991 DOI: 10.1007/s15010-019-01348-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
567 González-Del Vecchio M, Álvarez-Uria A, Marin M, Alcalá L, Martín A, Montilla P, Bouza E. Clinical Significance of Clostridium difficile in Children Less Than 2 Years Old: A Case-Control Study. Pediatr Infect Dis J 2016;35:281-5. [PMID: 26650114 DOI: 10.1097/INF.0000000000001008] [Cited by in Crossref: 19] [Cited by in F6Publishing: 5] [Article Influence: 3.2] [Reference Citation Analysis]
568 Hardesty JS, Juang P. Fidaxomicin: a macrocyclic antibiotic for the treatment of Clostridium difficile infection. Pharmacotherapy 2011;31:877-86. [PMID: 21923589 DOI: 10.1592/phco.31.9.877] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
569 Blakney R, Yanke E, Fink C, Wigton R, Safdar N. Optimizing diagnostic testing for Clostridium difficile: The perceptions of physicians and nurses on when to order testing for C difficile. Am J Infect Control 2015;43:889-91. [PMID: 25957816 DOI: 10.1016/j.ajic.2015.03.025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
570 Neuberger A, Saadi T, Shetern A, Schwartz E. Clostridium difficile Infection in travelers--a neglected pathogen? J Travel Med 2013;20:37-43. [PMID: 23279229 DOI: 10.1111/j.1708-8305.2012.00676.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
571 Tran TT, Beyda ND, Biehle LR, Cottreau JM, Echevarria K, Musick WL, Perez KK, Schilling AN. Significant publications on infectious diseases pharmacotherapy in 2011. American Journal of Health-System Pharmacy 2012;69:1671-81. [DOI: 10.2146/ajhp120151] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
572 Sandora TJ, Fung M, Flaherty K, Helsing L, Scanlon P, Potter-Bynoe G, Gidengil CA, Lee GM. Epidemiology and risk factors for Clostridium difficile infection in children. Pediatr Infect Dis J. 2011;30:580-584. [PMID: 21233782 DOI: 10.1097/inf.0b013e31820bfb29] [Cited by in Crossref: 108] [Cited by in F6Publishing: 37] [Article Influence: 9.8] [Reference Citation Analysis]
573 Kamboj M, Brite J, McMillen T, Robilotti E, Herrera A, Sepkowitz K, Babady NE. Potential of real-time PCR threshold cycle (CT) to predict presence of free toxin and clinically relevant C. difficile infection (CDI) in patients with cancer. J Infect 2018;76:369-75. [PMID: 29229281 DOI: 10.1016/j.jinf.2017.12.001] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 5.4] [Reference Citation Analysis]
574 Caulfield AJ, Bolster Lasalle CM, Chang YH, Grys TE. Evaluation of 4 molecular assays as part of a 2-step algorithm for the detection of Clostridium difficile in stool specimens. Diagnostic Microbiology and Infectious Disease 2018;91:1-5. [DOI: 10.1016/j.diagmicrobio.2017.12.018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
575 Peng Z, Addisu A, Alrabaa S, Sun X. Antibiotic Resistance and Toxin Production of Clostridium difficile Isolates from the Hospitalized Patients in a Large Hospital in Florida. Front Microbiol 2017;8:2584. [PMID: 29312258 DOI: 10.3389/fmicb.2017.02584] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
576 Hudson LE, Anderson SE, Corbett AH, Lamb TJ. Gleaning Insights from Fecal Microbiota Transplantation and Probiotic Studies for the Rational Design of Combination Microbial Therapies. Clin Microbiol Rev. 2017;30:191-231. [PMID: 27856521 DOI: 10.1128/cmr.00049-16] [Cited by in Crossref: 38] [Cited by in F6Publishing: 27] [Article Influence: 7.6] [Reference Citation Analysis]
577 Nassour I, Carchman EH, Simmons RL, Zuckerbraun BS. Novel management strategies in the treatment of severe Clostridium difficile infection. Adv Surg 2012;46:111-35. [PMID: 22873036 DOI: 10.1016/j.yasu.2012.03.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
578 Redding LE, Kelly BJ, Stefanovski D, Lautenbach JK, Tolomeo P, Cressman L, Gruber E, Meily P, Lautenbach E. Pet Ownership Protects Against Recurrence of Clostridioides difficile Infection. Open Forum Infect Dis 2020;7:ofz541. [PMID: 31976354 DOI: 10.1093/ofid/ofz541] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
579 Eckert C, Holscher E, Petit A, Lalande V, Barbut F. Molecular test based on isothermal helicase-dependent amplification for detection of the Clostridium difficile toxin A gene. J Clin Microbiol 2014;52:2386-9. [PMID: 24759714 DOI: 10.1128/JCM.00353-14] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
580 Navalkele BD, Chopra T. Bezlotoxumab: an emerging monoclonal antibody therapy for prevention of recurrent Clostridium difficile infection. Biologics 2018;12:11-21. [PMID: 29403263 DOI: 10.2147/BTT.S127099] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
581 Zhu Z, Shi L, Feng H, Zhou HS. Single domain antibody coated gold nanoparticles as enhancer for Clostridium difficile toxin detection by electrochemical impedance immunosensors. Bioelectrochemistry 2015;101:153-8. [PMID: 25460611 DOI: 10.1016/j.bioelechem.2014.10.003] [Cited by in Crossref: 37] [Cited by in F6Publishing: 27] [Article Influence: 6.2] [Reference Citation Analysis]
582 Dubberke ER, Schaefer E, Reske KA, Zilberberg M, Hollenbeak CS, Olsen MA. Attributable inpatient costs of recurrent Clostridium difficile infections. Infect Control Hosp Epidemiol. 2014;35:1400-1407. [PMID: 25333435 DOI: 10.1086/678428] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 4.3] [Reference Citation Analysis]
583 Cheng JW, Yang QW, Xiao M, Yu SY, Zhou ML, Kudinha T, Kong F, Liao JW, Xu YC. High in vitro activity of fidaxomicin against Clostridium difficile isolates from a university teaching hospital in China. J Microbiol Immunol Infect 2018;51:411-6. [PMID: 28693926 DOI: 10.1016/j.jmii.2017.06.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
584 Barkin JA, Sussman DA, Fifadara N, Barkin JS. Clostridium difficile Infection and Patient-Specific Antimicrobial Resistance Testing Reveals a High Metronidazole Resistance Rate. Dig Dis Sci 2017;62:1035-42. [DOI: 10.1007/s10620-017-4462-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
585 Stanley JD, Bartlett JG, Dart BW 4th, Ashcraft JH. Clostridium difficile infection. Curr Probl Surg 2013;50:302-37. [PMID: 23764494 DOI: 10.1067/j.cpsurg.2013.02.004] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
586 Lynch TJ. Choosing optimal antimicrobial therapies. Med Clin North Am 2012;96:1079-94. [PMID: 23102478 DOI: 10.1016/j.mcna.2012.08.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
587 Maxwell-Scott HG, Goldenberg SD. Existing and investigational therapies for the treatment of Clostridium difficile infection: A focus on narrow spectrum, microbiota-sparing agents. Med Mal Infect 2018;48:1-9. [PMID: 29169816 DOI: 10.1016/j.medmal.2017.10.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
588 Kim B, Seo M, Kim J, Pai H. Ribotype variability of Clostridioides difficile strains in patients with hospital-acquired C. difficile infections, community-acquired C. difficile infections, and colonization with toxigenic and non-toxigenic strains of C. difficile. Anaerobe 2019;60:102086. [DOI: 10.1016/j.anaerobe.2019.102086] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
589 Vindigni SM, Broussard EK, Surawicz CM. Alteration of the intestinal microbiome: fecal microbiota transplant and probiotics for Clostridium difficile and beyond. Expert Review of Gastroenterology & Hepatology 2014;7:615-28. [DOI: 10.1586/17474124.2013.832501] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
590 Tillotson GS, Tillotson J. Clostridium difficile--a moving target. F1000 Med Rep 2011;3:6. [PMID: 21654927 DOI: 10.3410/M3-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
591 Woodworth MH, Kraft CS. Diagnostic and Therapeutic Considerations for Oncology Patients With Clostridium difficile Infection. J Oncol Pract 2017;13:31-2. [PMID: 28084885 DOI: 10.1200/JOP.2016.019141] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
592 Oami T, Hattori N, Matsumura Y, Watanabe E, Abe R, Oshima T, Takahashi W, Yamazaki S, Suzuki T, Oda S. The Effects of Fasting and Massive Diarrhea on Absorption of Enteral Vancomycin in Critically Ill Patients: A Retrospective Observational Study. Front Med (Lausanne) 2017;4:70. [PMID: 28642864 DOI: 10.3389/fmed.2017.00070] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
593 Gweon TG, Kim J, Lim CH, Park JM, Lee DG, Lee IS, Cho YS, Kim SW, Choi MG. Fecal Microbiota Transplantation Using Upper Gastrointestinal Tract for the Treatment of Refractory or Severe Complicated Clostridium difficile Infection in Elderly Patients in Poor Medical Condition: The First Study in an Asian Country. Gastroenterol Res Pract 2016;2016:2687605. [PMID: 27127501 DOI: 10.1155/2016/2687605] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
594 Napierala M, Munson E, Skonieczny P, Rodriguez S, Riederer N, Land G, Luzinski M, Block D, Hryciuk JE. Impact of toxigenic Clostridium difficile polymerase chain reaction testing on the clinical microbiology laboratory and inpatient epidemiology. Diagn Microbiol Infect Dis 2013;76:534-8. [PMID: 23731555 DOI: 10.1016/j.diagmicrobio.2013.04.020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
595 Danielson P, Mckiernan H, Legg K. Integrated Polymerase Chain Reaction Technologies (Sample-to-Answer Technologies). Molecular Diagnostics. Elsevier; 2017. pp. 59-78. [DOI: 10.1016/b978-0-12-802971-8.00005-5] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
596 Trubiano JA, Cheng AC, Korman TM, Roder C, Campbell A, May ML, Blyth CC, Ferguson JK, Blackmore TK, Riley TV, Athan E. Australasian Society of Infectious Diseases updated guidelines for the management of Clostridium difficile infection in adults and children in Australia and New Zealand. Intern Med J 2016;46:479-93. [PMID: 27062204 DOI: 10.1111/imj.13027] [Cited by in Crossref: 62] [Cited by in F6Publishing: 54] [Article Influence: 12.4] [Reference Citation Analysis]
597 Bartsch SM, Umscheid CA, Nachamkin I, Hamilton K, Lee BY. Comparing the economic and health benefits of different approaches to diagnosing Clostridium difficile infection. Clin Microbiol Infect. 2015;21:77.e1-77.e9. [PMID: 25636938 DOI: 10.1016/j.cmi.2014.07.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
598 Kali A, Charles MV, Srirangaraj S. Cadazolid: A new hope in the treatment of Clostridium difficile infection. Australas Med J. 2015;8:253-262. [PMID: 26392822 DOI: 10.4066/amj.2015.2441] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
599 Storey DF, Pate PG, Nguyen AT, Chang F. Implementation of an antimicrobial stewardship program on the medical-surgical service of a 100-bed community hospital. Antimicrob Resist Infect Control 2012;1:32. [PMID: 23043720 DOI: 10.1186/2047-2994-1-32] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 3.9] [Reference Citation Analysis]
600 Williamson DA, Basu I, Freeman J, Swager T, Roberts SA. Improved detection of toxigenic Clostridium difficile using the Cepheid Xpert C difficile assay and impact on C difficile infection rates in a tertiary hospital: a double-edged sword. Am J Infect Control. 2013;41:270-272. [PMID: 22939418 DOI: 10.1016/j.ajic.2012.03.025] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
601 Garcia Reeves AB, Lewis JW, Trogdon JG, Stearns SC, Weber DJ, Weinberger M. Association between statewide adoption of the CDC's Core Elements of Hospital Antimicrobial Stewardship Programs and rates of methicillin-resistant Staphylococcus aureus bacteremia and Clostridioides difficile infection in the United States. Infect Control Hosp Epidemiol 2020;41:430-7. [PMID: 31858919 DOI: 10.1017/ice.2019.352] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
602 Bull AL, Worth LJ, Richards MJ. Implementation of standardised surveillance for Clostridium difficile infections in Australia: initial report from the Victorian Healthcare Associated Infection Surveillance System. Intern Med J 2012;42:715-8. [PMID: 22697155 DOI: 10.1111/j.1445-5994.2012.02804.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
603 Islam J, Cheek E, Navani V, Rajkumar C, Cohen J, Llewelyn MJ. Influence of cohorting patients with Clostridium difficile infection on risk of symptomatic recurrence. J Hosp Infect 2013;85:17-21. [PMID: 23910403 DOI: 10.1016/j.jhin.2013.06.009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
604 Xu B, Wu X, Gong Y, Cao J. IL-27 induces LL-37/CRAMP expression from intestinal epithelial cells: implications for immunotherapy of Clostridioides difficile infection. Gut Microbes 2021;13:1968258. [PMID: 34432564 DOI: 10.1080/19490976.2021.1968258] [Reference Citation Analysis]
605 Miller MA, Louie T, Mullane K, Weiss K, Lentnek A, Golan Y, Kean Y, Sears P. Derivation and validation of a simple clinical bedside score (ATLAS) for Clostridium difficile infection which predicts response to therapy. BMC Infect Dis 2013;13:148. [PMID: 23530807 DOI: 10.1186/1471-2334-13-148] [Cited by in Crossref: 80] [Cited by in F6Publishing: 73] [Article Influence: 8.9] [Reference Citation Analysis]
606 Wagner JL, Stover KR, Bell AM, Barber KE. Risk factors for development of initial Clostridioides difficile infection. J Glob Antimicrob Resist 2021;25:18-22. [PMID: 33667706 DOI: 10.1016/j.jgar.2021.02.012] [Reference Citation Analysis]
607 Clancy CJ, Buehrle D, Vu M, Wagener MM, Nguyen MH. Impact of Revised Infectious Diseases Society of America and Society for Healthcare Epidemiology of America Clinical Practice Guidelines on the Treatment of Clostridium difficile Infections in the United States. Clin Infect Dis 2021;72:1944-9. [PMID: 32343766 DOI: 10.1093/cid/ciaa484] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
608 Thabit AK, Nicolau DP. An exploratory study to evaluate Clostridium difficile polymerase chain reaction ribotypes and infection outcomes. Infect Drug Resist 2016;9:143-8. [PMID: 27390531 DOI: 10.2147/IDR.S108325] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
609 Walker AS, Eyre DW, Wyllie DH, Dingle KE, Harding RM, O'Connor L, Griffiths D, Vaughan A, Finney J, Wilcox MH, Crook DW, Peto TE. Characterisation of Clostridium difficile hospital ward-based transmission using extensive epidemiological data and molecular typing. PLoS Med 2012;9:e1001172. [PMID: 22346738 DOI: 10.1371/journal.pmed.1001172] [Cited by in Crossref: 141] [Cited by in F6Publishing: 132] [Article Influence: 14.1] [Reference Citation Analysis]
610 Thomas A, Khan F, Uddin N, Wallace MR. Tigecycline for severe Clostridium difficile infection. International Journal of Infectious Diseases 2014;26:171-2. [DOI: 10.1016/j.ijid.2014.04.025] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
611 Hannan MM, Husain S, Mattner F, Danziger-Isakov L, Drew RJ, Corey GR, Schueler S, Holman WL, Lawler LP, Gordon SM. Working formulation for the standardization of definitions of infections in patients using ventricular assist devices. J Heart Lung Transplant. 2011;30:375-384. [PMID: 21419995 DOI: 10.1016/j.healun.2011.01.717] [Cited by in Crossref: 221] [Cited by in F6Publishing: 172] [Article Influence: 20.1] [Reference Citation Analysis]
612 Casari E, De Luca C, Calabrò M, Scuderi C, Daleno C, Ferrario A. Reducing rates of Clostridium difficile infection by switching to a stand-alone NAAT with clear sampling criteria. Antimicrob Resist Infect Control 2018;7:40. [PMID: 29564088 DOI: 10.1186/s13756-018-0332-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
613 Karaali C, Emiroğlu M, Çalık B, Sert I, Kebapci E, Kaya T, Budak GG, Akbulut G, Aydın C. Evaluation of Antibiotic Prophylaxis and Discharge Prescriptions in the General Surgery Department. Cureus 2019;11:e4793. [PMID: 31497412 DOI: 10.7759/cureus.4793] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
614 Cui BT, Wang M, Ji GZ, Fan ZN, Zhang FM. Fecal microbiota transplantation: from the 4th century to 2013. Shijie Huaren Xiaohua Zazhi 2013; 21(30): 3222-3229 [DOI: 10.11569/wcjd.v21.i30.3222] [Reference Citation Analysis]
615 Halvorson SA, Cedfeldt AS, Hunter AJ. Fulminant, non-antibiotic associated Clostridium difficile colitis following Salmonella gastroenteritis. J Gen Intern Med 2011;26:95-7. [PMID: 20697966 DOI: 10.1007/s11606-010-1466-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
616 Oshima H, Yamazaki T, Benner L, Miki T, Michon I, Wojtkowski T, Kaibara A, Mujais S. Comparison of the safety, tolerability, and pharmacokinetics of fidaxomicin in healthy Japanese and caucasian subjects. Clin Drug Investig 2015;35:375-84. [PMID: 25972286 DOI: 10.1007/s40261-015-0291-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
617 Rogers GB, Bruce KD. Challenges and opportunities for faecal microbiota transplantation therapy. Epidemiol Infect 2013;141:2235-42. [PMID: 23735045 DOI: 10.1017/S0950268813001362] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
618 Mellace L, Consonni D, Jacchetti G, Del Medico M, Colombo R, Velati M, Formica S, Cappellini MD, Castaldi S, Fabio G. Epidemiology of Clostridium difficile-associated disease in internal medicine wards in northern Italy. Intern Emerg Med 2013;8:717-23. [DOI: 10.1007/s11739-012-0752-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
619 Inghammar M, Svanström H, Voldstedlund M, Melbye M, Hviid A, Mølbak K, Pasternak B. Proton-Pump Inhibitor Use and the Risk of Community-Associated Clostridium difficile Infection. Clin Infect Dis 2021;72:e1084-9. [PMID: 33629099 DOI: 10.1093/cid/ciaa1857] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
620 Marra F, Ng K. Controversies Around Epidemiology, Diagnosis and Treatment of Clostridium difficile Infection. Drugs 2015;75:1095-118. [PMID: 26113167 DOI: 10.1007/s40265-015-0422-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
621 Kelly SG, Yarrington M, Zembower TR, Sutton SH, Silkaitis C, Postelnick M, Mikolajczak A, Bolon MK. Inappropriate Clostridium difficile Testing and Consequent Overtreatment and Inaccurate Publicly Reported Metrics. Infect Control Hosp Epidemiol 2016;37:1395-400. [PMID: 27666285 DOI: 10.1017/ice.2016.210] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
622 Behar L, Chadwick D, Dunne A, Jones CI, Proctor C, Rajkumar C, Sharratt P, Stanley P, Whiley A, Wilks M, Llewelyn MJ. Toxigenic Clostridium difficile colonization among hospitalised adults; risk factors and impact on survival. J Infect 2017;75:20-5. [PMID: 28435086 DOI: 10.1016/j.jinf.2017.04.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
623 Bono-lunn D, Villeneuve C, Abdulhay NJ, Harker M, Parker W. Policy and regulations in light of the human body as a ‘superorganism’ containing multiple, intertwined symbiotic relationships. Clinical Research and Regulatory Affairs 2016;33:39-48. [DOI: 10.1080/10601333.2016.1210159] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
624 Rubin ZA, Martin EM, Allyn P. Primary Prevention of Clostridium difficile-Associated Diarrhea: Current Controversies and Future Tools. Curr Infect Dis Rep 2018;20:32. [PMID: 29959605 DOI: 10.1007/s11908-018-0639-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
625 Xu Q, Chen Y, Gu S, Lv T, Zheng B, Shen P, Quan J, Fang Y, Li L. Hospital-acquired Clostridium difficile infection in Mainland China: A seven-year (2009-2016) retrospective study in a large university hospital. Sci Rep 2017;7:9645. [PMID: 28852010 DOI: 10.1038/s41598-017-09961-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
626 Koo HL, Van JN, Zhao M, Ye X, Revell PA, Jiang ZD, Grimes CZ, Koo DC, Lasco T, Kozinetz CA, Garey KW, DuPont HL. Real-time polymerase chain reaction detection of asymptomatic Clostridium difficile colonization and rising C. difficile-associated disease rates. Infect Control Hosp Epidemiol 2014;35:667-73. [PMID: 24799643 DOI: 10.1086/676433] [Cited by in Crossref: 78] [Cited by in F6Publishing: 71] [Article Influence: 9.8] [Reference Citation Analysis]
627 Bailey J, Shaffer EA. Pneumatosis Coli Associated with Pseudomembranous Colitis in a Patient following Colonic Surgery. Case Rep Med 2010;2010:138369. [PMID: 21113293 DOI: 10.1155/2010/138369] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
628 Hebbard AI, Slavin MA, Reed C, Teh BW, Thursky KA, Trubiano JA, Worth LJ. The epidemiology of Clostridium difficile infection in patients with cancer. Expert Rev Anti Infect Ther 2016;14:1077-85. [PMID: 27606976 DOI: 10.1080/14787210.2016.1234376] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
629 Pawar D, Tsay R, Nelson DS, Elumalai MK, Lessa FC, Clifford McDonald L, Dumyati G. Burden of Clostridium difficile infection in long-term care facilities in Monroe County, New York. Infect Control Hosp Epidemiol 2012;33:1107-12. [PMID: 23041808 DOI: 10.1086/668031] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 4.8] [Reference Citation Analysis]
630 Berry AC, Learned M, Garland J, Berry L, Rodriguez S, Scott B, Berry BB. Intensive Care Unit Probiotic Utilization Rates: When Committee Recommendations and Physician Utilization Diverge. Infect Control Hosp Epidemiol 2017;38:1011-3. [PMID: 28592341 DOI: 10.1017/ice.2017.117] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
631 Lalani F, Young EH, Panchal RM, Reveles KR. GABAergic but not Antidepressant Medications Increase Risk for Clostridioides difficile Infection in a National Cohort of Veterans. Open Forum Infect Dis 2020;7:ofaa353. [PMID: 32939356 DOI: 10.1093/ofid/ofaa353] [Reference Citation Analysis]
632 Camacho-Ortiz A, Gutiérrez-Delgado EM, Garcia-Mazcorro JF, Mendoza-Olazarán S, Martínez-Meléndez A, Palau-Davila L, Baines SD, Maldonado-Garza H, Garza-González E. Randomized clinical trial to evaluate the effect of fecal microbiota transplant for initial Clostridium difficile infection in intestinal microbiome. PLoS One 2017;12:e0189768. [PMID: 29261736 DOI: 10.1371/journal.pone.0189768] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
633 Seltman AK. Surgical Management of Clostridium difficile Colitis. Clin Colon Rectal Surg 2012;25:204-9. [PMID: 24294121 DOI: 10.1055/s-0032-1329390] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
634 Kociolek LK, Patel SJ, Zheng X, Todd KM, Shulman ST, Gerding DN. Clinical and Microbiologic Assessment of Cases of Pediatric Community-associated Clostridium difficile Infection Reveals Opportunities for Improved Testing Decisions. Pediatr Infect Dis J 2016;35:157-61. [PMID: 26517329 DOI: 10.1097/INF.0000000000000954] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
635 Stevens V, Dumyati G, Fine LS, Fisher SG, van Wijngaarden E. Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection. Clin Infect Dis. 2011;53:42-48. [PMID: 21653301 DOI: 10.1093/cid/cir301] [Cited by in Crossref: 263] [Cited by in F6Publishing: 235] [Article Influence: 23.9] [Reference Citation Analysis]
636 Carson KC, Riley TV. Comparison of the Vidas C. difficile and Quik Chek-60 glutamate dehydrogenase assays for the detection of Clostridium difficile in faecal samples. Pathology 2016;48:506-8. [PMID: 27311869 DOI: 10.1016/j.pathol.2016.04.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
637 Khanna S, Aronson SL, Kammer PP, Baddour LM, Pardi DS. Gastric acid suppression and outcomes in Clostridium difficile infection: a population-based study. Mayo Clin Proc. 2012;87:636-642. [PMID: 22766083 DOI: 10.1016/j.mayocp.2011.12.021] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 4.2] [Reference Citation Analysis]
638 Kapel N, Thomas M, Corcos O, Mayeur C, Barbot-Trystram L, Bouhnik Y, Joly F. Practical implementation of faecal transplantation. Clin Microbiol Infect 2014;20:1098-105. [PMID: 25273614 DOI: 10.1111/1469-0691.12796] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
639 Wang YK, Yan YX, Kim HB, Ju X, Zhao S, Zhang K, Tzipori S, Sun X. A chimeric protein comprising the glucosyltransferase and cysteine proteinase domains of toxin B and the receptor binding domain of toxin A induces protective immunity against Clostridium difficile infection in mice and hamsters. Hum Vaccin Immunother 2015;11:2215-22. [PMID: 26036797 DOI: 10.1080/21645515.2015.1052352] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
640 Vega AD, Heil EL, Blackman AL, Banoub M, Kristie Johnson J, Leekha S, Claeys KC. Evaluation of Addition of Intravenous Metronidazole to Oral Vancomycin Therapy in Critically Ill Patients with Non-Fulminant Severe Clostridioides difficile Infection. Pharmacotherapy 2020;40:398-407. [PMID: 32246501 DOI: 10.1002/phar.2393] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
641 Gouliouris T, Brown NM, Aliyu SH. Prevention and treatment of Clostridium difficile infection. Clin Med (Lond) 2011;11:75-9. [PMID: 21404793 DOI: 10.7861/clinmedicine.11-1-75] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
642 Karadsheh Z, Sule S. Fecal transplantation for the treatment of recurrent clostridium difficile infection. N Am J Med Sci. 2013;5:339-343. [PMID: 23923106 DOI: 10.4103/1947-2714.114163] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
643 Goldberg EJ, Bhalodia S, Jacob S, Patel H, Trinh KV, Varghese B, Yang J, Young SR, Raffa RB. Clostridium difficile infection: A brief update on emerging therapies. Am J Health Syst Pharm 2015;72:1007-12. [PMID: 26025991 DOI: 10.2146/ajhp140645] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
644 Alonso CD, Braun DA, Patel I, Akbari M, Oh DJ, Jun T, McMasters M, Hammond SP, Glotzbecker B, Cutler C, Leffler DA, Ballen KK, Kelly CP. A multicenter, retrospective, case-cohort study of the epidemiology and risk factors for Clostridium difficile infection among cord blood transplant recipients. Transpl Infect Dis 2017;19. [PMID: 28544102 DOI: 10.1111/tid.12728] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
645 Mascio CT, Mortin LI, Howland KT, Van Praagh AD, Zhang S, Arya A, Chuong CL, Kang C, Li T, Silverman JA. In vitro and in vivo characterization of CB-183,315, a novel lipopeptide antibiotic for treatment of Clostridium difficile. Antimicrob Agents Chemother 2012;56:5023-30. [PMID: 22802252 DOI: 10.1128/AAC.00057-12] [Cited by in Crossref: 62] [Cited by in F6Publishing: 27] [Article Influence: 6.2] [Reference Citation Analysis]
646 Khan FY, Abu-Khattab M, Anand D, Baager K, Alaini A, Siddique MA, Mohamed SF, Ali MI, Al Bedawi MM, Naser MS. Epidemiological features of Clostridium difficile infection among inpatients at Hamad General Hospital in the state of Qatar, 2006-2009. Travel Med Infect Dis. 2012;10:179-185. [PMID: 22800937 DOI: 10.1016/j.tmaid.2012.06.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
647 Sun J, Mc Millen T, Babady NE, Kamboj M. Role of Coinfecting Strains in Recurrent Clostridium difficile Infection. Infect Control Hosp Epidemiol 2016;37:1481-4. [PMID: 27572118 DOI: 10.1017/ice.2016.187] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
648 Leis JA, Powis JE, McGeer A, Ricciuto DR, Agnihotri T, Coyle N, Williams V, Moore C, Salt N, Wong L, McCreight L, Sivaramakrishna S, Junaid S, Cao X, Muller M. Introduction of Group Electronic Monitoring of Hand Hygiene on Inpatient Units: A Multicenter Cluster Randomized Quality Improvement Study. Clin Infect Dis 2020;71:e680-5. [PMID: 32270865 DOI: 10.1093/cid/ciaa412] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
649 Chihara S, Shimizu R, Furukata S, Hoshino K. Oral vancomycin may have significant absorption in patients with Clostridium difficile colitis. Scandinavian Journal of Infectious Diseases 2010;43:149-50. [DOI: 10.3109/00365548.2010.513066] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
650 Bishop PA, Isache C, McCarter YS, Smotherman C, Gautam S, Jankowski CA. Clinical impact of a pharmacist-led antimicrobial stewardship initiative evaluating patients with Clostridioides difficile colitis. J Investig Med 2020;68:888-92. [PMID: 32066570 DOI: 10.1136/jim-2019-001173] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
651 Banawas SS. Clostridium difficile Infections: A Global Overview of Drug Sensitivity and Resistance Mechanisms. Biomed Res Int 2018;2018:8414257. [PMID: 29682562 DOI: 10.1155/2018/8414257] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
652 Fu N, Wong T. Clostridium difficile Infection in Patients with Inflammatory Bowel Disease. Curr Infect Dis Rep 2016;18. [DOI: 10.1007/s11908-016-0525-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
653 Fisher A, Dembry LM. Norovirus and Clostridium difficile outbreaks: squelching the wildfire. Curr Opin Infect Dis 2017;30:440-7. [PMID: 28538249 DOI: 10.1097/QCO.0000000000000382] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
654 Huang H, Wu S, Chen R, Xu S, Fang H, Weintraub A, Nord CE. Risk factors of Clostridium difficile infections among patients in a university hospital in Shanghai, China. Anaerobe. 2014;30:65-69. [PMID: 25219941 DOI: 10.1016/j.anaerobe.2014.08.015] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 3.9] [Reference Citation Analysis]
655 Slayton RB, Scott RD, Baggs J, Lessa FC, McDonald LC, Jernigan JA. The cost-benefit of federal investment in preventing Clostridium difficile infections through the use of a multifaceted infection control and antimicrobial stewardship program. Infect Control Hosp Epidemiol 2015;36:681-7. [PMID: 25783204 DOI: 10.1017/ice.2015.43] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
656 Aulagnon F, Scemla A, DeWolf S, Legendre C, Zuber J. Diarrhea after kidney transplantation: a new look at a frequent symptom. Transplantation 2014;98:806-16. [PMID: 25073040 DOI: 10.1097/TP.0000000000000335] [Cited by in Crossref: 40] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
657 Stuart RL, Marshall C, Harrington G, Sasko L, McLaws ML, Ferguson J. ASID/ACIPC position statement - Infection control for patients with Clostridium difficile infection in healthcare facilities. Infect Dis Health 2019;24:32-43. [PMID: 30691583 DOI: 10.1016/j.idh.2018.10.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
658 Park S, Hitchcock MM, Gomez CA, Banaei N. Is Follow-Up Testing with the FilmArray Gastrointestinal Multiplex PCR Panel Necessary? J Clin Microbiol 2017;55:1154-61. [PMID: 28122874 DOI: 10.1128/JCM.02354-16] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 2.6] [Reference Citation Analysis]
659 Hamdeh S, Abdelrahman AAM, Elsallabi O, Pathak R, Giri S, Mosalpuria K, Bhatt VR. Clinical approach to diarrheal disorders in allogeneic hematopoietic stem cell transplant recipients. World J Hematol 2016; 5(1): 23-30 [DOI: 10.5315/wjh.v5.i1.23] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
660 Karanika S, Grigoras C, Flokas ME, Alevizakos M, Kinamon T, Kojic EM, Mylonakis E. The Attributable Burden of Clostridium difficile Infection to Long-Term Care Facilities Stay: A Clinical Study. J Am Geriatr Soc 2017;65:1733-40. [PMID: 28306141 DOI: 10.1111/jgs.14863] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
661 Munson E, Bilbo D, Paul M, Napierala M, Hryciuk JE. Modifications of commercial toxigenic Clostridium difficile PCR resulting in improved economy and workflow efficiency. J Clin Microbiol 2011;49:2279-82. [PMID: 21450967 DOI: 10.1128/JCM.00261-11] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
662 Daley P, Louie T, Lutz JE, Khanna S, Stoutenburgh U, Jin M, Adedoyin A, Chesnel L, Guris D, Larson KB, Murata Y. Surotomycin versus vancomycin in adults with Clostridium difficile infection: primary clinical outcomes from the second pivotal, randomized, double-blind, Phase 3 trial. Journal of Antimicrobial Chemotherapy 2017;72:3462-70. [DOI: 10.1093/jac/dkx299] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 8.0] [Reference Citation Analysis]
663 Thabit AK, Alam MJ, Khaleduzzaman M, Garey KW, Nicolau DP. A pilot study to assess bacterial and toxin reduction in patients with Clostridium difficile infection given fidaxomicin or vancomycin. Ann Clin Microbiol Antimicrob 2016;15:22. [PMID: 27071986 DOI: 10.1186/s12941-016-0140-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
664 Dubberke ER, Carling P, Carrico R, Donskey CJ, Loo VG, McDonald LC, Maragakis LL, Sandora TJ, Weber DJ, Yokoe DS, Gerding DN. Strategies to prevent Clostridium difficile infections in acute care hospitals: 2014 Update. Infect Control Hosp Epidemiol 2014;35:628-45. [PMID: 24799639 DOI: 10.1086/676023] [Cited by in Crossref: 113] [Cited by in F6Publishing: 88] [Article Influence: 16.1] [Reference Citation Analysis]
665 Ngam C, Schoofs Hundt A, Haun N, Carayon P, Stevens L, Safdar N. Barriers and facilitators to Clostridium difficile infection prevention: A nursing perspective. Am J Infect Control 2017;45:1363-8. [PMID: 28939012 DOI: 10.1016/j.ajic.2017.07.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
666 Cherian PT, Wu X, Yang L, Scarborough JS, Singh AP, Alam ZA, Lee RE, Hurdle JG. Gastrointestinal localization of metronidazole by a lactobacilli-inspired tetramic acid motif improves treatment outcomes in the hamster model of Clostridium difficile infection. J Antimicrob Chemother 2015;70:3061-9. [PMID: 26286574 DOI: 10.1093/jac/dkv231] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
667 Lee JH, Park SJ, Lee YM, Lee CH, Cho JH. Evaluation of the diagnostic algorithm consisting of enzyme immunoassay for toxins and polymerase chain reaction, for the diagnosis of Clostridium difficile-associated diarrhoea. Scand J Infect Dis 2012;44:969-72. [PMID: 22813084 DOI: 10.3109/00365548.2012.695456] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
668 Wang MS, Evans CT, Rodriguez T, Gerding DN, Johnson S. Clostridium difficile infection and limitations of markers for severity in patients with hematologic malignancy. Infect Control Hosp Epidemiol. 2013;34:127-132. [PMID: 23295558 DOI: 10.1086/669081] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
669 Fehér C, Soriano A, Mensa J. A Review of Experimental and Off-Label Therapies for Clostridium difficile Infection. Infect Dis Ther 2017;6:1-35. [PMID: 27910000 DOI: 10.1007/s40121-016-0140-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
670 Tart SB. The Role of Vancomycin and Metronidazole for the Treatment of Clostridium difficile– Associated Diarrhea. Journal of Pharmacy Practice 2013;26:488-90. [DOI: 10.1177/0897190013499525] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
671 Szvalb AD, El Haddad H, Rolston KV, Sabir SH, Jiang Y, Raad II, Viola GM. Risk factors for recurrent percutaneous nephrostomy catheter-related infections. Infection 2019;47:239-45. [PMID: 30406481 DOI: 10.1007/s15010-018-1245-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
672 Bishop EJ, Tiruvoipati R, Metcalfe J, Marshall C, Botha J, Kelley PG. The outcome of patients with severe and severe-complicated Clostridium difficile infection treated with tigecycline combination therapy: a retrospective observational study: Tigecycline combination therapy for CDI. Intern Med J 2018;48:651-60. [DOI: 10.1111/imj.13742] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
673 Vandell AG, Inoue S, Dennie J, Nagasawa Y, Gajee R, Pav J, Zhang G, Zamora C, Masuda N, Senaldi G. Phase 1 Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Oral Doses of DS-2969b, a Novel GyrB Inhibitor, in Healthy Subjects. Antimicrob Agents Chemother 2018;62:e02537-17. [PMID: 29439973 DOI: 10.1128/AAC.02537-17] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
674 Shim JO. Clostridium difficile in Children: To Treat or Not to Treat? Pediatr Gastroenterol Hepatol Nutr 2014;17:80-4. [PMID: 25061582 DOI: 10.5223/pghn.2014.17.2.80] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
675 Okumura H, Ueyama M, Shoji S, English M. Cost-effectiveness analysis of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in Japan. Journal of Infection and Chemotherapy 2020;26:611-8. [DOI: 10.1016/j.jiac.2020.01.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
676 Tattevin P, Buffet-Bataillon S, Donnio PY, Revest M, Michelet C. Clostridium difficile infections: do we know the real dimensions of the problem? Int J Antimicrob Agents 2013;42 Suppl:S36-40. [PMID: 23664578 DOI: 10.1016/j.ijantimicag.2013.04.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
677 Kim JH, Toy D, Muder RR. Clostridium difficile Infection in a Long-Term Care Facility: Hospital-Associated Illness Compared with Long-Term Care-Associated Illness. Infect Control Hosp Epidemiol 2011;32:656-60. [DOI: 10.1086/660767] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 6.3] [Reference Citation Analysis]
678 De Rosa FG, Corcione S, Pagani N, Di Perri G. From ESKAPE to ESCAPE, From KPC to CCC. Clinical Infectious Diseases 2015;60:1289-90. [DOI: 10.1093/cid/ciu1170] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
679 Berro ZZ, Hamdan RH, Dandache IH, Saab MN, Karnib HH, Younes MH. Fecal microbiota transplantation for severe clostridium difficile infection after left ventricular assist device implantation: a case control study and concise review on the local and regional therapies. BMC Infect Dis 2016;16:234. [PMID: 27233894 DOI: 10.1186/s12879-016-1571-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
680 Alghounaim M, Longtin Y, Gonzales M, Merckx J, Winters N, Quach C. Clostridium difficile Infections in Children: Impact of the Diagnostic Method on Infection Rates. Infect Control Hosp Epidemiol 2016;37:1087-93. [DOI: 10.1017/ice.2016.123] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
681 Collins DA, Sohn KM, Wu Y, Ouchi K, Ishii Y, Elliott B, Riley TV, Tateda K; Clostridioides difficile Asia-Pacific Study Group. Clostridioides difficile infection in the Asia-Pacific region. Emerg Microbes Infect 2020;9:42-52. [PMID: 31873046 DOI: 10.1080/22221751.2019.1702480] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
682 Hui W, Li T, Liu W, Zhou C, Gao F. Fecal microbiota transplantation for treatment of recurrent C. difficile infection: An updated randomized controlled trial meta-analysis. PLoS One. 2019;14:e0210016. [PMID: 30673716 DOI: 10.1371/journal.pone.0210016] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 15.7]